{"255feb1171da9c27aff041b372dab71ea1d8697f": [["MikrobiologieDie \u00fcblichen Ursachen der akuten Bronchitis sind virale Infektionen der oberen Luftwege mit Influenza A, Influenza B, Parainfluenza, Coronavirus (Typen 1-3), Rhinoviren, Respiratory Syncytial Virus und humanen Metapneumovirus.", [["Influenza A", "DISEASE", 105, 116], ["Influenza B", "DISEASE", 118, 129], ["Typen 1-3", "CELL", 159, 168], ["Respiratory Syncytial Virus", "ORGANISM", 183, 210], ["MikrobiologieDie", "TEST", 0, 16], ["Bronchitis", "PROBLEM", 46, 56], ["virale", "TEST", 62, 68], ["Infektionen", "TEST", 69, 80], ["Influenza B", "PROBLEM", 118, 129], ["Parainfluenza", "PROBLEM", 131, 144], ["Coronavirus", "TEST", 146, 157], ["Typen", "TEST", 159, 164], ["Rhinoviren", "TEST", 171, 181], ["Respiratory Syncytial Virus", "PROBLEM", 183, 210], ["Metapneumovirus", "PROBLEM", 223, 238], ["Respiratory Syncytial", "ANATOMY", 183, 204]]], ["Bei einer Vielzahl von mikrobiologischen Untersuchungen zur \u00c4tiologie der akuten Bronchitis bei Patienten ohne zugrundeliegender Lungenerkrankung kann eine \u00e4tiologische Ursache nur in einer Minderheit der F\u00e4lle (16-29%) identifiziert werden.", [["Bei einer Vielzahl von mikrobiologischen Untersuchungen zur \u00c4tiologie der akuten Bronchitis bei Patienten ohne zugrundeliegender Lungenerkrankung kann eine \u00e4tiologische Ursache nur in einer Minderheit der F\u00e4lle", "SPECIES", 0, 210], ["Bronchitis", "PROBLEM", 81, 91]]], ["Manchmal gibt es den Verdacht, dass bakterielle Erreger, die eine Pneumonie verursachen k\u00f6nnen, wie Streptokokkus pneumoniae, Haemophilus influenzae, Staphylokokkus aureus, Moraxella catarrhalis oder sogar gramnegative St\u00e4bchen, auch eine akute Bronchitis verursachen k\u00f6nnen.", [["Streptokokkus pneumoniae", "DISEASE", 100, 124], ["Haemophilus influenzae", "DISEASE", 126, 148], ["wie Streptokokkus pneumoniae", "ORGANISM", 96, 124], ["Haemophilus influenzae", "ORGANISM", 126, 148], ["Staphylokokkus aureus", "ORGANISM", 150, 171], ["Streptokokkus pneumoniae", "SPECIES", 100, 124], ["Haemophilus influenzae", "SPECIES", 126, 148], ["Staphylokokkus aureus", "SPECIES", 150, 171], ["Moraxella catarrhalis", "SPECIES", 173, 194], ["Streptokokkus pneumoniae", "SPECIES", 100, 124], ["Haemophilus influenzae", "SPECIES", 126, 148], ["Staphylokokkus aureus", "SPECIES", 150, 171], ["Moraxella catarrhalis", "SPECIES", 173, 194], ["Streptokokkus pneumoniae", "PROBLEM", 100, 124], ["Haemophilus influenzae", "PROBLEM", 126, 148], ["Staphylokokkus aureus", "PROBLEM", 150, 171], ["Moraxella catarrhalis", "PROBLEM", 173, 194], ["Haemophilus influenzae", "OBSERVATION", 126, 148], ["Moraxella catarrhalis", "OBSERVATION", 173, 194]]], ["Im medizinischen Schrifttum findet sich keine \u00fcberzeugende Evidenz, die das Konzept einer akuten bakteriellen Bronchitis durch diese Erreger bei Lungen-gesunden Erwachsenen best\u00e4tigt.", [["Bronchitis", "PROBLEM", 110, 120]]], ["Bei Patienten mit Verletzungen der Luftwege durch Tracheostomie oder endotrachealer Intubation oder bei solchen mit einer akuten Exazerbation einer COPD gilt das nicht.InfluenzaDie Influenza ist eine akute Viruserkrankung, die durch Tr\u00f6pfcheninfektion \u00fcbertragen wird.", [["Influenza", "SPECIES", 181, 190], ["Bei Patienten mit Verletzungen der Luftwege durch Tracheostomie oder endotrachealer Intubation oder bei solchen mit einer akuten Exazerbation einer COPD gilt das nicht", "SPECIES", 0, 167], ["Bei Patienten mit Verletzungen der Luftwege durch Tracheostomie", "TREATMENT", 0, 63], ["Intubation", "TREATMENT", 84, 94], ["COPD", "PROBLEM", 148, 152], ["InfluenzaDie", "TREATMENT", 168, 180], ["Influenza ist eine akute Viruserkrankung", "TREATMENT", 181, 221]]], ["Ihre Ausbreitung erfolgt vor allem in dichten Menschenansammlungen, in Verkehrsmitteln, Arbeitsst\u00e4tten, Schulen, Kaufh\u00e4usern etc., besonders durch Anhusten und Niesen, sowie auch durch Husten und Niesen in die rechte Handfl\u00e4che, die man dann seinen Mitmenschen zur Begr\u00fc\u00dfung reicht.Nur Pertussis antibiotisch behandeln\u00dcbertragung der Influenza durch freundliches H\u00e4ndesch\u00fctteln nach dem Niesen Nach einer Inkubationszeit von 1-4 Tagen beginnt die Krankheit pl\u00f6tzlich mit Schnupfen, Fr\u00f6stelgef\u00fchl, Kopf-und Gliederschmerzen.", [["Pertussis antibiotisch behandeln\u00dcbertragung der Influenza durch freundliches H\u00e4ndesch\u00fctteln nach dem Niesen Nach einer Inkubationszeit von 1-4 Tagen beginnt die Krankheit pl\u00f6tzlich mit Schnupfen, Fr\u00f6stelgef\u00fchl, Kopf-und Gliederschmerzen", "SPECIES", 286, 522], ["Pertussis antibiotisch", "TREATMENT", 286, 308], ["Kopf", "TREATMENT", 497, 501]]], ["Danach erfolgt ein rascher Anstieg der K\u00f6rpertemperatur auf 39-40 Grad Celsius, zugleich tritt der f\u00fcr die Erkrankung der Atemwege charakteristische Husten bereits in den Vordergrund.", [["Danach erfolgt ein rascher Anstieg der K\u00f6rpertemperatur auf 39-40 Grad Celsius", "SPECIES", 0, 78], ["Danach", "TREATMENT", 0, 6], ["zugleich tritt der", "TREATMENT", 80, 98]]], ["Die Patienten klagen au\u00dferdem \u00fcber Brennen im Rachen und Schmerzen hinter dem Sternum.", [["Die Patienten klagen au\u00dferdem \u00fcber Brennen im Rachen und Schmerzen hinter dem Sternum", "SPECIES", 0, 85], ["Die", "PROBLEM", 0, 3], ["Sternum", "ANATOMY", 78, 85]]], ["Die Entfieberung erfolgt meistens nach 4-6-t\u00e4gigem Krankheitsverlauf.", [["Die Entfieberung erfolgt meistens nach 4-6-t\u00e4gigem Krankheitsverlauf", "SPECIES", 0, 68]]], ["Es kann aber auch zu gef\u00e4hrlichen Komplikationen kommen, dazu geh\u00f6rt die Pneumonie, f\u00fcr die besonders Hochrisikopatienten (die mit pulmonalen oder cardiovascul\u00e4ren Grunderkrankungen, Patienten mit Diabetes mellitus, Nierenerkrankungen, H\u00e4moglobinopathien oder Immunsuppression, Patienten in Pflegeheimen und \u00e4ltere Patienten) ein Risiko aufweisen.", [["Diabetes mellitus", "DISEASE", 197, 214], ["cardiovascul\u00e4ren", "TREATMENT", 147, 163], ["mit Diabetes mellitus", "PROBLEM", 193, 214], ["Nierenerkrankungen", "TREATMENT", 216, 234]]], ["Auf der einen Seite kann es sich dabei um eine prim\u00e4re Influenzapneumonie handeln, die insbesondere dann auftreten kann, wenn sich die prim\u00e4reGastro\u00f6sophagealer RefluxGastro\u00f6sophagealer Reflux ist eine h\u00e4ufige chronische Hustenursache, die in beinahe 40% der Patienten auftritt.", [["Gastro\u00f6sophagealer", "TEST", 142, 160], ["Reflux", "PROBLEM", 186, 192], ["Reflux", "OBSERVATION", 186, 192]]], ["Viele dieser Patienten haben zus\u00e4tzlich typische klassische Refluxbeschwerden, wie Herzbrennen, Herzstechen oder einen sauren Geschmack im Mund.", [["Viele", "TEST", 0, 5], ["Herzbrennen", "TREATMENT", 83, 94], ["Herzstechen", "TREATMENT", 96, 107]]], ["Diese letzteren Befunde k\u00f6nnen jedoch bei bis zu 40% der Patienten abwesend sein, bei denen der Husten durch den Reflux bedingt ist [14] .BehandlungDie meisten Patienten mit einer akuten Bronchitis haben assoziierte Symptome eines viralen Infektes und profitieren von symptomatischer Therapie.", [["Diese letzteren Befunde k\u00f6nnen jedoch bei bis zu 40% der Patienten abwesend sein, bei denen der Husten durch den Reflux bedingt", "SPECIES", 0, 127], ["Diese letzteren", "TREATMENT", 0, 15], ["Bronchitis", "PROBLEM", 187, 197]]], ["Diese besteht aus nicht steroidalen antiinflammatorischen Arzneimitteln, Aspirin, Acetaminophen, Paracetamol und/oder nasaler antiobstruktiver Therapie.", [["Arzneimitteln", "CHEMICAL", 58, 71], ["Aspirin", "CHEMICAL", 73, 80], ["Acetaminophen", "CHEMICAL", 82, 95], ["Paracetamol", "CHEMICAL", 97, 108], ["Aspirin", "CHEMICAL", 73, 80], ["Acetaminophen", "CHEMICAL", 82, 95], ["Paracetamol", "CHEMICAL", 97, 108], ["Arzneimitteln", "SIMPLE_CHEMICAL", 58, 71], ["Aspirin", "SIMPLE_CHEMICAL", 73, 80], ["Acetaminophen", "SIMPLE_CHEMICAL", 82, 95], ["Paracetamol", "SIMPLE_CHEMICAL", 97, 108], ["Diese besteht aus nicht steroidalen antiinflammatorischen Arzneimitteln", "TREATMENT", 0, 71], ["Aspirin", "TREATMENT", 73, 80], ["Acetaminophen", "TREATMENT", 82, 95], ["Paracetamol", "TREATMENT", 97, 108], ["nasaler antiobstruktiver Therapie", "TREATMENT", 118, 151]]], ["Eine Metaanalyse zeigte, dass Beta 2 Agonisten f\u00fcr die Behandlung der akuten Bronchitis sinnlos sind bei Husten, der weniger als 4 Wochen dauert, sowohl bei Kindern als auch bei Erwachsenen, falls keine Atemwegsobstruktion vorhanden war.", [["Bronchitis", "PROBLEM", 77, 87]]], ["Bei der allergischen Rhinitis werden intranasale Kortikosteroide und/oder Antihistaminika empfohlen.", [["Bei der allergischen Rhinitis werden intranasale Kortikosteroide und/oder Antihistaminika empfohlen", "SPECIES", 0, 99], ["Rhinitis", "PROBLEM", 21, 29], ["intranasale Kortikosteroide", "TREATMENT", 37, 64], ["Antihistaminika empfohlen", "TREATMENT", 74, 99], ["Rhinitis", "OBSERVATION", 21, 29]]], ["Patienten mit Influenza A Infektionen profitieren von einer fr\u00fchzeitig, am besten innerhalb von 12 Stunden ab Symptombeginn eingeleiteten Therapie mit Oseltamivir [8, 15] .Fehlen eines Effektes einer antibiotischen Therapie als BehandlungsroutineDie wesentliche therapeutische Fragestellung der meisten F\u00e4lle der akuten Bronchitis ist der Einsatz von antibakteriellen Substanzen.", [["Oseltamivir", "CHEMICAL", 151, 162], ["Oseltamivir", "CHEMICAL", 151, 162], ["Fehlen eines Effektes einer antibiotischen Therapie als BehandlungsroutineDie wesentliche therapeutische Fragestellung der meisten F\u00e4lle der akuten Bronchitis ist der Einsatz von antibakteriellen Substanzen", "SPECIES", 172, 378], ["Therapie mit Oseltamivir", "TREATMENT", 138, 162], ["Fehlen eines Effektes einer antibiotischen Therapie", "TREATMENT", 172, 223]]], ["Eine Vielzahl von Studien zeigt, dass Patienten mit akuter Bronchitis keinen Vorteil von einer antibiotischen Therapie haben, vermutlich, da Bakterien nicht f\u00fcr die Infektion verantwortlich gemacht werden k\u00f6nnen.", [["Bronchitis", "PROBLEM", 59, 69]]], ["In einer gro\u00dfen Metaanalyse wurden 9 Placebokontrollierte doppelblinde Studien zur antibiotischen Therapie bei akuter Bronchitis untersucht.", [["Bronchitis", "PROBLEM", 118, 128], ["Bronchitis", "OBSERVATION", 118, 128]]]], "PMC7440156": [], "e9026277a49ca5c99f7a32f0873a467eda233a34": [["It is true there were several limitations in our study.", [["our study", "TEST", 45, 54]]], ["However, we still believe that D-dimer level at admission could be an effective and easily available predictor in patients with coronavirus disease 2019 (COVID-19).", [["coronavirus disease", "DISEASE", 128, 147], ["D-dimer", "GENE_OR_GENE_PRODUCT", 31, 38], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["D-dimer level", "TEST", 31, 44], ["coronavirus disease", "PROBLEM", 128, 147], ["COVID", "TEST", 154, 159]]]], "043a98822a07f37e86fdf0dbfacff62851897c18": [["IntroductionA novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was discovered in December 2019 in Wuhan, China, and an ongoing pandemic of coronavirus disease 2019 (COVID-19) has been spreading around the world as of early April 2020.", [["coronavirus", "DISEASE", 20, 31], ["acute respiratory syndrome coronavirus", "DISEASE", 46, 84], ["coronavirus disease", "DISEASE", 177, 196], ["COVID-19", "CHEMICAL", 203, 211], ["coronavirus", "ORGANISM", 20, 31], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 39, 86], ["SARS-CoV-2", "ORGANISM", 88, 98], ["coronavirus", "ORGANISM", 177, 188], ["severe acute respiratory syndrome coronavirus", "SPECIES", 39, 84], ["SARS-CoV-2", "SPECIES", 88, 98], ["IntroductionA novel coronavirus", "PROBLEM", 0, 31], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 39, 84], ["SARS-CoV", "TEST", 88, 96], ["coronavirus disease", "PROBLEM", 177, 196], ["COVID", "TEST", 203, 208], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory syndrome", "OBSERVATION", 52, 72], ["coronavirus disease", "OBSERVATION", 177, 196]]], ["The clinical spectrum of COVID-19 ranges from asymptomatic upper respiratory infection to critically ill pneumonia associated with acute respiratory distress syndrome (ARDS) [1] [2] [3] .", [["respiratory", "ANATOMY", 65, 76], ["respiratory", "ANATOMY", 137, 148], ["respiratory infection", "DISEASE", 65, 86], ["critically ill", "DISEASE", 90, 104], ["pneumonia", "DISEASE", 105, 114], ["acute respiratory distress syndrome", "DISEASE", 131, 166], ["ARDS", "DISEASE", 168, 172], ["COVID-19", "CELL", 25, 33], ["COVID", "TEST", 25, 30], ["asymptomatic upper respiratory infection", "PROBLEM", 46, 86], ["critically ill pneumonia", "PROBLEM", 90, 114], ["acute respiratory distress syndrome", "PROBLEM", 131, 166], ["upper", "ANATOMY_MODIFIER", 59, 64], ["respiratory", "ANATOMY", 65, 76], ["infection", "OBSERVATION", 77, 86], ["pneumonia", "OBSERVATION", 105, 114], ["acute", "OBSERVATION_MODIFIER", 131, 136], ["respiratory distress", "OBSERVATION", 137, 157]]], ["In initial reports from China, the prevalence of older age, hypertension, diabetes mellitus, and cardiovascular disease (CVD) was high in COVID-19 patients, and individuals with these comorbidities tended to have greater case fatality rates [3, 4] .", [["cardiovascular", "ANATOMY", 97, 111], ["hypertension", "DISEASE", 60, 72], ["diabetes mellitus", "DISEASE", 74, 91], ["cardiovascular disease", "DISEASE", 97, 119], ["CVD", "DISEASE", 121, 124], ["cardiovascular", "ANATOMICAL_SYSTEM", 97, 111], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["hypertension", "PROBLEM", 60, 72], ["diabetes mellitus", "PROBLEM", 74, 91], ["cardiovascular disease", "PROBLEM", 97, 119], ["CVD", "PROBLEM", 121, 124], ["these comorbidities", "PROBLEM", 178, 197], ["hypertension", "OBSERVATION", 60, 72], ["diabetes mellitus", "OBSERVATION", 74, 91], ["cardiovascular", "ANATOMY", 97, 111], ["disease", "OBSERVATION", 112, 119]]], ["In addition, it has been shown that angiotensin-converting enzyme 2 (ACE2) is a functional receptor for SARS-CoV-2 infection [5] [6] [7] .", [["angiotensin", "CHEMICAL", 36, 47], ["infection", "DISEASE", 115, 124], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 36, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 69, 73], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["[5] [6] [7]", "SIMPLE_CHEMICAL", 125, 136], ["angiotensin-converting enzyme 2", "PROTEIN", 36, 67], ["ACE2", "PROTEIN", 69, 73], ["angiotensin", "TEST", 36, 47], ["converting enzyme", "TEST", 48, 65], ["ACE2", "TEST", 69, 73], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["2 infection", "PROBLEM", 113, 124]]], ["Given that experimental studies suggested that angiotensin receptor blockers (ARBs) and an ACE inhibitor (ACEI) could increase ACE2 expression in cardiovascular and renal systems [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , concerns may have been raised regarding whether ARBs and ACEIs would augment the infection of SARS-CoV-2 and the severity of COVID-19 in hypertension and CVD patients receiving these drugs [21] .", [["cardiovascular", "ANATOMY", 146, 160], ["renal", "ANATOMY", 165, 170], ["angiotensin", "CHEMICAL", 47, 58], ["ARBs", "CHEMICAL", 78, 82], ["ACE inhibitor", "CHEMICAL", 91, 104], ["ACEI", "CHEMICAL", 106, 110], ["8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19]", "CHEMICAL", 180, 236], ["ARBs", "CHEMICAL", 292, 296], ["ACEIs", "CHEMICAL", 301, 306], ["infection", "DISEASE", 325, 334], ["SARS", "DISEASE", 338, 342], ["COVID-19", "CHEMICAL", 369, 377], ["hypertension", "DISEASE", 381, 393], ["CVD", "DISEASE", 398, 401], ["COVID-19", "CHEMICAL", 369, 377], ["angiotensin receptor blockers", "GENE_OR_GENE_PRODUCT", 47, 76], ["ARBs", "SIMPLE_CHEMICAL", 78, 82], ["ACE", "GENE_OR_GENE_PRODUCT", 91, 94], ["ACEI", "SIMPLE_CHEMICAL", 106, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 127, 131], ["cardiovascular", "ANATOMICAL_SYSTEM", 146, 160], ["renal", "ORGAN", 165, 170], ["[8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20]", "SIMPLE_CHEMICAL", 179, 241], ["ARBs", "SIMPLE_CHEMICAL", 292, 296], ["ACEIs", "SIMPLE_CHEMICAL", 301, 306], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 338, 348], ["patients", "ORGANISM", 402, 410], ["ACE2", "PROTEIN", 127, 131], ["patients", "SPECIES", 402, 410], ["SARS-CoV", "SPECIES", 338, 346], ["experimental studies", "TEST", 11, 31], ["angiotensin receptor blockers", "TREATMENT", 47, 76], ["ARBs", "TREATMENT", 78, 82], ["an ACE inhibitor (ACEI", "TREATMENT", 88, 110], ["cardiovascular and renal systems", "TEST", 146, 178], ["ARBs", "TREATMENT", 292, 296], ["ACEIs", "TREATMENT", 301, 306], ["the infection of SARS", "PROBLEM", 321, 342], ["CoV", "TEST", 343, 346], ["COVID", "TEST", 369, 374], ["hypertension", "PROBLEM", 381, 393], ["CVD", "PROBLEM", 398, 401], ["these drugs", "TREATMENT", 421, 432], ["renal", "ANATOMY", 165, 170], ["infection", "OBSERVATION", 325, 334], ["hypertension", "OBSERVATION", 381, 393]]], ["In contrast, ARBs have potential benefits in the prevention and treatment of lung injury caused by COVID-19 [22] .", [["lung", "ANATOMY", 77, 81], ["ARBs", "CHEMICAL", 13, 17], ["lung injury", "DISEASE", 77, 88], ["COVID-19", "CHEMICAL", 99, 107], ["COVID-19", "CHEMICAL", 99, 107], ["ARBs", "SIMPLE_CHEMICAL", 13, 17], ["lung", "ORGAN", 77, 81], ["ARBs", "TREATMENT", 13, 17], ["lung injury", "PROBLEM", 77, 88], ["COVID", "TEST", 99, 104], ["lung", "ANATOMY", 77, 81], ["injury", "OBSERVATION", 82, 88]]], ["These conflicting views appear to arise based on the results of experimental studies, especially those of severe acute respiratory syndrome coronavirus (SARS-CoV), because direct clinical data on COVID-19 are lacking at present.", [["acute respiratory syndrome coronavirus", "DISEASE", 113, 151], ["SARS-CoV", "DISEASE", 153, 161], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 106, 151], ["SARS-CoV", "ORGANISM", 153, 161], ["severe acute respiratory syndrome coronavirus", "SPECIES", 106, 151], ["SARS-CoV", "SPECIES", 153, 161], ["experimental studies", "TEST", 64, 84], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 106, 151], ["direct clinical data", "TEST", 172, 192], ["COVID", "TEST", 196, 201], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["respiratory syndrome", "OBSERVATION", 119, 139]]], ["SARS-CoV caused the SARS epidemic in China in [2002] [2003] , and its virological characteristics are closely related to those of SARS-CoV-2 [23, 24] .", [["SARS-CoV", "DISEASE", 0, 8], ["SARS", "DISEASE", 20, 24], ["SARS", "DISEASE", 130, 134], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 130, 140], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 130, 138], ["SARS", "PROBLEM", 0, 4], ["the SARS", "PROBLEM", 16, 24], ["SARS", "TEST", 130, 134], ["CoV", "TEST", 135, 138]]], ["Here, available investigations on the association of the renin-angiotensin system (RAS), particularly ACE2 and angiotensin II, with SARS-CoV-induced lung injury and the latest information on COVID-19 were reviewed as of early April 2020, which would provide insight into COVID-19 and the direction of future research on COVID-19.IntroductionACE2 as a receptor for SARS-CoV and SARS-CoV-2 ACE2 belongs to the membrane-bound carboxydipeptidase family and is widely distributed in the human body, including the heart, kidney, small intestine, and, to a lesser extent, the lung.", [["lung", "ANATOMY", 149, 153], ["membrane", "ANATOMY", 408, 416], ["body", "ANATOMY", 488, 492], ["heart", "ANATOMY", 508, 513], ["kidney", "ANATOMY", 515, 521], ["small intestine", "ANATOMY", 523, 538], ["lung", "ANATOMY", 569, 573], ["angiotensin", "CHEMICAL", 63, 74], ["angiotensin II", "CHEMICAL", 111, 125], ["SARS", "DISEASE", 132, 136], ["lung injury", "DISEASE", 149, 160], ["SARS", "DISEASE", 364, 368], ["COVID-19", "CHEMICAL", 320, 328], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 57, 81], ["RAS", "GENE_OR_GENE_PRODUCT", 83, 86], ["ACE2", "GENE_OR_GENE_PRODUCT", 102, 106], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 111, 125], ["SARS-CoV", "ORGANISM", 132, 140], ["lung", "ORGAN", 149, 153], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 364, 372], ["SARS-CoV-2 ACE2", "GENE_OR_GENE_PRODUCT", 377, 392], ["membrane", "CELLULAR_COMPONENT", 408, 416], ["carboxydipeptidase", "GENE_OR_GENE_PRODUCT", 423, 441], ["human", "ORGANISM", 482, 487], ["body", "ORGANISM_SUBDIVISION", 488, 492], ["heart", "ORGAN", 508, 513], ["kidney", "ORGAN", 515, 521], ["small intestine", "ORGAN", 523, 538], ["lung", "ORGAN", 569, 573], ["renin", "PROTEIN", 57, 62], ["ACE2", "PROTEIN", 102, 106], ["angiotensin II", "PROTEIN", 111, 125], ["IntroductionACE2", "PROTEIN", 329, 345], ["SARS-CoV and SARS-CoV-2 ACE2", "PROTEIN", 364, 392], ["membrane-bound carboxydipeptidase family", "PROTEIN", 408, 448], ["human", "SPECIES", 482, 487], ["SARS-CoV", "SPECIES", 364, 372], ["SARS-CoV", "SPECIES", 377, 385], ["human", "SPECIES", 482, 487], ["angiotensin II", "TREATMENT", 111, 125], ["SARS", "PROBLEM", 132, 136], ["lung injury", "PROBLEM", 149, 160], ["COVID", "TEST", 191, 196], ["COVID", "TEST", 271, 276], ["COVID", "TEST", 320, 325], ["SARS", "TEST", 364, 368], ["CoV", "TEST", 369, 372], ["SARS", "TEST", 377, 381], ["CoV", "TEST", 382, 385], ["lung", "ANATOMY", 149, 153], ["injury", "OBSERVATION", 154, 160], ["human body", "ANATOMY_MODIFIER", 482, 492], ["heart", "ANATOMY", 508, 513], ["kidney", "ANATOMY", 515, 521], ["small intestine", "ANATOMY", 523, 538], ["lesser extent", "OBSERVATION_MODIFIER", 550, 563], ["lung", "ANATOMY", 569, 573]]], ["Lung ACE2 expression is concentrated mainly in type II alveolar cells and macrophages and modestly in bronchial and tracheal epithelial cells [25] .", [["Lung", "ANATOMY", 0, 4], ["type II alveolar cells", "ANATOMY", 47, 69], ["macrophages", "ANATOMY", 74, 85], ["bronchial", "ANATOMY", 102, 111], ["tracheal epithelial cells", "ANATOMY", 116, 141], ["Lung", "ORGAN", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["type II alveolar cells", "CELL", 47, 69], ["macrophages", "CELL", 74, 85], ["bronchial", "CELL", 102, 111], ["tracheal epithelial cells", "CELL", 116, 141], ["ACE2", "PROTEIN", 5, 9], ["type II alveolar cells", "CELL_TYPE", 47, 69], ["macrophages", "CELL_TYPE", 74, 85], ["bronchial and tracheal epithelial cells", "CELL_TYPE", 102, 141], ["Lung ACE2 expression", "TEST", 0, 20], ["type II alveolar cells", "PROBLEM", 47, 69], ["macrophages", "PROBLEM", 74, 85], ["modestly in bronchial and tracheal epithelial cells", "PROBLEM", 90, 141], ["ACE2", "OBSERVATION", 5, 9], ["concentrated", "OBSERVATION_MODIFIER", 24, 36], ["type II", "OBSERVATION_MODIFIER", 47, 54], ["alveolar cells", "OBSERVATION", 55, 69], ["macrophages", "OBSERVATION", 74, 85], ["modestly", "OBSERVATION_MODIFIER", 90, 98], ["bronchial", "ANATOMY", 102, 111], ["tracheal", "ANATOMY", 116, 124], ["epithelial cells", "OBSERVATION", 125, 141]]], ["ACE2 degrades angiotensin II to generate angiotensin 1-7, which activates the mas oncogene receptor that negatively regulates a variety of angiotensin II actions mediated by angiotensin II type 1 receptor (AT1R) [26] .", [["angiotensin II", "CHEMICAL", 14, 28], ["angiotensin 1-7", "CHEMICAL", 41, 56], ["angiotensin II", "CHEMICAL", 139, 153], ["angiotensin II", "CHEMICAL", 174, 188], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 14, 28], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 41, 56], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 139, 153], ["angiotensin II type 1 receptor", "GENE_OR_GENE_PRODUCT", 174, 204], ["AT1R", "GENE_OR_GENE_PRODUCT", 206, 210], ["ACE2", "PROTEIN", 0, 4], ["angiotensin II", "PROTEIN", 14, 28], ["mas oncogene receptor", "PROTEIN", 78, 99], ["angiotensin II", "PROTEIN", 139, 153], ["angiotensin II type 1 receptor", "PROTEIN", 174, 204], ["AT1R", "PROTEIN", 206, 210], ["ACE2 degrades angiotensin II", "TREATMENT", 0, 28], ["angiotensin", "TEST", 41, 52], ["the mas oncogene receptor", "TREATMENT", 74, 99], ["angiotensin II actions", "TREATMENT", 139, 161], ["angiotensin II type 1 receptor (AT1R)", "TREATMENT", 174, 211]]], ["Therefore, it is thought that the ACE2/angiotensin 1-7/mas receptor axis has counteracting effects against the excessively activated ACE/angiotensin II/AT1R axis, as seen in hypertension, cardiac hypertrophy, heart failure, and other CVDs [26] .IntroductionOn the other hand, human ACE2 is an established functional receptor by which SARS-CoV enters host target cells ( Fig. 1) [23, 24] .", [["cardiac", "ANATOMY", 188, 195], ["heart", "ANATOMY", 209, 214], ["cells", "ANATOMY", 362, 367], ["angiotensin", "CHEMICAL", 39, 50], ["angiotensin II", "CHEMICAL", 137, 151], ["hypertension", "DISEASE", 174, 186], ["cardiac hypertrophy", "DISEASE", 188, 207], ["heart failure", "DISEASE", 209, 222], ["CVDs", "DISEASE", 234, 238], ["SARS", "DISEASE", 334, 338], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 39, 54], ["mas receptor", "GENE_OR_GENE_PRODUCT", 55, 67], ["ACE", "GENE_OR_GENE_PRODUCT", 133, 136], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 137, 151], ["AT1R", "GENE_OR_GENE_PRODUCT", 152, 156], ["cardiac", "ORGAN", 188, 195], ["heart", "ORGAN", 209, 214], ["human", "ORGANISM", 276, 281], ["ACE2", "GENE_OR_GENE_PRODUCT", 282, 286], ["SARS-CoV", "ORGANISM", 334, 342], ["cells", "CELL", 362, 367], ["ACE2", "PROTEIN", 34, 38], ["ACE", "PROTEIN", 133, 136], ["angiotensin II", "PROTEIN", 137, 151], ["AT1R", "PROTEIN", 152, 156], ["human ACE2", "PROTEIN", 276, 286], ["host target cells", "CELL_TYPE", 350, 367], ["human", "SPECIES", 276, 281], ["human", "SPECIES", 276, 281], ["SARS-CoV", "SPECIES", 334, 342], ["the ACE2/angiotensin", "TREATMENT", 30, 50], ["activated ACE/angiotensin II/AT1R axis", "TREATMENT", 123, 161], ["hypertension", "PROBLEM", 174, 186], ["cardiac hypertrophy", "PROBLEM", 188, 207], ["heart failure", "PROBLEM", 209, 222], ["other CVDs", "PROBLEM", 228, 238], ["hypertension", "OBSERVATION", 174, 186], ["cardiac", "ANATOMY", 188, 195], ["hypertrophy", "OBSERVATION", 196, 207], ["heart", "ANATOMY", 209, 214], ["failure", "OBSERVATION", 215, 222]]], ["The transmembrane spike glycoprotein (S protein) of SARS-CoV binds to the cellular membrane ACE2; SARS-CoV then attaches to the target cells, followed by SARS-CoV-S protein priming by cellular surface proteases, such as transmembrane protease serine 2 (TMPRSS2), allowing the fusion of viral and cellular membranes and resulting in SARS-CoV entry and replication in the target cells [6] .", [["transmembrane", "ANATOMY", 4, 17], ["cellular membrane", "ANATOMY", 74, 91], ["cells", "ANATOMY", 135, 140], ["cellular surface", "ANATOMY", 184, 200], ["cellular membranes", "ANATOMY", 296, 314], ["cells", "ANATOMY", 377, 382], ["serine", "CHEMICAL", 243, 249], ["transmembrane", "CELLULAR_COMPONENT", 4, 17], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 52, 60], ["cellular membrane", "CELLULAR_COMPONENT", 74, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 98, 106], ["cells", "CELL", 135, 140], ["cellular", "CELL", 184, 192], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 220, 251], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 253, 260], ["cellular membranes", "CELLULAR_COMPONENT", 296, 314], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 332, 340], ["cells", "CELL", 377, 382], ["transmembrane spike glycoprotein", "PROTEIN", 4, 36], ["S protein", "PROTEIN", 38, 47], ["SARS-CoV", "PROTEIN", 52, 60], ["ACE2", "PROTEIN", 92, 96], ["SARS-CoV", "PROTEIN", 98, 106], ["target cells", "CELL_TYPE", 128, 140], ["SARS-CoV-S protein", "PROTEIN", 154, 172], ["cellular surface proteases", "PROTEIN", 184, 210], ["transmembrane protease serine 2", "PROTEIN", 220, 251], ["TMPRSS2", "PROTEIN", 253, 260], ["target cells", "CELL_TYPE", 370, 382], ["SARS-CoV", "SPECIES", 52, 60], ["SARS-CoV", "SPECIES", 98, 106], ["SARS-CoV", "SPECIES", 332, 340], ["The transmembrane spike glycoprotein", "TEST", 0, 36], ["SARS", "PROBLEM", 52, 56], ["CoV binds", "PROBLEM", 57, 66], ["the cellular membrane ACE2", "TEST", 70, 96], ["SARS", "PROBLEM", 98, 102], ["SARS", "TEST", 154, 158], ["CoV-S protein priming", "TREATMENT", 159, 180], ["cellular surface proteases", "TREATMENT", 184, 210], ["transmembrane protease serine", "TREATMENT", 220, 249], ["viral and cellular membranes", "PROBLEM", 286, 314], ["SARS", "PROBLEM", 332, 336], ["cellular membrane", "ANATOMY", 74, 91], ["cellular membranes", "OBSERVATION", 296, 314]]], ["Moreover, ACE2 knockout greatly reduces viral infection and replication in mice after experimental SARS-CoV infection [27] .", [["viral infection", "DISEASE", 40, 55], ["SARS-CoV infection", "DISEASE", 99, 117], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["mice", "ORGANISM", 75, 79], ["SARS-CoV", "ORGANISM", 99, 107], ["ACE2", "PROTEIN", 10, 14], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["SARS-CoV", "SPECIES", 99, 107], ["ACE2 knockout", "TREATMENT", 10, 23], ["viral infection", "PROBLEM", 40, 55], ["experimental SARS", "PROBLEM", 86, 103], ["CoV infection", "PROBLEM", 104, 117], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 46, 55]]], ["Thus, it is suggested that the binding of the SARS-CoV-S protein to ACE2 is crucial for SARS-CoV infection.IntroductionRecently, it has been shown that the SARS-CoV-2-S protein shares nearly 80% amino acid identity with the SARS-CoV-S protein, and the binding affinity of the SARS-CoV-2-S protein to human ACE2 is similar to that of the SARS-CoV-S protein [5] [6] [7] .", [["SARS", "DISEASE", 46, 50], ["SARS-CoV infection", "DISEASE", 88, 106], ["SARS", "DISEASE", 156, 160], ["amino acid", "CHEMICAL", 195, 205], ["amino acid", "CHEMICAL", 195, 205], ["SARS-CoV-S", "GENE_OR_GENE_PRODUCT", 46, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["SARS-CoV", "ORGANISM", 88, 96], ["amino acid", "AMINO_ACID", 195, 205], ["SARS-CoV-2-S", "GENE_OR_GENE_PRODUCT", 276, 288], ["human", "ORGANISM", 300, 305], ["ACE2", "GENE_OR_GENE_PRODUCT", 306, 310], ["[5] [6] [7]", "SIMPLE_CHEMICAL", 356, 367], ["SARS-CoV-S protein", "PROTEIN", 46, 64], ["ACE2", "PROTEIN", 68, 72], ["SARS-CoV-2-S protein", "PROTEIN", 156, 176], ["SARS-CoV-S protein", "PROTEIN", 224, 242], ["SARS-CoV-2-S protein", "PROTEIN", 276, 296], ["human ACE2", "PROTEIN", 300, 310], ["SARS-CoV-S protein", "PROTEIN", 337, 355], ["human", "SPECIES", 300, 305], ["SARS-CoV", "SPECIES", 88, 96], ["human", "SPECIES", 300, 305], ["the SARS", "TEST", 42, 50], ["CoV", "TEST", 51, 54], ["ACE2", "TEST", 68, 72], ["SARS", "PROBLEM", 88, 92], ["CoV infection", "PROBLEM", 93, 106], ["the SARS", "TEST", 152, 160], ["CoV", "TEST", 161, 164], ["S protein", "TEST", 167, 176], ["amino acid identity", "TEST", 195, 214], ["the SARS", "TEST", 220, 228], ["CoV-S protein", "TEST", 229, 242], ["the binding affinity", "TEST", 248, 268], ["the SARS", "TEST", 272, 280], ["CoV", "TEST", 281, 284], ["human ACE2", "TEST", 300, 310], ["the SARS", "TEST", 333, 341], ["CoV-S protein", "TEST", 342, 355], ["infection", "OBSERVATION", 97, 106]]], ["Anti-human ACE2 antibodies or antisera can inhibit SARS-CoV-2-S proteinmediated entry into cultured cells in vitro [5] [6] [7] .", [["cells", "ANATOMY", 100, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 11, 15], ["cells", "CELL", 100, 105], ["Anti-human ACE2 antibodies", "PROTEIN", 0, 26], ["cultured cells", "CELL_LINE", 91, 105], ["Anti-human ACE2 antibodies", "TEST", 0, 26], ["antisera", "TEST", 30, 38], ["SARS", "TEST", 51, 55], ["CoV", "TEST", 56, 59]]], ["Accordingly, SARS-CoV-2 utilizes ACE2 for target cell entry as well.", [["cell", "ANATOMY", 49, 53], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["cell", "CELL", 49, 53], ["ACE2", "PROTEIN", 33, 37], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "TEST", 13, 17], ["ACE2", "TREATMENT", 33, 37], ["cell entry", "OBSERVATION", 49, 59]]], ["However, it is still not clear whether ACE2 is the sole receptor for SARS-CoV-2 infection because CD209L (a glycoprotein of C-type lectin also called L-SIGN) is identified as a possible secondary receptor for SARS-CoV in cultured Chinese hamster ovary cells [28] .ACE2 and acute lung injuryExperimental SARS-CoV infection induces acute respiratory failure and lung parenchymal injury characterized by alveolar wall thickening, pulmonary vascular hyperpermeability, and inflammatory cell infiltration in mice [27] .", [["hamster ovary cells", "ANATOMY", 238, 257], ["lung", "ANATOMY", 279, 283], ["respiratory", "ANATOMY", 336, 347], ["lung parenchymal", "ANATOMY", 360, 376], ["alveolar wall", "ANATOMY", 401, 414], ["pulmonary vascular", "ANATOMY", 427, 445], ["inflammatory cell", "ANATOMY", 469, 486], ["infection", "DISEASE", 80, 89], ["SARS", "DISEASE", 209, 213], ["infection", "DISEASE", 312, 321], ["respiratory failure", "DISEASE", 336, 355], ["lung parenchymal injury", "DISEASE", 360, 383], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["SARS-CoV-2", "ORGANISM", 69, 79], ["CD209L", "GENE_OR_GENE_PRODUCT", 98, 104], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 124, 137], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 150, 156], ["SARS-CoV", "ORGANISM", 209, 217], ["hamster ovary cells", "CELL", 238, 257], ["ACE2", "GENE_OR_GENE_PRODUCT", 264, 268], ["lung", "ORGAN", 279, 283], ["CoV", "ORGANISM", 308, 311], ["lung parenchymal", "MULTI-TISSUE_STRUCTURE", 360, 376], ["alveolar wall", "MULTI-TISSUE_STRUCTURE", 401, 414], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 427, 445], ["inflammatory cell", "CELL", 469, 486], ["mice", "ORGANISM", 503, 507], ["ACE2", "PROTEIN", 39, 43], ["CD209L", "PROTEIN", 98, 104], ["glycoprotein of C-type lectin", "PROTEIN", 108, 137], ["L", "PROTEIN", 150, 151], ["SIGN", "PROTEIN", 152, 156], ["cultured Chinese hamster ovary cells", "CELL_LINE", 221, 257], ["ACE2", "PROTEIN", 264, 268], ["mice", "SPECIES", 503, 507], ["SARS-CoV", "SPECIES", 209, 217], ["Chinese hamster", "SPECIES", 230, 245], ["SARS-CoV", "SPECIES", 303, 311], ["mice", "SPECIES", 503, 507], ["ACE2", "TEST", 39, 43], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77], ["2 infection", "PROBLEM", 78, 89], ["CD209L", "TEST", 98, 104], ["SARS", "PROBLEM", 209, 213], ["CoV", "PROBLEM", 214, 217], ["ACE2", "TEST", 264, 268], ["acute lung injuryExperimental SARS", "PROBLEM", 273, 307], ["CoV infection", "PROBLEM", 308, 321], ["acute respiratory failure", "PROBLEM", 330, 355], ["lung parenchymal injury", "PROBLEM", 360, 383], ["alveolar wall thickening", "PROBLEM", 401, 425], ["pulmonary vascular hyperpermeability", "PROBLEM", 427, 463], ["inflammatory cell infiltration", "PROBLEM", 469, 499], ["acute", "OBSERVATION_MODIFIER", 273, 278], ["lung", "ANATOMY", 279, 283], ["injuryExperimental SARS", "OBSERVATION", 284, 307], ["CoV infection", "OBSERVATION", 308, 321], ["acute", "OBSERVATION_MODIFIER", 330, 335], ["respiratory failure", "OBSERVATION", 336, 355], ["lung", "ANATOMY", 360, 364], ["parenchymal", "ANATOMY_MODIFIER", 365, 376], ["injury", "OBSERVATION", 377, 383], ["alveolar", "ANATOMY_MODIFIER", 401, 409], ["wall", "ANATOMY_MODIFIER", 410, 414], ["thickening", "OBSERVATION", 415, 425], ["pulmonary", "ANATOMY_MODIFIER", 427, 436], ["vascular", "ANATOMY", 437, 445], ["hyperpermeability", "OBSERVATION", 446, 463], ["inflammatory", "OBSERVATION_MODIFIER", 469, 481], ["cell infiltration", "OBSERVATION", 482, 499]]], ["After SARS-CoV infection in mice, lung ACE2 Fig. 1 Possible scheme of the association of ACE2, angiotensin II, and AT1R and acute lung injury of SARS and COVID-19.", [["lung", "ANATOMY", 34, 38], ["lung", "ANATOMY", 130, 134], ["SARS-CoV infection", "DISEASE", 6, 24], ["angiotensin II", "CHEMICAL", 95, 109], ["acute lung injury", "DISEASE", 124, 141], ["SARS", "DISEASE", 145, 149], ["SARS-CoV", "ORGANISM", 6, 14], ["mice", "ORGANISM", 28, 32], ["lung", "ORGAN", 34, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 95, 109], ["AT1R", "GENE_OR_GENE_PRODUCT", 115, 119], ["lung", "ORGAN", 130, 134], ["ACE2", "PROTEIN", 39, 43], ["ACE2", "PROTEIN", 89, 93], ["angiotensin II", "PROTEIN", 95, 109], ["AT1R", "PROTEIN", 115, 119], ["mice", "SPECIES", 28, 32], ["SARS-CoV", "SPECIES", 6, 14], ["mice", "SPECIES", 28, 32], ["SARS", "PROBLEM", 6, 10], ["CoV infection in mice", "PROBLEM", 11, 32], ["lung ACE2 Fig", "TREATMENT", 34, 47], ["ACE2", "PROBLEM", 89, 93], ["angiotensin II", "PROBLEM", 95, 109], ["AT1R", "PROBLEM", 115, 119], ["acute lung injury of SARS", "PROBLEM", 124, 149], ["COVID", "TEST", 154, 159], ["CoV", "OBSERVATION_MODIFIER", 11, 14], ["infection", "OBSERVATION", 15, 24], ["lung", "ANATOMY", 34, 38], ["ACE2 Fig", "OBSERVATION", 39, 47], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["lung", "ANATOMY", 130, 134], ["injury", "OBSERVATION", 135, 141]]], ["Ang II, angiotensin II; ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; ACEI, angiotensin-converting enzyme inhibitor; AT1R, angiotensin II type-1 receptor; ARB, angiotensin II type-1 receptor blocker; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S-protein, spike-glycoprotein protein levels are greatly reduced, while ACE levels are not changed [27] .", [["Ang II", "CHEMICAL", 0, 6], ["angiotensin II", "CHEMICAL", 8, 22], ["angiotensin", "CHEMICAL", 29, 40], ["angiotensin", "CHEMICAL", 66, 77], ["ACEI", "CHEMICAL", 99, 103], ["angiotensin", "CHEMICAL", 105, 116], ["angiotensin II", "CHEMICAL", 152, 166], ["ARB", "CHEMICAL", 184, 187], ["angiotensin II type-1 receptor blocker", "CHEMICAL", 189, 227], ["SARS-CoV", "DISEASE", 229, 237], ["acute respiratory syndrome coronavirus", "DISEASE", 246, 284], ["SARS", "DISEASE", 286, 290], ["acute respiratory syndrome coronavirus", "DISEASE", 305, 343], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 8, 22], ["ACE", "GENE_OR_GENE_PRODUCT", 24, 27], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 29, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 66, 97], ["ACEI", "SIMPLE_CHEMICAL", 99, 103], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 105, 134], ["AT1R", "GENE_OR_GENE_PRODUCT", 146, 150], ["angiotensin II type-1 receptor", "GENE_OR_GENE_PRODUCT", 152, 182], ["ARB", "SIMPLE_CHEMICAL", 184, 187], ["angiotensin II type-1 receptor", "GENE_OR_GENE_PRODUCT", 189, 219], ["SARS-CoV", "ORGANISM", 229, 237], ["SARS-CoV-2", "ORGANISM", 286, 296], ["S-protein", "GENE_OR_GENE_PRODUCT", 347, 356], ["spike-glycoprotein", "GENE_OR_GENE_PRODUCT", 358, 376], ["ACE", "GENE_OR_GENE_PRODUCT", 419, 422], ["Ang II", "PROTEIN", 0, 6], ["angiotensin II", "PROTEIN", 8, 22], ["ACE", "PROTEIN", 24, 27], ["angiotensin-converting enzyme", "PROTEIN", 29, 58], ["ACE2", "PROTEIN", 60, 64], ["angiotensin-converting enzyme 2", "PROTEIN", 66, 97], ["AT1R", "PROTEIN", 146, 150], ["angiotensin II type-1 receptor", "PROTEIN", 152, 182], ["glycoprotein protein", "PROTEIN", 364, 384], ["ACE", "PROTEIN", 419, 422], ["SARS-CoV", "SPECIES", 229, 237], ["severe acute respiratory syndrome coronavirus", "SPECIES", 239, 284], ["SARS-CoV-2, severe acute respiratory syndrome coronavirus", "SPECIES", 286, 343], ["Ang II, angiotensin II", "PROBLEM", 0, 22], ["ACE", "TREATMENT", 24, 27], ["angiotensin", "TEST", 29, 40], ["converting enzyme", "TREATMENT", 41, 58], ["ACE2", "TEST", 60, 64], ["angiotensin", "TREATMENT", 66, 77], ["converting enzyme", "TREATMENT", 78, 95], ["ACEI", "TREATMENT", 99, 103], ["angiotensin", "TREATMENT", 105, 116], ["converting enzyme inhibitor", "TREATMENT", 117, 144], ["AT1R", "TREATMENT", 146, 150], ["angiotensin II type", "TREATMENT", 152, 171], ["ARB", "TREATMENT", 184, 187], ["angiotensin II type", "TREATMENT", 189, 208], ["1 receptor blocker", "TREATMENT", 209, 227], ["SARS", "PROBLEM", 229, 233], ["CoV", "PROBLEM", 234, 237], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 239, 284], ["SARS", "PROBLEM", 286, 290], ["CoV", "TEST", 291, 294], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 298, 343], ["S-protein", "TEST", 347, 356], ["spike-glycoprotein protein levels", "TEST", 358, 391], ["ACE levels", "TEST", 419, 429], ["severe", "OBSERVATION_MODIFIER", 239, 245], ["acute", "OBSERVATION_MODIFIER", 246, 251], ["respiratory syndrome", "OBSERVATION", 252, 272], ["severe", "OBSERVATION_MODIFIER", 298, 304], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["respiratory syndrome", "OBSERVATION", 311, 331]]], ["These findings are consistent with the previous observation that coronaviruses specifically downregulate ACE2 expression in host cells, depending on virus replication [29] .", [["cells", "ANATOMY", 129, 134], ["coronaviruses", "ORGANISM", 65, 78], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["host cells", "CELL", 124, 134], ["ACE2", "PROTEIN", 105, 109], ["host cells", "CELL_TYPE", 124, 134], ["coronaviruses", "PROBLEM", 65, 78], ["ACE2 expression in host cells", "PROBLEM", 105, 134], ["virus replication", "TREATMENT", 149, 166], ["consistent with", "UNCERTAINTY", 19, 34], ["host cells", "OBSERVATION", 124, 134]]], ["In addition, SARS-CoV-induced acute lung injury is remarkably attenuated in ACE2 knockout mice compared with wild-type mice [27] .", [["lung", "ANATOMY", 36, 40], ["SARS", "DISEASE", 13, 17], ["lung injury", "DISEASE", 36, 47], ["SARS-CoV", "ORGANISM", 13, 21], ["lung", "ORGAN", 36, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["mice", "ORGANISM", 90, 94], ["mice", "ORGANISM", 119, 123], ["ACE2", "PROTEIN", 76, 80], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 119, 123], ["SARS-CoV", "SPECIES", 13, 21], ["mice", "SPECIES", 90, 94], ["SARS", "PROBLEM", 13, 17], ["acute lung injury", "PROBLEM", 30, 47], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["lung", "ANATOMY", 36, 40], ["injury", "OBSERVATION", 41, 47], ["attenuated", "OBSERVATION_MODIFIER", 62, 72]]], ["Lung angiotensin II levels increase in wild-type mice after SARS-CoV infection [27] .", [["Lung", "ANATOMY", 0, 4], ["angiotensin II", "CHEMICAL", 5, 19], ["SARS-CoV infection", "DISEASE", 60, 78], ["Lung", "ORGAN", 0, 4], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 5, 19], ["mice", "ORGANISM", 49, 53], ["SARS-CoV", "ORGANISM", 60, 68], ["mice", "SPECIES", 49, 53], ["mice", "SPECIES", 49, 53], ["SARS-CoV", "SPECIES", 60, 68], ["Lung angiotensin II levels", "TEST", 0, 26], ["SARS", "PROBLEM", 60, 64], ["CoV infection", "PROBLEM", 65, 78], ["angiotensin", "OBSERVATION", 5, 16], ["increase", "OBSERVATION_MODIFIER", 27, 35]]], ["Acid aspiration mice, an ARDS model, show functional and pathological changes mimicking SARS-CoV-induced lung injury [30] .", [["lung", "ANATOMY", 105, 109], ["ARDS", "DISEASE", 25, 29], ["lung injury", "DISEASE", 105, 116], ["Acid", "SIMPLE_CHEMICAL", 0, 4], ["mice", "ORGANISM", 16, 20], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 88, 96], ["lung", "ORGAN", 105, 109], ["mice", "SPECIES", 16, 20], ["SARS-CoV", "SPECIES", 88, 96], ["Acid aspiration mice", "PROBLEM", 0, 20], ["an ARDS model", "TEST", 22, 35], ["functional and pathological changes mimicking SARS", "PROBLEM", 42, 92], ["lung injury", "PROBLEM", 105, 116], ["ARDS", "OBSERVATION", 25, 29], ["lung", "ANATOMY", 105, 109], ["injury", "OBSERVATION", 110, 116]]], ["The lung angiotensin II levels increase after acid aspiration, and SARS-CoV-S protein treatment elicits a further angiotensin II increase [27] .", [["lung", "ANATOMY", 4, 8], ["angiotensin II", "CHEMICAL", 9, 23], ["angiotensin II", "CHEMICAL", 114, 128], ["lung", "ORGAN", 4, 8], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 9, 23], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 114, 128], ["SARS-CoV-S protein", "PROTEIN", 67, 85], ["angiotensin II", "PROTEIN", 114, 128], ["The lung angiotensin II levels", "TEST", 0, 30], ["acid aspiration", "PROBLEM", 46, 61], ["SARS", "PROBLEM", 67, 71], ["CoV-S protein treatment", "TREATMENT", 72, 95], ["a further angiotensin II increase", "TREATMENT", 104, 137], ["lung", "ANATOMY", 4, 8], ["angiotensin", "OBSERVATION", 9, 20]]], ["Interestingly, exogenous recombinant ACE2 treatment rescues acid aspirationinduced acute lung injury [30] .", [["lung", "ANATOMY", 89, 93], ["acute lung injury", "DISEASE", 83, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["lung", "ORGAN", 89, 93], ["ACE2", "PROTEIN", 37, 41], ["exogenous recombinant ACE2 treatment", "TREATMENT", 15, 51], ["acid aspirationinduced acute lung injury", "PROBLEM", 60, 100], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["lung", "ANATOMY", 89, 93], ["injury", "OBSERVATION", 94, 100]]], ["Taking this evidence together, the following hypothesis has been raised for the mechanism underlying SARS-CoV-induced lung injury: SARS-CoV infection downregulates lung ACE2 and in turn, shifts the balance toward the dominance of the ACE/ angiotensin II/AT1R system over the ACE2/angiotensin 1-7/mas receptor system in the lung.", [["lung", "ANATOMY", 118, 122], ["lung", "ANATOMY", 164, 168], ["lung", "ANATOMY", 323, 327], ["SARS", "DISEASE", 101, 105], ["lung injury", "DISEASE", 118, 129], ["SARS", "DISEASE", 131, 135], ["infection", "DISEASE", 140, 149], ["angiotensin II", "CHEMICAL", 239, 253], ["angiotensin", "CHEMICAL", 280, 291], ["SARS-CoV", "ORGANISM", 101, 109], ["lung", "ORGAN", 118, 122], ["SARS-CoV", "ORGANISM", 131, 139], ["lung", "ORGAN", 164, 168], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["ACE", "GENE_OR_GENE_PRODUCT", 234, 237], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 239, 253], ["AT1R", "GENE_OR_GENE_PRODUCT", 254, 258], ["ACE2", "GENE_OR_GENE_PRODUCT", 275, 279], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 280, 295], ["lung", "ORGAN", 323, 327], ["lung ACE2", "PROTEIN", 164, 173], ["ACE", "PROTEIN", 234, 237], ["angiotensin II", "PROTEIN", 239, 253], ["AT1R", "PROTEIN", 254, 258], ["ACE2", "PROTEIN", 275, 279], ["angiotensin 1-7", "PROTEIN", 280, 295], ["SARS-CoV", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 131, 139], ["SARS", "PROBLEM", 101, 105], ["lung injury", "PROBLEM", 118, 129], ["SARS", "PROBLEM", 131, 135], ["CoV infection", "PROBLEM", 136, 149], ["lung ACE2", "PROBLEM", 164, 173], ["the ACE/ angiotensin II/AT1R system", "TREATMENT", 230, 265], ["the ACE2/angiotensin", "TREATMENT", 271, 291], ["SARS", "OBSERVATION", 101, 105], ["lung", "ANATOMY", 118, 122], ["injury", "OBSERVATION", 123, 129], ["CoV", "OBSERVATION_MODIFIER", 136, 139], ["infection", "OBSERVATION", 140, 149], ["lung", "ANATOMY", 164, 168], ["lung", "ANATOMY", 323, 327]]], ["As a result, noncompeting angiotensin II accumulation occurs, resulting in acute lung injury through AT1R activation [27] .SARS-It should be noted that a similar mechanism is proposed for the severe lung injury caused by the avian influenza A virus H5N1, which has spread worldwide in humans with a high mortality rate.", [["lung", "ANATOMY", 81, 85], ["lung", "ANATOMY", 199, 203], ["angiotensin II", "CHEMICAL", 26, 40], ["acute lung injury", "DISEASE", 75, 92], ["SARS", "DISEASE", 123, 127], ["lung injury", "DISEASE", 199, 210], ["influenza A virus H5N1", "DISEASE", 231, 253], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 26, 40], ["lung", "ORGAN", 81, 85], ["AT1R", "GENE_OR_GENE_PRODUCT", 101, 105], ["lung", "ORGAN", 199, 203], ["avian", "ORGANISM", 225, 230], ["influenza A virus H5N1", "ORGANISM", 231, 253], ["humans", "ORGANISM", 285, 291], ["angiotensin II", "PROTEIN", 26, 40], ["AT1R", "PROTEIN", 101, 105], ["avian influenza", "SPECIES", 225, 240], ["A virus H5N1", "SPECIES", 241, 253], ["humans", "SPECIES", 285, 291], ["avian influenza A virus H5N1", "SPECIES", 225, 253], ["humans", "SPECIES", 285, 291], ["noncompeting angiotensin II accumulation", "PROBLEM", 13, 53], ["acute lung injury through AT1R activation", "PROBLEM", 75, 116], ["SARS", "PROBLEM", 123, 127], ["the severe lung injury", "PROBLEM", 188, 210], ["the avian influenza A virus H5N1", "PROBLEM", 221, 253], ["a high mortality rate", "PROBLEM", 297, 318], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["lung", "ANATOMY", 81, 85], ["injury", "OBSERVATION", 86, 92], ["severe", "OBSERVATION_MODIFIER", 192, 198], ["lung", "ANATOMY", 199, 203], ["injury", "OBSERVATION", 204, 210]]], ["After H5N1 virus infection in mice, lung ACE2 expression is downregulated, and serum angiotensin II levels increase [31] .", [["lung", "ANATOMY", 36, 40], ["serum", "ANATOMY", 79, 84], ["H5N1 virus infection", "DISEASE", 6, 26], ["angiotensin II", "CHEMICAL", 85, 99], ["H5N1 virus", "ORGANISM", 6, 16], ["mice", "ORGANISM", 30, 34], ["lung", "ORGAN", 36, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 85, 99], ["ACE2", "PROTEIN", 41, 45], ["serum angiotensin II", "PROTEIN", 79, 99], ["H5N1 virus", "SPECIES", 6, 16], ["mice", "SPECIES", 30, 34], ["H5N1 virus", "SPECIES", 6, 16], ["mice", "SPECIES", 30, 34], ["H5N1 virus infection", "PROBLEM", 6, 26], ["lung ACE2 expression", "TEST", 36, 56], ["serum angiotensin II levels", "TEST", 79, 106], ["lung", "ANATOMY", 36, 40]]], ["Acute lung injury is augmented by ACE2 knockout in H5N1-infected mice, while the administration of recombinant human ACE2 ameliorates H5N1-induced lung injury in mice [31] .", [["lung", "ANATOMY", 6, 10], ["lung", "ANATOMY", 147, 151], ["lung injury", "DISEASE", 6, 17], ["H5N1-infected", "DISEASE", 51, 64], ["H5N1", "DISEASE", 134, 138], ["lung injury", "DISEASE", 147, 158], ["lung", "ORGAN", 6, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["H5N1-infected", "ORGANISM", 51, 64], ["mice", "ORGANISM", 65, 69], ["human", "ORGANISM", 111, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 117, 121], ["H5N1", "ORGANISM", 134, 138], ["lung", "ORGAN", 147, 151], ["mice", "ORGANISM", 162, 166], ["ACE2", "PROTEIN", 34, 38], ["recombinant human ACE2", "PROTEIN", 99, 121], ["mice", "SPECIES", 65, 69], ["human", "SPECIES", 111, 116], ["mice", "SPECIES", 162, 166], ["mice", "SPECIES", 65, 69], ["human", "SPECIES", 111, 116], ["mice", "SPECIES", 162, 166], ["Acute lung injury", "PROBLEM", 0, 17], ["H5N1", "PROBLEM", 51, 55], ["recombinant human ACE2 ameliorates", "TREATMENT", 99, 133], ["H5N1", "PROBLEM", 134, 138], ["lung injury", "PROBLEM", 147, 158], ["lung", "ANATOMY", 6, 10], ["injury", "OBSERVATION", 11, 17], ["lung", "ANATOMY", 147, 151], ["injury", "OBSERVATION", 152, 158]]], ["Moreover, in other mouse models of acute lung injury/ ARDS, such as acid aspiration, sepsis, and drug-induced lung fibrosis, it has been shown that ACE2 expression is downregulated in response to noxious stimuli and that acute lung injury is aggravated by ACE2 knockout and rescued by exogenous ACE2 administration or AT1R knockout [30, 32] .", [["lung", "ANATOMY", 41, 45], ["lung", "ANATOMY", 110, 114], ["lung", "ANATOMY", 227, 231], ["acute lung injury", "DISEASE", 35, 52], ["ARDS", "DISEASE", 54, 58], ["sepsis", "DISEASE", 85, 91], ["lung fibrosis", "DISEASE", 110, 123], ["lung injury", "DISEASE", 227, 238], ["mouse", "ORGANISM", 19, 24], ["lung", "ORGAN", 41, 45], ["lung", "ORGAN", 110, 114], ["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["lung", "ORGAN", 227, 231], ["ACE2", "GENE_OR_GENE_PRODUCT", 256, 260], ["ACE2", "GENE_OR_GENE_PRODUCT", 295, 299], ["AT1R", "GENE_OR_GENE_PRODUCT", 318, 322], ["ACE2", "PROTEIN", 148, 152], ["ACE2", "PROTEIN", 256, 260], ["ACE2", "PROTEIN", 295, 299], ["AT1R", "PROTEIN", 318, 322], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 19, 24], ["acute lung injury", "PROBLEM", 35, 52], ["ARDS", "PROBLEM", 54, 58], ["acid aspiration", "PROBLEM", 68, 83], ["sepsis", "PROBLEM", 85, 91], ["drug-induced lung fibrosis", "PROBLEM", 97, 123], ["ACE2 expression", "PROBLEM", 148, 163], ["noxious stimuli", "TEST", 196, 211], ["acute lung injury", "PROBLEM", 221, 238], ["exogenous ACE2 administration", "TREATMENT", 285, 314], ["AT1R knockout", "TEST", 318, 331], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["lung", "ANATOMY", 41, 45], ["injury", "OBSERVATION", 46, 52], ["ARDS", "OBSERVATION", 54, 58], ["sepsis", "OBSERVATION", 85, 91], ["lung", "ANATOMY", 110, 114], ["fibrosis", "OBSERVATION", 115, 123], ["acute", "OBSERVATION_MODIFIER", 221, 226], ["lung", "ANATOMY", 227, 231], ["injury", "OBSERVATION", 232, 238]]], ["Accordingly, it is suggested that the angiotensin II/ AT1R-induced aggravation resulting from ACE2 downregulation and the protective effects of ACE2 are not specific to lung injury in SARS but rather may be common to acute lung injury/ARDS induced by various viral infections and lung diseases.Effects of RAS inhibitors on ACE2 and SARS-CoV-induced lung injurySeveral kinds of ARBs (e.g., olmesartan, telmisartan, losartan, and azilsartan) have been shown to increase the mRNA or protein levels of ACE2 in animal models of heart diseases (hypertensive hypertrophy, autoimmune myocarditis, dilated cardiomyopathy, myocardial infarction, and diabetic cardiomyopathy) [8] [9] [10] [11] [12] [13] [14] and chronic kidney disease (hypertensive nephropathy and diabetic nephropathy) [15, 16] , as well as normal rat heart and renal vasculature [17, 18] and hypertensive rat aorta (but not the carotid artery) [19, 20] .", [["lung", "ANATOMY", 169, 173], ["lung", "ANATOMY", 223, 227], ["lung", "ANATOMY", 280, 284], ["lung", "ANATOMY", 349, 353], ["heart", "ANATOMY", 523, 528], ["myocardial", "ANATOMY", 613, 623], ["kidney", "ANATOMY", 710, 716], ["heart", "ANATOMY", 810, 815], ["renal vasculature", "ANATOMY", 820, 837], ["aorta", "ANATOMY", 868, 873], ["carotid artery", "ANATOMY", 887, 901], ["angiotensin II", "CHEMICAL", 38, 52], ["lung injury", "DISEASE", 169, 180], ["SARS", "DISEASE", 184, 188], ["acute lung injury", "DISEASE", 217, 234], ["ARDS", "DISEASE", 235, 239], ["viral infections", "DISEASE", 259, 275], ["lung diseases", "DISEASE", 280, 293], ["ARBs", "CHEMICAL", 377, 381], ["olmesartan", "CHEMICAL", 389, 399], ["telmisartan", "CHEMICAL", 401, 412], ["losartan", "CHEMICAL", 414, 422], ["azilsartan", "CHEMICAL", 428, 438], ["heart diseases", "DISEASE", 523, 537], ["hypertensive hypertrophy", "DISEASE", 539, 563], ["autoimmune myocarditis", "DISEASE", 565, 587], ["dilated cardiomyopathy", "DISEASE", 589, 611], ["myocardial infarction", "DISEASE", 613, 634], ["diabetic cardiomyopathy", "DISEASE", 640, 663], ["8] [9] [10] [11] [12] [13] [14]", "CHEMICAL", 666, 697], ["chronic kidney disease", "DISEASE", 702, 724], ["hypertensive nephropathy", "DISEASE", 726, 750], ["diabetic nephropathy", "DISEASE", 755, 775], ["hypertensive", "DISEASE", 851, 863], ["olmesartan", "CHEMICAL", 389, 399], ["telmisartan", "CHEMICAL", 401, 412], ["losartan", "CHEMICAL", 414, 422], ["azilsartan", "CHEMICAL", 428, 438], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 38, 52], ["AT1R", "GENE_OR_GENE_PRODUCT", 54, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 94, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 144, 148], ["lung", "ORGAN", 169, 173], ["lung", "ORGAN", 223, 227], ["lung", "ORGAN", 280, 284], ["RAS", "GENE_OR_GENE_PRODUCT", 305, 308], ["ACE2", "GENE_OR_GENE_PRODUCT", 323, 327], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 332, 340], ["lung", "ORGAN", 349, 353], ["ARBs", "SIMPLE_CHEMICAL", 377, 381], ["olmesartan", "SIMPLE_CHEMICAL", 389, 399], ["telmisartan", "SIMPLE_CHEMICAL", 401, 412], ["losartan", "SIMPLE_CHEMICAL", 414, 422], ["azilsartan", "SIMPLE_CHEMICAL", 428, 438], ["ACE2", "GENE_OR_GENE_PRODUCT", 498, 502], ["heart", "ORGAN", 523, 528], ["myocardial", "MULTI-TISSUE_STRUCTURE", 613, 623], ["diabetic cardiomyopathy) [8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 640, 697], ["kidney", "ORGAN", 710, 716], ["rat", "ORGANISM", 806, 809], ["heart", "ORGAN", 810, 815], ["renal vasculature", "MULTI-TISSUE_STRUCTURE", 820, 837], ["rat", "ORGANISM", 864, 867], ["aorta", "MULTI-TISSUE_STRUCTURE", 868, 873], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 887, 901], ["angiotensin II", "PROTEIN", 38, 52], ["AT1R", "PROTEIN", 54, 58], ["ACE2", "PROTEIN", 94, 98], ["ACE2", "PROTEIN", 144, 148], ["ACE2", "PROTEIN", 323, 327], ["ACE2", "PROTEIN", 498, 502], ["rat", "SPECIES", 806, 809], ["rat", "SPECIES", 864, 867], ["SARS-CoV", "SPECIES", 332, 340], ["the angiotensin II/ AT1R", "TREATMENT", 34, 58], ["induced aggravation", "PROBLEM", 59, 78], ["ACE2 downregulation", "PROBLEM", 94, 113], ["ACE2", "TREATMENT", 144, 148], ["lung injury", "PROBLEM", 169, 180], ["SARS", "PROBLEM", 184, 188], ["acute lung injury", "PROBLEM", 217, 234], ["ARDS", "PROBLEM", 235, 239], ["various viral infections", "PROBLEM", 251, 275], ["lung diseases", "PROBLEM", 280, 293], ["RAS inhibitors", "TREATMENT", 305, 319], ["ACE2", "TEST", 323, 327], ["SARS", "TEST", 332, 336], ["CoV", "TEST", 337, 340], ["ARBs", "TREATMENT", 377, 381], ["olmesartan", "TREATMENT", 389, 399], ["telmisartan", "TREATMENT", 401, 412], ["losartan", "TREATMENT", 414, 422], ["azilsartan", "TREATMENT", 428, 438], ["protein levels", "TEST", 480, 494], ["ACE2", "TEST", 498, 502], ["heart diseases", "PROBLEM", 523, 537], ["hypertensive hypertrophy", "PROBLEM", 539, 563], ["autoimmune myocarditis", "PROBLEM", 565, 587], ["dilated cardiomyopathy", "PROBLEM", 589, 611], ["myocardial infarction", "PROBLEM", 613, 634], ["diabetic cardiomyopathy", "PROBLEM", 640, 663], ["chronic kidney disease", "PROBLEM", 702, 724], ["hypertensive nephropathy", "PROBLEM", 726, 750], ["diabetic nephropathy", "PROBLEM", 755, 775], ["hypertensive rat aorta", "PROBLEM", 851, 873], ["lung", "ANATOMY", 169, 173], ["injury", "OBSERVATION", 174, 180], ["acute", "OBSERVATION_MODIFIER", 217, 222], ["lung", "ANATOMY", 223, 227], ["injury", "OBSERVATION", 228, 234], ["ARDS", "OBSERVATION", 235, 239], ["various", "OBSERVATION_MODIFIER", 251, 258], ["viral", "OBSERVATION_MODIFIER", 259, 264], ["infections", "OBSERVATION", 265, 275], ["lung", "ANATOMY", 280, 284], ["diseases", "OBSERVATION", 285, 293], ["lung", "ANATOMY", 349, 353], ["heart", "ANATOMY", 523, 528], ["diseases", "OBSERVATION", 529, 537], ["hypertensive", "OBSERVATION_MODIFIER", 539, 551], ["hypertrophy", "OBSERVATION", 552, 563], ["autoimmune myocarditis", "OBSERVATION", 565, 587], ["dilated", "OBSERVATION_MODIFIER", 589, 596], ["cardiomyopathy", "OBSERVATION", 597, 611], ["myocardial", "ANATOMY", 613, 623], ["infarction", "OBSERVATION", 624, 634], ["chronic", "OBSERVATION_MODIFIER", 702, 709], ["kidney", "ANATOMY", 710, 716], ["disease", "OBSERVATION", 717, 724], ["hypertensive", "OBSERVATION_MODIFIER", 726, 738], ["nephropathy", "OBSERVATION", 739, 750], ["diabetic", "OBSERVATION_MODIFIER", 755, 763], ["nephropathy", "OBSERVATION", 764, 775], ["normal", "OBSERVATION", 799, 805], ["rat", "ANATOMY_MODIFIER", 806, 809], ["heart", "ANATOMY", 810, 815], ["renal vasculature", "ANATOMY", 820, 837], ["hypertensive", "OBSERVATION", 851, 863], ["aorta", "ANATOMY", 868, 873], ["carotid artery", "ANATOMY", 887, 901]]], ["ACEI does not inhibit ACE2 as a pharmacological property.", [["ACEI", "CHEMICAL", 0, 4], ["ACEI", "SIMPLE_CHEMICAL", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["ACE2", "PROTEIN", 22, 26], ["ACEI", "TREATMENT", 0, 4]]], ["In normal rats, lisinopril has been shown to modestly increase cardiac ACE2 mRNA levels c Effects of losartan (15 mg/kg) on lung edema (wet/dry weight ratio) in acid plus spike-Fc protein-treated mice (n = 4-6 per group).", [["cardiac", "ANATOMY", 63, 70], ["lung", "ANATOMY", 124, 128], ["lisinopril", "CHEMICAL", 16, 26], ["losartan", "CHEMICAL", 101, 109], ["lung edema", "DISEASE", 124, 134], ["lisinopril", "CHEMICAL", 16, 26], ["losartan", "CHEMICAL", 101, 109], ["rats", "ORGANISM", 10, 14], ["lisinopril", "SIMPLE_CHEMICAL", 16, 26], ["cardiac", "ORGAN", 63, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["losartan", "SIMPLE_CHEMICAL", 101, 109], ["lung", "ORGAN", 124, 128], ["edema", "PATHOLOGICAL_FORMATION", 129, 134], ["mice", "ORGANISM", 196, 200], ["ACE2 mRNA", "RNA", 71, 80], ["Fc protein", "PROTEIN", 177, 187], ["rats", "SPECIES", 10, 14], ["mice", "SPECIES", 196, 200], ["mice", "SPECIES", 196, 200], ["lisinopril", "TREATMENT", 16, 26], ["losartan", "TREATMENT", 101, 109], ["lung edema", "PROBLEM", 124, 134], ["wet/dry weight ratio", "TEST", 136, 156], ["acid plus spike", "TEST", 161, 176], ["Fc protein", "TEST", 177, 187], ["normal rats", "OBSERVATION", 3, 14], ["lung", "ANATOMY", 124, 128], ["edema", "OBSERVATION", 129, 134]]], ["P < 0.05 vs. vehicle-treated wild-type mice after acid injury.", [["vehicle", "SIMPLE_CHEMICAL", 13, 20], ["mice", "ORGANISM", 39, 43], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["acid injury", "PROBLEM", 50, 61]]], ["AT1, angiotensin II type-1 receptor.", [["angiotensin II", "CHEMICAL", 5, 19], ["AT1", "GENE_OR_GENE_PRODUCT", 0, 3], ["angiotensin II type-1 receptor", "GENE_OR_GENE_PRODUCT", 5, 35], ["AT1", "PROTEIN", 0, 3], ["angiotensin II type-1 receptor", "PROTEIN", 5, 35], ["AT1", "PROBLEM", 0, 3], ["angiotensin II type-1 receptor", "TREATMENT", 5, 35]]], ["[27] while not changing cardiac ACE2 activity [17] .", [["cardiac", "ANATOMY", 24, 31], ["cardiac", "ORGAN", 24, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["ACE2", "PROTEIN", 32, 36]]], ["In the myocardial infarction model, valsartan, ramipril, and their combination have no effects on cardiac ACE2 expression [33] .", [["myocardial", "ANATOMY", 7, 17], ["cardiac", "ANATOMY", 98, 105], ["myocardial infarction", "DISEASE", 7, 28], ["valsartan", "CHEMICAL", 36, 45], ["ramipril", "CHEMICAL", 47, 55], ["valsartan", "CHEMICAL", 36, 45], ["ramipril", "CHEMICAL", 47, 55], ["myocardial", "MULTI-TISSUE_STRUCTURE", 7, 17], ["valsartan", "SIMPLE_CHEMICAL", 36, 45], ["ramipril", "SIMPLE_CHEMICAL", 47, 55], ["cardiac", "ORGAN", 98, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 106, 110], ["ACE2", "PROTEIN", 106, 110], ["the myocardial infarction model", "PROBLEM", 3, 34], ["valsartan", "TREATMENT", 36, 45], ["ramipril", "TREATMENT", 47, 55], ["myocardial", "ANATOMY", 7, 17], ["infarction", "OBSERVATION", 18, 28]]], ["It should be noted that the doses of ARBs and ACEIs used in these animal studies were much greater than those in clinical practice so that the observed effects of these drugs on ACE2 expression and activity could not be extrapolated to clinical situations in humans.", [["ARBs", "CHEMICAL", 37, 41], ["ACEIs", "CHEMICAL", 46, 51], ["ARBs", "SIMPLE_CHEMICAL", 37, 41], ["ACEIs", "SIMPLE_CHEMICAL", 46, 51], ["ACE2", "GENE_OR_GENE_PRODUCT", 178, 182], ["humans", "ORGANISM", 259, 265], ["ACE2", "PROTEIN", 178, 182], ["humans", "SPECIES", 259, 265], ["humans", "SPECIES", 259, 265], ["ARBs", "TREATMENT", 37, 41], ["ACEIs", "TREATMENT", 46, 51], ["these animal studies", "TEST", 60, 80], ["these drugs", "TREATMENT", 163, 174], ["ACE2 expression", "TREATMENT", 178, 193]]], ["Importantly, no clinical data exist regarding the effects of ARBs and ACEIs on human tissue ACE2 expression or activity in vivo.", [["tissue", "ANATOMY", 85, 91], ["ARBs", "CHEMICAL", 61, 65], ["ACEIs", "CHEMICAL", 70, 75], ["ARBs", "SIMPLE_CHEMICAL", 61, 65], ["ACEIs", "SIMPLE_CHEMICAL", 70, 75], ["human", "ORGANISM", 79, 84], ["tissue", "TISSUE", 85, 91], ["ACE2", "GENE_OR_GENE_PRODUCT", 92, 96], ["ACE2", "PROTEIN", 92, 96], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["clinical data", "TEST", 16, 29], ["ARBs", "TREATMENT", 61, 65], ["ACEIs", "TREATMENT", 70, 75], ["human tissue ACE2 expression", "TREATMENT", 79, 107]]], ["Although there are several clinical studies investigating the changes in plasma or urine levels of the soluble form of ACE2 in hypertension and CVD patients receiving ARBs or ACEIs, the soluble form of ACE2 in the plasma and urine is not a reliable indicator of the activity of tissue ACE2, namely, membrane-bound ACE2 [22] .", [["plasma", "ANATOMY", 73, 79], ["urine", "ANATOMY", 83, 88], ["plasma", "ANATOMY", 214, 220], ["urine", "ANATOMY", 225, 230], ["tissue", "ANATOMY", 278, 284], ["membrane", "ANATOMY", 299, 307], ["hypertension", "DISEASE", 127, 139], ["CVD", "DISEASE", 144, 147], ["plasma", "ORGANISM_SUBSTANCE", 73, 79], ["urine", "ORGANISM_SUBSTANCE", 83, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 119, 123], ["patients", "ORGANISM", 148, 156], ["ARBs", "SIMPLE_CHEMICAL", 167, 171], ["ACEIs", "SIMPLE_CHEMICAL", 175, 180], ["ACE2", "GENE_OR_GENE_PRODUCT", 202, 206], ["plasma", "ORGANISM_SUBSTANCE", 214, 220], ["urine", "ORGANISM_SUBSTANCE", 225, 230], ["tissue", "TISSUE", 278, 284], ["ACE2", "GENE_OR_GENE_PRODUCT", 285, 289], ["membrane", "CELLULAR_COMPONENT", 299, 307], ["ACE2", "GENE_OR_GENE_PRODUCT", 314, 318], ["ACE2", "PROTEIN", 119, 123], ["ACE2", "PROTEIN", 202, 206], ["ACE2", "PROTEIN", 285, 289], ["ACE2", "PROTEIN", 314, 318], ["patients", "SPECIES", 148, 156], ["several clinical studies", "TEST", 19, 43], ["the changes in plasma", "PROBLEM", 58, 79], ["urine levels", "TEST", 83, 95], ["ACE2", "PROBLEM", 119, 123], ["hypertension", "PROBLEM", 127, 139], ["CVD", "PROBLEM", 144, 147], ["ARBs", "TREATMENT", 167, 171], ["ACEIs", "TREATMENT", 175, 180], ["ACE2", "TEST", 202, 206], ["the plasma and urine", "TEST", 210, 230], ["hypertension", "OBSERVATION", 127, 139]]], ["Importantly, there are no data on the effects of ARBs and ACEIs on lung ACE2 expression either in animal models or humans.", [["lung", "ANATOMY", 67, 71], ["ARBs", "CHEMICAL", 49, 53], ["ACEIs", "CHEMICAL", 58, 63], ["ARBs", "SIMPLE_CHEMICAL", 49, 53], ["ACEIs", "SIMPLE_CHEMICAL", 58, 63], ["lung", "ORGAN", 67, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["humans", "ORGANISM", 115, 121], ["ACE2", "PROTEIN", 72, 76], ["humans", "SPECIES", 115, 121], ["humans", "SPECIES", 115, 121], ["ARBs", "TREATMENT", 49, 53], ["ACEIs", "TREATMENT", 58, 63], ["lung ACE2 expression", "TREATMENT", 67, 87], ["no", "UNCERTAINTY", 23, 25], ["lung", "ANATOMY", 67, 71], ["ACE2 expression", "OBSERVATION", 72, 87]]], ["It is still unknown whether the changes in ACE2 levels (for example, ARB-induced upregulation) actually facilitate greater engagement and entry of SARS-CoV and other viruses, even in animal models.Effects of RAS inhibitors on ACE2 and SARS-CoV-induced lung injuryOn the other hand, it has been shown that pretreatment with losartan, an ARB, ameliorates acute pulmonary edema and lung injury in SARS-CoV-S protein-treated mice after acid aspiration (Fig. 2) [27] .", [["lung", "ANATOMY", 252, 256], ["pulmonary", "ANATOMY", 359, 368], ["lung", "ANATOMY", 379, 383], ["ARB", "CHEMICAL", 69, 72], ["SARS", "DISEASE", 147, 151], ["losartan", "CHEMICAL", 323, 331], ["ARB", "CHEMICAL", 336, 339], ["acute pulmonary edema", "DISEASE", 353, 374], ["lung injury", "DISEASE", 379, 390], ["SARS", "DISEASE", 394, 398], ["losartan", "CHEMICAL", 323, 331], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["ARB", "SIMPLE_CHEMICAL", 69, 72], ["SARS-CoV", "ORGANISM", 147, 155], ["RAS", "GENE_OR_GENE_PRODUCT", 208, 211], ["ACE2", "GENE_OR_GENE_PRODUCT", 226, 230], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 235, 243], ["lung", "ORGAN", 252, 256], ["losartan", "SIMPLE_CHEMICAL", 323, 331], ["ARB", "SIMPLE_CHEMICAL", 336, 339], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 359, 374], ["lung", "ORGAN", 379, 383], ["SARS-CoV-S protein", "GENE_OR_GENE_PRODUCT", 394, 412], ["mice", "ORGANISM", 421, 425], ["ACE2", "PROTEIN", 43, 47], ["ACE2", "PROTEIN", 226, 230], ["S protein", "PROTEIN", 403, 412], ["mice", "SPECIES", 421, 425], ["SARS-CoV", "SPECIES", 147, 155], ["SARS-CoV", "SPECIES", 235, 243], ["SARS-CoV", "SPECIES", 394, 402], ["mice", "SPECIES", 421, 425], ["the changes in ACE2 levels", "PROBLEM", 28, 54], ["ARB", "TEST", 69, 72], ["SARS", "PROBLEM", 147, 151], ["CoV", "PROBLEM", 152, 155], ["other viruses", "PROBLEM", 160, 173], ["RAS inhibitors", "TREATMENT", 208, 222], ["ACE2", "TEST", 226, 230], ["SARS", "PROBLEM", 235, 239], ["CoV", "PROBLEM", 240, 243], ["losartan", "TREATMENT", 323, 331], ["an ARB", "TREATMENT", 333, 339], ["acute pulmonary edema", "PROBLEM", 353, 374], ["lung injury", "PROBLEM", 379, 390], ["SARS", "PROBLEM", 394, 398], ["CoV", "TEST", 399, 402], ["S protein", "TEST", 403, 412], ["acid aspiration", "PROBLEM", 432, 447], ["lung", "ANATOMY", 252, 256], ["injuryOn", "OBSERVATION", 257, 265], ["acute", "OBSERVATION_MODIFIER", 353, 358], ["pulmonary", "ANATOMY", 359, 368], ["edema", "OBSERVATION", 369, 374], ["lung", "ANATOMY", 379, 383], ["injury", "OBSERVATION", 384, 390]]], ["Taken together with the lung angiotensin II level elevation [27] , this evidence suggested that even after considering the speculation that viral load would be enhanced by ACE2 upregulation, the net effects of ARBs would be favorable to prevent SARS-CoVinduced acute lung injury in this model.", [["lung", "ANATOMY", 24, 28], ["lung", "ANATOMY", 267, 271], ["angiotensin II", "CHEMICAL", 29, 43], ["ARBs", "CHEMICAL", 210, 214], ["SARS", "DISEASE", 245, 249], ["lung injury", "DISEASE", 267, 278], ["lung", "ORGAN", 24, 28], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 29, 43], ["ACE2", "GENE_OR_GENE_PRODUCT", 172, 176], ["ARBs", "SIMPLE_CHEMICAL", 210, 214], ["lung", "ORGAN", 267, 271], ["lung angiotensin II", "PROTEIN", 24, 43], ["ACE2", "PROTEIN", 172, 176], ["the lung angiotensin II level elevation", "PROBLEM", 20, 59], ["viral load", "PROBLEM", 140, 150], ["ACE2 upregulation", "TREATMENT", 172, 189], ["ARBs", "TREATMENT", 210, 214], ["SARS", "PROBLEM", 245, 249], ["CoVinduced acute lung injury", "PROBLEM", 250, 278], ["lung", "ANATOMY", 24, 28], ["angiotensin", "OBSERVATION", 29, 40], ["viral load", "OBSERVATION", 140, 150], ["acute", "OBSERVATION_MODIFIER", 261, 266], ["lung", "ANATOMY", 267, 271], ["injury", "OBSERVATION", 272, 278]]], ["In addition, there is another possibility that the ARB pretreatment-induced baseline ACE2 increase prior to SARS-CoV infection would result in higher ACE2 levels that remained after SARS-CoV-induced downregulation and consequently conferred protection against lung injury in this model [22, 34] .", [["lung", "ANATOMY", 260, 264], ["ARB", "CHEMICAL", 51, 54], ["SARS", "DISEASE", 108, 112], ["infection", "DISEASE", 117, 126], ["lung injury", "DISEASE", 260, 271], ["ARB", "SIMPLE_CHEMICAL", 51, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["SARS-CoV", "ORGANISM", 108, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 150, 154], ["CoV", "ORGANISM", 187, 190], ["lung", "ORGAN", 260, 264], ["ACE2", "PROTEIN", 85, 89], ["ACE2", "PROTEIN", 150, 154], ["SARS-CoV", "SPECIES", 108, 116], ["the ARB pretreatment", "PROBLEM", 47, 67], ["baseline ACE2 increase", "PROBLEM", 76, 98], ["SARS", "PROBLEM", 108, 112], ["CoV infection", "PROBLEM", 113, 126], ["higher ACE2 levels", "PROBLEM", 143, 161], ["SARS", "PROBLEM", 182, 186], ["induced downregulation", "PROBLEM", 191, 213], ["lung injury", "PROBLEM", 260, 271], ["another possibility", "UNCERTAINTY", 22, 41], ["lung", "ANATOMY", 260, 264], ["injury", "OBSERVATION", 265, 271]]], ["However, in interpreting the results of this study, it should be noted that the effects of losartan have been observed merely in mice treated with SARS-CoV-S protein in addition to acid aspiration but not in mice treated with SARS-CoV-S protein alone.", [["losartan", "CHEMICAL", 91, 99], ["losartan", "CHEMICAL", 91, 99], ["losartan", "SIMPLE_CHEMICAL", 91, 99], ["mice", "ORGANISM", 129, 133], ["SARS-CoV-S protein", "GENE_OR_GENE_PRODUCT", 147, 165], ["mice", "ORGANISM", 208, 212], ["SARS-CoV-S protein", "GENE_OR_GENE_PRODUCT", 226, 244], ["SARS-CoV-S protein", "PROTEIN", 147, 165], ["SARS-CoV-S protein", "PROTEIN", 226, 244], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 208, 212], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 208, 212], ["this study", "TEST", 40, 50], ["losartan", "TREATMENT", 91, 99], ["SARS", "PROBLEM", 147, 151], ["CoV-S protein", "TREATMENT", 152, 165], ["acid aspiration", "PROBLEM", 181, 196], ["SARS", "PROBLEM", 226, 230], ["CoV-S protein alone", "TREATMENT", 231, 250], ["aspiration", "OBSERVATION", 186, 196]]], ["Additionally, data on lung ACE2 levels before and after treatment with SARS-CoV-S protein and acid aspiration are lacking in mice pretreated with or without losartan.Current evidence in COVID-19Earlier studies reported that the case fatality rate was high in COVID-19 patients with comorbidities such as older age, hypertension, diabetes mellitus, CVD, chronic pulmonary disease, and malignancy [3, 4] .", [["lung", "ANATOMY", 22, 26], ["pulmonary", "ANATOMY", 361, 370], ["losartan", "CHEMICAL", 157, 165], ["hypertension", "DISEASE", 315, 327], ["diabetes mellitus", "DISEASE", 329, 346], ["CVD", "DISEASE", 348, 351], ["chronic pulmonary disease", "DISEASE", 353, 378], ["malignancy", "DISEASE", 384, 394], ["losartan", "CHEMICAL", 157, 165], ["lung", "ORGAN", 22, 26], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["SARS-CoV-S protein", "GENE_OR_GENE_PRODUCT", 71, 89], ["mice", "ORGANISM", 125, 129], ["losartan", "SIMPLE_CHEMICAL", 157, 165], ["patients", "ORGANISM", 268, 276], ["pulmonary", "ORGAN", 361, 370], ["ACE2", "PROTEIN", 27, 31], ["SARS-CoV-S protein", "PROTEIN", 71, 89], ["mice", "SPECIES", 125, 129], ["patients", "SPECIES", 268, 276], ["mice", "SPECIES", 125, 129], ["lung ACE2 levels", "TEST", 22, 38], ["treatment", "TREATMENT", 56, 65], ["SARS", "PROBLEM", 71, 75], ["CoV-S protein", "TREATMENT", 76, 89], ["acid aspiration", "PROBLEM", 94, 109], ["losartan", "TREATMENT", 157, 165], ["fatality rate", "TEST", 233, 246], ["comorbidities", "PROBLEM", 282, 295], ["hypertension", "PROBLEM", 315, 327], ["diabetes mellitus", "PROBLEM", 329, 346], ["CVD", "PROBLEM", 348, 351], ["chronic pulmonary disease", "PROBLEM", 353, 378], ["malignancy", "PROBLEM", 384, 394], ["lung", "ANATOMY", 22, 26], ["hypertension", "OBSERVATION", 315, 327], ["diabetes mellitus", "OBSERVATION", 329, 346], ["chronic", "OBSERVATION_MODIFIER", 353, 360], ["pulmonary", "ANATOMY", 361, 370], ["disease", "OBSERVATION", 371, 378], ["malignancy", "OBSERVATION", 384, 394]]], ["Because patients with hypertension and CVD are likely treated with ACEIs or ARBs, the concern is raised regarding whether the use of ACEIs and ARBs may aggravate the morbidity and mortality of COVID-19 [21] .", [["hypertension", "DISEASE", 22, 34], ["CVD", "DISEASE", 39, 42], ["ACEIs", "CHEMICAL", 133, 138], ["ARBs", "CHEMICAL", 143, 147], ["COVID-19", "CHEMICAL", 193, 201], ["patients", "ORGANISM", 8, 16], ["ACEIs", "SIMPLE_CHEMICAL", 67, 72], ["ARBs", "SIMPLE_CHEMICAL", 76, 80], ["ACEIs", "SIMPLE_CHEMICAL", 133, 138], ["ARBs", "SIMPLE_CHEMICAL", 143, 147], ["patients", "SPECIES", 8, 16], ["hypertension", "PROBLEM", 22, 34], ["CVD", "PROBLEM", 39, 42], ["ACEIs", "TREATMENT", 67, 72], ["ARBs", "TREATMENT", 76, 80], ["ACEIs", "TREATMENT", 133, 138], ["ARBs", "TREATMENT", 143, 147], ["the morbidity", "PROBLEM", 162, 175], ["COVID", "TEST", 193, 198], ["hypertension", "OBSERVATION", 22, 34]]], ["However, it was possible that the observed phenomenon would result from reverse causality because older patients are at the highest risk for COVID-19 and concurrently tend to have multiple comorbidities, including hypertension and CVD, and because adjustments for age and other possible confounding factors were not performed in such earlier studies [22, 35, 36] .", [["hypertension", "DISEASE", 214, 226], ["CVD", "DISEASE", 231, 234], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["the observed phenomenon", "PROBLEM", 30, 53], ["COVID", "TEST", 141, 146], ["multiple comorbidities", "PROBLEM", 180, 202], ["hypertension", "PROBLEM", 214, 226], ["CVD", "PROBLEM", 231, 234], ["confounding factors", "PROBLEM", 287, 306], ["multiple", "OBSERVATION_MODIFIER", 180, 188], ["comorbidities", "OBSERVATION", 189, 202], ["hypertension", "OBSERVATION", 214, 226]]], ["Indeed, in a recent retrospective, multicenter cohort study enrolling 191 confirmed COVID-19 patients in Wuhan, China, multivariable regression analysis revealed that independent risk factors for in-hospital death are older age, higher Sequential Organ Failure Assessment score, and higher Ddimer levels at the early stage of COVID-19, although hypertension, diabetes, and coronary artery disease were not included [37] .Current evidence in COVID-19A small case study reported that plasma angiotensin II levels were markedly elevated and linearly associated with viral load and lung injury severity in COVID-19 pneumonia patients [38] .", [["coronary artery", "ANATOMY", 373, 388], ["plasma", "ANATOMY", 482, 488], ["lung", "ANATOMY", 578, 582], ["death", "DISEASE", 208, 213], ["hypertension", "DISEASE", 345, 357], ["diabetes", "DISEASE", 359, 367], ["coronary artery disease", "DISEASE", 373, 396], ["angiotensin II", "CHEMICAL", 489, 503], ["lung injury", "DISEASE", 578, 589], ["pneumonia", "DISEASE", 611, 620], ["patients", "ORGANISM", 93, 101], ["Ddimer", "GENE_OR_GENE_PRODUCT", 290, 296], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 373, 388], ["plasma", "ORGANISM_SUBSTANCE", 482, 488], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 489, 503], ["lung", "ORGAN", 578, 582], ["patients", "ORGANISM", 621, 629], ["Ddimer", "PROTEIN", 290, 296], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 621, 629], ["multicenter cohort study", "TEST", 35, 59], ["COVID", "TEST", 84, 89], ["multivariable regression analysis", "TEST", 119, 152], ["higher Sequential Organ Failure", "PROBLEM", 229, 260], ["Assessment score", "TEST", 261, 277], ["higher Ddimer levels", "PROBLEM", 283, 303], ["COVID", "TEST", 326, 331], ["hypertension", "PROBLEM", 345, 357], ["diabetes", "PROBLEM", 359, 367], ["coronary artery disease", "PROBLEM", 373, 396], ["COVID", "TEST", 441, 446], ["small case study", "TEST", 451, 467], ["plasma angiotensin II levels", "TEST", 482, 510], ["markedly elevated", "PROBLEM", 516, 533], ["viral load", "PROBLEM", 563, 573], ["lung injury severity", "PROBLEM", 578, 598], ["COVID", "TEST", 602, 607], ["pneumonia", "PROBLEM", 611, 620], ["hypertension", "OBSERVATION", 345, 357], ["diabetes", "OBSERVATION", 359, 367], ["coronary artery", "ANATOMY", 373, 388], ["viral load", "OBSERVATION", 563, 573], ["lung", "ANATOMY", 578, 582], ["injury", "OBSERVATION", 583, 589], ["pneumonia", "OBSERVATION", 611, 620]]], ["Given that a remarkable elevation of circulating levels was also documented in various kinds of cytokines (IL-6, IL-10, TNF-alpha, etc.), it is unknown whether these findings of angiotensin II are the cause or result of a systemic cytokine storm in COVID-19 patients [39] .", [["angiotensin II", "CHEMICAL", 178, 192], ["IL-6", "GENE_OR_GENE_PRODUCT", 107, 111], ["IL-10", "GENE_OR_GENE_PRODUCT", 113, 118], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 120, 129], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 178, 192], ["patients", "ORGANISM", 258, 266], ["cytokines", "PROTEIN", 96, 105], ["IL-6, IL-10", "PROTEIN", 107, 118], ["TNF", "PROTEIN", 120, 123], ["angiotensin II", "PROTEIN", 178, 192], ["cytokine", "PROTEIN", 231, 239], ["patients", "SPECIES", 258, 266], ["a remarkable elevation of circulating levels", "PROBLEM", 11, 55], ["cytokines", "TEST", 96, 105], ["IL", "TEST", 107, 109], ["IL", "TEST", 113, 115], ["TNF", "TEST", 120, 123], ["angiotensin II", "PROBLEM", 178, 192], ["a systemic cytokine storm", "PROBLEM", 220, 245], ["COVID", "TEST", 249, 254], ["elevation", "OBSERVATION_MODIFIER", 24, 33]]], ["In the context of the effects of ARBs and AECIs, a retrospective, single-center analysis enrolling 112 COVID-19 patients showed that the use of ARBs and ACEIs had no effects on the morbidity and mortality of COVID-19 patients with CVD [40] .", [["ARBs", "CHEMICAL", 144, 148], ["ACEIs", "CHEMICAL", 153, 158], ["COVID", "DISEASE", 208, 213], ["CVD", "DISEASE", 231, 234], ["ARBs", "SIMPLE_CHEMICAL", 33, 37], ["patients", "ORGANISM", 112, 120], ["ARBs", "SIMPLE_CHEMICAL", 144, 148], ["ACEIs", "SIMPLE_CHEMICAL", 153, 158], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 217, 225], ["ARBs", "TREATMENT", 33, 37], ["AECIs", "TREATMENT", 42, 47], ["COVID", "TEST", 103, 108], ["ARBs", "TREATMENT", 144, 148], ["ACEIs", "TREATMENT", 153, 158], ["the morbidity", "PROBLEM", 177, 190], ["COVID", "TEST", 208, 213], ["CVD", "PROBLEM", 231, 234]]], ["Currently, a case-control study is underway to clarify the effects of ACEIs and ARBs on the severity of COVID-19 in Italy (NCT04318418).", [["ACEIs", "CHEMICAL", 70, 75], ["ARBs", "CHEMICAL", 80, 84], ["ACEIs", "SIMPLE_CHEMICAL", 70, 75], ["ARBs", "SIMPLE_CHEMICAL", 80, 84], ["a case-control study", "TEST", 11, 31], ["ACEIs", "TREATMENT", 70, 75], ["ARBs", "TREATMENT", 80, 84], ["COVID", "TEST", 104, 109]]], ["Most importantly, at present, there is no large-scale study with convincing evidence to determine whether ARBs and ACEIs play a neutral, beneficial, or harmful role in the susceptibility to SARS-CoV-2 and the severity and outcomes of COVID-19 patients [22, [34] [35] [36] 41] .Potential therapies targeting ACE2 and angiotensin IIIn addition to vaccine development and antiviral agents, the modulation of the RAS, especially by ACE2 and angiotensin II, is highlighted as a potential therapeutic target for COVID-19.", [["ARBs", "CHEMICAL", 106, 110], ["ACEIs", "CHEMICAL", 115, 120], ["SARS", "DISEASE", 190, 194], ["angiotensin", "CHEMICAL", 316, 327], ["angiotensin II", "CHEMICAL", 437, 451], ["COVID-19", "CHEMICAL", 506, 514], ["ARBs", "SIMPLE_CHEMICAL", 106, 110], ["ACEIs", "SIMPLE_CHEMICAL", 115, 120], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 190, 200], ["patients", "ORGANISM", 243, 251], ["[34] [35] [36] 41", "SIMPLE_CHEMICAL", 257, 274], ["ACE2", "GENE_OR_GENE_PRODUCT", 307, 311], ["angiotensin IIIn", "GENE_OR_GENE_PRODUCT", 316, 332], ["RAS", "GENE_OR_GENE_PRODUCT", 409, 412], ["ACE2", "GENE_OR_GENE_PRODUCT", 428, 432], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 437, 451], ["ACE2", "PROTEIN", 307, 311], ["RAS", "PROTEIN", 409, 412], ["ACE2", "PROTEIN", 428, 432], ["angiotensin II", "PROTEIN", 437, 451], ["patients", "SPECIES", 243, 251], ["SARS-CoV", "SPECIES", 190, 198], ["large-scale study", "TEST", 42, 59], ["ARBs", "TEST", 106, 110], ["ACEIs", "TREATMENT", 115, 120], ["SARS", "TEST", 190, 194], ["CoV", "TEST", 195, 198], ["the severity", "TEST", 205, 217], ["COVID", "TEST", 234, 239], ["Potential therapies", "TREATMENT", 277, 296], ["ACE2", "TREATMENT", 307, 311], ["angiotensin IIIn", "TREATMENT", 316, 332], ["vaccine development", "TREATMENT", 345, 364], ["antiviral agents", "TREATMENT", 369, 385], ["COVID", "TEST", 506, 511], ["no", "UNCERTAINTY", 39, 41], ["large", "OBSERVATION_MODIFIER", 42, 47]]], ["Based on an animal study suggesting the beneficial net effects of ARB in SARS-CoV-infected acute lung injury mice [27] , multicenter, double-blinded placebo-controlled, randomized trials (RCTs) are currently being conducted to investigate the effects of losartan on mortality and hospital admission in COVID-19 patients requiring hospital admission (NCT04312009) and not requiring hospital admission (NCT04311177), respectively.", [["lung", "ANATOMY", 97, 101], ["ARB", "CHEMICAL", 66, 69], ["SARS-CoV-infected", "DISEASE", 73, 90], ["acute lung injury", "DISEASE", 91, 108], ["losartan", "CHEMICAL", 254, 262], ["losartan", "CHEMICAL", 254, 262], ["ARB", "SIMPLE_CHEMICAL", 66, 69], ["SARS-CoV", "ORGANISM", 73, 81], ["lung", "ORGAN", 97, 101], ["mice", "ORGANISM", 109, 113], ["losartan", "SIMPLE_CHEMICAL", 254, 262], ["patients", "ORGANISM", 311, 319], ["mice", "SPECIES", 109, 113], ["patients", "SPECIES", 311, 319], ["SARS-CoV", "SPECIES", 73, 81], ["mice", "SPECIES", 109, 113], ["an animal study", "TEST", 9, 24], ["ARB", "TREATMENT", 66, 69], ["SARS", "PROBLEM", 73, 77], ["CoV", "PROBLEM", 78, 81], ["infected acute lung injury", "PROBLEM", 82, 108], ["double-blinded placebo", "TREATMENT", 134, 156], ["randomized trials (RCTs", "TREATMENT", 169, 192], ["losartan", "TREATMENT", 254, 262], ["infected", "OBSERVATION_MODIFIER", 82, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["lung", "ANATOMY", 97, 101], ["injury", "OBSERVATION", 102, 108]]], ["Recombinant ACE2 is another candidate to prevent COVID-19 pneumonia.", [["pneumonia", "DISEASE", 58, 67], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["ACE2", "PROTEIN", 12, 16], ["COVID", "TEST", 49, 54], ["pneumonia", "PROBLEM", 58, 67], ["pneumonia", "OBSERVATION", 58, 67]]], ["As described above, the efficacy of exogenous recombinant ACE2 has been shown in animal models of acute lung injury/ARDS [30, 31] .", [["lung", "ANATOMY", 104, 108], ["acute lung injury", "DISEASE", 98, 115], ["ARDS", "DISEASE", 116, 120], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["lung", "ORGAN", 104, 108], ["ACE2", "PROTEIN", 58, 62], ["exogenous recombinant ACE2", "TREATMENT", 36, 62], ["acute lung injury", "PROBLEM", 98, 115], ["ARDS", "PROBLEM", 116, 120], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["lung", "ANATOMY", 104, 108], ["injury", "OBSERVATION", 109, 115], ["ARDS", "OBSERVATION", 116, 120]]], ["It is also possible that the circulating soluble form of ACE2 may act as a decoy receptor that binds to SARS-CoV-2 and competitively inhibits virus entry to host target cells mediated by membrane-bound ACE2.", [["cells", "ANATOMY", 169, 174], ["membrane", "ANATOMY", 187, 195], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["cells", "CELL", 169, 174], ["membrane", "CELLULAR_COMPONENT", 187, 195], ["ACE2", "GENE_OR_GENE_PRODUCT", 202, 206], ["ACE2", "PROTEIN", 57, 61], ["decoy receptor", "PROTEIN", 75, 89], ["host target cells", "CELL_TYPE", 157, 174], ["ACE2", "PROTEIN", 202, 206], ["SARS-CoV", "SPECIES", 104, 112], ["ACE2", "TREATMENT", 57, 61], ["a decoy receptor", "TREATMENT", 73, 89], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["also possible", "UNCERTAINTY", 6, 19]]], ["To investigate the efficacy of human recombinant ACE2 in the treatment of COVID-19 patients, a randomized, controlled, pilot clinical study was planned (NCT04287686).", [["COVID", "DISEASE", 74, 79], ["human", "ORGANISM", 31, 36], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["patients", "ORGANISM", 83, 91], ["human recombinant ACE2", "PROTEIN", 31, 53], ["human", "SPECIES", 31, 36], ["patients", "SPECIES", 83, 91], ["human", "SPECIES", 31, 36], ["human recombinant ACE2", "TREATMENT", 31, 53], ["pilot clinical study", "TEST", 119, 139]]], ["However, this study was withdrawn on March 17, 2020.Potential therapies targeting ACE2 and angiotensin IITMPRSS2 is a membrane protease for ACE2 priming, which is a crucial step for the fusion of SARS-CoV-2 and target cell membranes and the resultant viral entry into the cells [6] .", [["membrane", "ANATOMY", 118, 126], ["cell membranes", "ANATOMY", 218, 232], ["cells", "ANATOMY", 272, 277], ["angiotensin", "CHEMICAL", 91, 102], ["SARS", "DISEASE", 196, 200], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["angiotensin IITMPRSS2", "GENE_OR_GENE_PRODUCT", 91, 112], ["membrane", "CELLULAR_COMPONENT", 118, 126], ["ACE2", "GENE_OR_GENE_PRODUCT", 140, 144], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 196, 206], ["cell membranes", "CELLULAR_COMPONENT", 218, 232], ["cells", "CELL", 272, 277], ["ACE2", "PROTEIN", 82, 86], ["IITMPRSS2", "PROTEIN", 103, 112], ["membrane protease", "PROTEIN", 118, 135], ["ACE2", "PROTEIN", 140, 144], ["this study", "TEST", 9, 19], ["Potential therapies", "TREATMENT", 52, 71], ["ACE2 and angiotensin IITMPRSS2", "TREATMENT", 82, 112], ["a membrane protease", "TREATMENT", 116, 135], ["ACE2 priming", "TREATMENT", 140, 152], ["SARS", "TEST", 196, 200], ["CoV", "TEST", 201, 204], ["target cell membranes", "TREATMENT", 211, 232], ["cell membranes", "OBSERVATION", 218, 232]]], ["Nafamostat mesylate and camostat mesylate are TMPRSS2 inhibitors that have been used for the treatment of acute pancreatitis in Japan.", [["Nafamostat mesylate", "CHEMICAL", 0, 19], ["camostat mesylate", "CHEMICAL", 24, 41], ["pancreatitis", "DISEASE", 112, 124], ["Nafamostat mesylate", "CHEMICAL", 0, 19], ["camostat mesylate", "CHEMICAL", 24, 41], ["Nafamostat mesylate", "SIMPLE_CHEMICAL", 0, 19], ["camostat mesylate", "SIMPLE_CHEMICAL", 24, 41], ["TMPRSS2", "SIMPLE_CHEMICAL", 46, 53], ["Nafamostat mesylate", "TREATMENT", 0, 19], ["camostat mesylate", "TREATMENT", 24, 41], ["TMPRSS2 inhibitors", "TREATMENT", 46, 64], ["acute pancreatitis", "PROBLEM", 106, 124], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["pancreatitis", "OBSERVATION", 112, 124]]], ["Currently, a clinical trial evaluating the efficacy of nafamostat and camostat for treating COVID-19 is underway in Japan (https://www.utokyo.ac.jp/focus/en/articles/z0508_00083.html).Risk limits of RAS inhibitor therapy in the COVID-19 pandemicThe concern regarding whether ARBs and ACEIs may have harmful effects on the morbidity and mortality of COVID-19 patients is based on the speculation that these drugs would upregulate ACE2, a receptor for SARS-CoV-2, which would increase the viral load and then augment lung injury.", [["lung", "ANATOMY", 515, 519], ["nafamostat", "CHEMICAL", 55, 65], ["camostat", "CHEMICAL", 70, 78], ["COVID", "DISEASE", 92, 97], ["ARBs", "CHEMICAL", 275, 279], ["ACEIs", "CHEMICAL", 284, 289], ["COVID", "DISEASE", 349, 354], ["lung injury", "DISEASE", 515, 526], ["nafamostat", "CHEMICAL", 55, 65], ["nafamostat", "SIMPLE_CHEMICAL", 55, 65], ["camostat", "SIMPLE_CHEMICAL", 70, 78], ["RAS", "GENE_OR_GENE_PRODUCT", 199, 202], ["ARBs", "SIMPLE_CHEMICAL", 275, 279], ["ACEIs", "SIMPLE_CHEMICAL", 284, 289], ["patients", "ORGANISM", 358, 366], ["ACE2", "GENE_OR_GENE_PRODUCT", 429, 433], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 450, 460], ["lung", "ORGAN", 515, 519], ["ACE2", "PROTEIN", 429, 433], ["patients", "SPECIES", 358, 366], ["nafamostat", "TREATMENT", 55, 65], ["camostat", "TREATMENT", 70, 78], ["COVID", "TREATMENT", 92, 97], ["RAS inhibitor therapy", "TREATMENT", 199, 220], ["ARBs", "TREATMENT", 275, 279], ["ACEIs", "TREATMENT", 284, 289], ["the morbidity", "PROBLEM", 318, 331], ["COVID", "TEST", 349, 354], ["these drugs", "TREATMENT", 400, 411], ["ACE2", "TREATMENT", 429, 433], ["SARS", "PROBLEM", 450, 454], ["CoV", "TEST", 455, 458], ["the viral load", "PROBLEM", 483, 497], ["augment lung injury", "PROBLEM", 507, 526], ["viral load", "OBSERVATION", 487, 497], ["lung", "ANATOMY", 515, 519], ["injury", "OBSERVATION", 520, 526]]], ["However, the evidence of ACE2 upregulation is limited only in animal studies using the relatively high (namely, pharmacological) doses of several ARBs and one ACEI.", [["ACEI", "CHEMICAL", 159, 163], ["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["ACEI", "SIMPLE_CHEMICAL", 159, 163], ["ACE2", "PROTEIN", 25, 29], ["ACE2 upregulation", "PROBLEM", 25, 42], ["animal studies", "TEST", 62, 76], ["several ARBs", "TREATMENT", 138, 150], ["one ACEI", "TREATMENT", 155, 163], ["ACE2 upregulation", "OBSERVATION", 25, 42]]], ["Additionally, it remains unclear whether the ARB/ ACE-induced ACE2 increase actually enhances the susceptibility to SARS-CoV-2 or SAR-CoV.", [["ARB", "CHEMICAL", 45, 48], ["SARS", "DISEASE", 116, 120], ["ARB", "GENE_OR_GENE_PRODUCT", 45, 48], ["ACE", "GENE_OR_GENE_PRODUCT", 50, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 116, 126], ["SAR-CoV", "GENE_OR_GENE_PRODUCT", 130, 137], ["ACE", "PROTEIN", 50, 53], ["ACE2", "PROTEIN", 62, 66], ["SARS-CoV", "SPECIES", 116, 124], ["the ARB", "TEST", 41, 48], ["ACE", "TEST", 50, 53], ["ACE2 increase", "PROBLEM", 62, 75], ["SARS", "TEST", 116, 120], ["CoV", "TEST", 121, 124], ["SAR", "PROBLEM", 130, 133], ["CoV", "PROBLEM", 134, 137]]], ["Importantly, no clinical studies exist supporting that ARBs and ACEIs augment susceptibility to infection and worsen (or improve) all-cause and cardiovascular outcomes in not only COVID-19 patients but also SARS patients at present.", [["cardiovascular", "ANATOMY", 144, 158], ["ARBs", "CHEMICAL", 55, 59], ["ACEIs", "CHEMICAL", 64, 69], ["infection", "DISEASE", 96, 105], ["SARS", "DISEASE", 207, 211], ["ARBs", "SIMPLE_CHEMICAL", 55, 59], ["ACEIs", "SIMPLE_CHEMICAL", 64, 69], ["cardiovascular", "ANATOMICAL_SYSTEM", 144, 158], ["patients", "ORGANISM", 189, 197], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 189, 197], ["patients", "SPECIES", 212, 220], ["clinical studies", "TEST", 16, 32], ["ARBs", "TREATMENT", 55, 59], ["ACEIs", "TREATMENT", 64, 69], ["infection", "PROBLEM", 96, 105], ["infection", "OBSERVATION", 96, 105]]], ["Therefore, the hypothesis underlying the concern would not be readily extrapolated to humans, particularly to COVID-19 patients.Risk limits of RAS inhibitor therapy in the COVID-19 pandemicIn patients with heart failure, prior myocardial infarction, other CVDs, and cerebrovascular disease, the benefit of ARBs and ACEIs has been established in the improvement of quality of life and survival outcomes, while the discontinuation leads to new onset or exacerbation of heart failure, CVD, and stroke and the worsening of the prognosis [42] .", [["heart", "ANATOMY", 206, 211], ["myocardial", "ANATOMY", 227, 237], ["cerebrovascular", "ANATOMY", 266, 281], ["heart", "ANATOMY", 467, 472], ["pandemicIn", "DISEASE", 181, 191], ["heart failure", "DISEASE", 206, 219], ["myocardial infarction", "DISEASE", 227, 248], ["CVDs", "DISEASE", 256, 260], ["cerebrovascular disease", "DISEASE", 266, 289], ["ARBs", "CHEMICAL", 306, 310], ["ACEIs", "CHEMICAL", 315, 320], ["heart failure", "DISEASE", 467, 480], ["CVD", "DISEASE", 482, 485], ["stroke", "DISEASE", 491, 497], ["humans", "ORGANISM", 86, 92], ["patients", "ORGANISM", 119, 127], ["RAS", "GENE_OR_GENE_PRODUCT", 143, 146], ["patients", "ORGANISM", 192, 200], ["heart", "ORGAN", 206, 211], ["myocardial", "MULTI-TISSUE_STRUCTURE", 227, 237], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 266, 281], ["ARBs", "SIMPLE_CHEMICAL", 306, 310], ["ACEIs", "SIMPLE_CHEMICAL", 315, 320], ["heart", "ORGAN", 467, 472], ["humans", "SPECIES", 86, 92], ["patients", "SPECIES", 119, 127], ["patients", "SPECIES", 192, 200], ["humans", "SPECIES", 86, 92], ["RAS inhibitor therapy", "TREATMENT", 143, 164], ["heart failure", "PROBLEM", 206, 219], ["prior myocardial infarction", "PROBLEM", 221, 248], ["other CVDs", "PROBLEM", 250, 260], ["cerebrovascular disease", "PROBLEM", 266, 289], ["ARBs", "TREATMENT", 306, 310], ["ACEIs", "TREATMENT", 315, 320], ["survival outcomes", "TREATMENT", 384, 401], ["heart failure", "PROBLEM", 467, 480], ["CVD", "PROBLEM", 482, 485], ["stroke", "PROBLEM", 491, 497], ["heart", "ANATOMY", 206, 211], ["failure", "OBSERVATION", 212, 219], ["myocardial", "ANATOMY", 227, 237], ["infarction", "OBSERVATION", 238, 248], ["cerebrovascular", "ANATOMY", 266, 281], ["disease", "OBSERVATION", 282, 289], ["heart", "ANATOMY", 467, 472], ["failure", "OBSERVATION", 473, 480], ["worsening", "OBSERVATION_MODIFIER", 506, 515]]], ["Thus, RAS inhibitors should be continued in high-risk patients who have received guideline-directed medical therapy (GDMT).", [["RAS", "GENE_OR_GENE_PRODUCT", 6, 9], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["RAS inhibitors", "TREATMENT", 6, 20], ["guideline", "TREATMENT", 81, 90], ["directed medical therapy", "TREATMENT", 91, 115]]], ["In general, switching from one to another class of antihypertensive agents does not infrequently result in destabilization of blood pressure control and requires frequent visits for drug titration to achieve appropriate and stable blood pressure control and to avoid adverse effects.", [["blood", "ANATOMY", 126, 131], ["blood", "ANATOMY", 231, 236], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["blood", "ORGANISM_SUBSTANCE", 231, 236], ["antihypertensive agents", "TREATMENT", 51, 74], ["blood pressure control", "TREATMENT", 126, 148], ["drug titration", "TREATMENT", 182, 196], ["stable blood pressure control", "TREATMENT", 224, 253], ["adverse effects", "PROBLEM", 267, 282]]], ["Blood pressure destabilization increases the incidence of heart failure, stroke, and other CVDs.", [["Blood", "ANATOMY", 0, 5], ["heart", "ANATOMY", 58, 63], ["heart failure", "DISEASE", 58, 71], ["stroke", "DISEASE", 73, 79], ["CVDs", "DISEASE", 91, 95], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["heart", "ORGAN", 58, 63], ["Blood pressure destabilization", "TEST", 0, 30], ["heart failure", "PROBLEM", 58, 71], ["stroke", "PROBLEM", 73, 79], ["other CVDs", "PROBLEM", 85, 95], ["pressure", "OBSERVATION_MODIFIER", 6, 14], ["destabilization", "OBSERVATION", 15, 30], ["heart", "ANATOMY", 58, 63], ["failure", "OBSERVATION", 64, 71], ["stroke", "OBSERVATION", 73, 79]]], ["In addition, frequent visits to the clinic or hospital expose patients to a greater risk of infection in a COVID-19 pandemic situation.", [["infection", "DISEASE", 92, 101], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["infection", "PROBLEM", 92, 101], ["infection", "OBSERVATION", 92, 101]]], ["Accordingly, even in stably controlled hypertension patients without compelling indications, it is thought that not only simple discontinuation but also switching from ARB or ACEI to other antihypertensive agents should be avoided unless physicians make a decision based on specific considerations.Risk limits of RAS inhibitor therapy in the COVID-19 pandemicCardiovascular comorbidities are common in COVID-19 patients, and such patients are at great risk for morbidity and mortality [1] [2] [3] [4] .", [["pandemicCardiovascular", "ANATOMY", 351, 373], ["hypertension", "DISEASE", 39, 51], ["ARB", "CHEMICAL", 168, 171], ["ACEI", "CHEMICAL", 175, 179], ["pandemicCardiovascular comorbidities", "DISEASE", 351, 387], ["patients", "ORGANISM", 52, 60], ["ARB", "SIMPLE_CHEMICAL", 168, 171], ["ACEI", "SIMPLE_CHEMICAL", 175, 179], ["RAS", "GENE_OR_GENE_PRODUCT", 313, 316], ["patients", "ORGANISM", 411, 419], ["patients", "ORGANISM", 430, 438], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 485, 500], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 411, 419], ["patients", "SPECIES", 430, 438], ["ARB", "TREATMENT", 168, 171], ["ACEI", "TREATMENT", 175, 179], ["other antihypertensive agents", "TREATMENT", 183, 212], ["RAS inhibitor therapy", "TREATMENT", 313, 334], ["the COVID", "TEST", 338, 347], ["pandemicCardiovascular comorbidities", "PROBLEM", 351, 387], ["morbidity", "PROBLEM", 461, 470], ["mortality", "TEST", 475, 484], ["hypertension", "OBSERVATION", 39, 51]]], ["Myocardial damage ranging from silent troponin T elevation to fulminant myocarditis has been documented in COVID-19 patients [35] .", [["Myocardial", "ANATOMY", 0, 10], ["Myocardial damage", "DISEASE", 0, 17], ["myocarditis", "DISEASE", 72, 83], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 0, 10], ["troponin T", "GENE_OR_GENE_PRODUCT", 38, 48], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["Myocardial damage", "PROBLEM", 0, 17], ["silent troponin T elevation", "PROBLEM", 31, 58], ["fulminant myocarditis", "PROBLEM", 62, 83], ["COVID", "TEST", 107, 112], ["damage", "OBSERVATION", 11, 17], ["fulminant", "OBSERVATION_MODIFIER", 62, 71], ["myocarditis", "OBSERVATION", 72, 83]]], ["In confirmed or suspected COVID-19 patients, ACEI and ARB medications are recommended for the treatment of heart failure and other CVD according to GDMT based on the available evidence at this time [35] .Risk limits of RAS inhibitor therapy in the COVID-19 pandemicIn conclusion, at present, the use of ARBs and AECIs should not be withheld in established standard therapy for not only high-risk patients such as those with heart failure, prior myocardial infarction, other CVD, and cerebrovascular disease but also patients with hypertension in stable condition according to the recent statements released by the European Society of Hypertension, the European Society of Cardiology, and the American Heart Association/ Heart Failure Society of America/American College of Cardiology [43] [44] [45] .", [["heart", "ANATOMY", 107, 112], ["heart", "ANATOMY", 424, 429], ["myocardial", "ANATOMY", 445, 455], ["cerebrovascular", "ANATOMY", 483, 498], ["ACEI", "CHEMICAL", 45, 49], ["ARB", "CHEMICAL", 54, 57], ["heart failure", "DISEASE", 107, 120], ["CVD", "DISEASE", 131, 134], ["ARBs", "CHEMICAL", 303, 307], ["heart failure", "DISEASE", 424, 437], ["myocardial infarction", "DISEASE", 445, 466], ["CVD", "DISEASE", 474, 477], ["cerebrovascular disease", "DISEASE", 483, 506], ["hypertension", "DISEASE", 530, 542], ["Hypertension", "DISEASE", 634, 646], ["Heart Failure", "DISEASE", 720, 733], ["patients", "ORGANISM", 35, 43], ["ACEI", "SIMPLE_CHEMICAL", 45, 49], ["ARB", "SIMPLE_CHEMICAL", 54, 57], ["heart", "ORGAN", 107, 112], ["RAS", "GENE_OR_GENE_PRODUCT", 219, 222], ["ARBs", "SIMPLE_CHEMICAL", 303, 307], ["AECIs", "SIMPLE_CHEMICAL", 312, 317], ["patients", "ORGANISM", 396, 404], ["heart", "ORGAN", 424, 429], ["myocardial", "MULTI-TISSUE_STRUCTURE", 445, 455], ["cerebrovascular", "ANATOMICAL_SYSTEM", 483, 498], ["patients", "ORGANISM", 516, 524], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 396, 404], ["patients", "SPECIES", 516, 524], ["COVID", "TEST", 26, 31], ["ACEI", "TREATMENT", 45, 49], ["ARB medications", "TREATMENT", 54, 69], ["heart failure", "PROBLEM", 107, 120], ["other CVD", "PROBLEM", 125, 134], ["RAS inhibitor therapy", "TREATMENT", 219, 240], ["ARBs", "TREATMENT", 303, 307], ["AECIs", "TREATMENT", 312, 317], ["heart failure", "PROBLEM", 424, 437], ["prior myocardial infarction", "PROBLEM", 439, 466], ["other CVD", "PROBLEM", 468, 477], ["cerebrovascular disease", "PROBLEM", 483, 506], ["hypertension", "PROBLEM", 530, 542], ["Hypertension", "PROBLEM", 634, 646], ["Heart Failure", "PROBLEM", 720, 733], ["heart", "ANATOMY", 107, 112], ["failure", "OBSERVATION", 113, 120], ["heart", "ANATOMY", 424, 429], ["failure", "OBSERVATION", 430, 437], ["myocardial", "ANATOMY", 445, 455], ["infarction", "OBSERVATION", 456, 466], ["cerebrovascular", "ANATOMY", 483, 498], ["disease", "OBSERVATION", 499, 506], ["hypertension", "OBSERVATION", 530, 542], ["stable", "OBSERVATION_MODIFIER", 546, 552], ["Hypertension", "OBSERVATION", 634, 646], ["Heart", "ANATOMY", 701, 706], ["Heart", "ANATOMY", 720, 725], ["Failure", "OBSERVATION", 726, 733]]], ["The evidence on COVID-19 is being accumulated each day.", [["COVID-19", "DNA", 16, 24], ["COVID", "TEST", 16, 21]]], ["Large-scale clinical studies with convincing evidence, not only RCTs but also real-world big data analyses as well as experimental studies, are awaited to solve the question of whether ARBs and ACEIs have neutral, favorable, or harmful effects on the susceptibility to SARS-CoV-2 and the severity and outcomes of COVID-19.Risk limits of RAS inhibitor therapy in the COVID-19 pandemicFinally, we should learn from the lessons of COVID-19 without being bound by common sense in the ante-COVID-19 era.", [["ARBs", "CHEMICAL", 185, 189], ["ACEIs", "CHEMICAL", 194, 199], ["SARS", "DISEASE", 269, 273], ["COVID-19", "CHEMICAL", 313, 321], ["COVID-19", "CHEMICAL", 428, 436], ["ARBs", "SIMPLE_CHEMICAL", 185, 189], ["ACEIs", "SIMPLE_CHEMICAL", 194, 199], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 269, 279], ["RAS", "GENE_OR_GENE_PRODUCT", 337, 340], ["SARS-CoV", "SPECIES", 269, 277], ["Large-scale clinical studies", "TEST", 0, 28], ["world big data analyses", "TEST", 83, 106], ["experimental studies", "TEST", 118, 138], ["ARBs", "TEST", 185, 189], ["ACEIs", "TREATMENT", 194, 199], ["SARS", "TEST", 269, 273], ["CoV", "TEST", 274, 277], ["COVID", "TEST", 313, 318], ["RAS inhibitor therapy", "TREATMENT", 337, 358], ["COVID", "TEST", 428, 433], ["-scale", "OBSERVATION_MODIFIER", 5, 11]]], ["In addition, we should reconstruct a novel strategy for the treatment of hypertension and CVD in the post-COVID-19 era.Risk limits of RAS inhibitor therapy in the COVID-19 pandemicFunding This work was supported in part by a JSPS KAKENHI Grant (19K08503).Compliance with ethical standardsConflict of interest The authors declare that they have no conflict of interest.Compliance with ethical standardsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [["hypertension", "DISEASE", 73, 85], ["CVD", "DISEASE", 90, 93], ["RAS", "GENE_OR_GENE_PRODUCT", 134, 137], ["a novel strategy", "TREATMENT", 35, 51], ["hypertension", "PROBLEM", 73, 85], ["CVD", "PROBLEM", 90, 93], ["RAS inhibitor therapy", "TREATMENT", 134, 155], ["the COVID", "TEST", 159, 168], ["ethical standards", "TREATMENT", 271, 288], ["ethical standards", "TREATMENT", 384, 401], ["hypertension", "OBSERVATION", 73, 85]]]], "e6275761649fa674dca923f90753f8a1f720290a": [["Ingresa por lo que se realiza estudio de fiebre sin foco siendo la PCR COVID-19 positiva.", [["COVID-19 positiva", "ORGANISM", 71, 88], ["COVID-19 positiva", "SPECIES", 71, 88], ["COVID", "TEST", 71, 76]]], ["A las 24 horas de ingreso presenta aumento de la frecuencia respiratoria y card\u00edaca por lo que se realiza radiograf\u00eda de t\u00f3rax y ecocardiograf\u00eda, ambas con resultado normal, y ecograf\u00eda tor\u00e1cica donde se evidencia engrosamiento pleural, convergencia de l\u00edneas B en campos posteriores y una consolidaci\u00f3n subpleural.", [["pleural", "PROBLEM", 228, 235], ["subpleural", "PROBLEM", 304, 314], ["pleural", "ANATOMY", 228, 235], ["subpleural", "ANATOMY_MODIFIER", 304, 314]]], ["Posteriormente inicia apneas y aumento de requerimientos de ox\u00edgeno precisando tratamiento con cafe\u00edna y ox\u00edgeno con mejor\u00eda posterior.", [["apneas", "PROBLEM", 22, 28], ["tratamiento con cafe\u00edna y ox\u00edgeno con mejor\u00eda posterior", "TREATMENT", 79, 134], ["posterior", "ANATOMY_MODIFIER", 125, 134]]], ["Destacar el estudio de COVID-19 en neomatos con fiebre sin foco as\u00ed como la importancia de la ecograf\u00eda tor\u00e1cica dado que en nuestro paciente mostraba alteraciones previas al inicio de las apneas y requerimientos de ox\u00edgeno.", [["COVID", "TEST", 23, 28]]], ["Hay formas verbales no concordantes en algunas frases; faltan preposiciones y el escrito es excesivamente telegr\u00e1fico para un manuscrito publicable.", [["concordantes", "PROBLEM", 23, 35]]], ["Se debe intentar que el texto tenga continuidad para el lector.Resumen:-Hemos modificado los tiempos verbales, a\u00f1adido preposiciones y minimizado el lenguaje telegr\u00e1fico de manera que el texto tenga mayor comprensi\u00f3n y continuidad para el lector.Resumen:3.", [["Se", "CHEMICAL", 0, 2]]], ["La f\u00f3rmula de leucocitos del hemograma deber\u00eda describirse en %, para comprender bien las cifras aportadas.Resumen:-Hemos modificado la f\u00f3rmula de leucocitos del hemograma en porcentajes para mejorar la comprensi\u00f3n de las cifras aportadas.Resumen:Todas estas modificaciones las hemos resaltado en rojo para facilitar su revisi\u00f3n adjunt\u00e1ndola en el apartado \"adjuntar archivos\" con el nombre \"hoja aparte modificado en rojo\".Resumen:4.", [["Todas estas modificaciones las hemos resaltado en rojo para facilitar su revisi\u00f3n adjunt\u00e1ndola en el apartado \"adjuntar archivos\" con el nombre \"hoja aparte modificado en rojo", "SPECIES", 247, 422], ["Hemos modificado la f\u00f3rmula", "TREATMENT", 116, 143]]], ["Deber\u00edan valorar citar el caso neonatal publicado en Anales previamente.", [["Deber\u00edan", "TEST", 0, 8]]], ["Las citas bibliogr\u00e1ficas deben seguir las recomendaciones para autores de nuestra revista.Resumen:-Hemos modificado las citas bibliogr\u00e1ficas de manera que hemos incluido el art\u00edculo publicado anteriormente en anales de pediatr\u00eda t\u00edtulado \"Primer caso de infecci\u00f3n neonatal por SARS-CoV-2 en Espa\u00f1a, as\u00ed como adaptado a las recomendaciones para autores de su revista.Resumen:Muchas gracias.", [["Muchas gracias", "ORGANISM", 374, 388], ["Muchas gracias", "SPECIES", 374, 388], ["CoV", "TEST", 282, 285]]], ["El inter\u00e9s de este caso cl\u00ednico radica en que dada la actual pandemia por coronavirus (SARS-CoV-2), han empezado a publicarse datos sobre adultos donde la enfermedad inicialmente parece que es m\u00e1s agresiva.", [["pandemia por coronavirus", "DISEASE", 61, 85], ["SARS", "DISEASE", 87, 91], ["coronavirus", "PROBLEM", 74, 85]]], ["Actualmente en la poblaci\u00f3n pedi\u00e1trica y sobre todo en los neonatos la literatura es muy escasa, de manera que pensamos que es importante dar a conocer los casos en esta poblaci\u00f3n para poder entender el comportamiento que tiene en este grupo de edad.Con tecnolog\u00eda de Editorial Manager\u00ae y ProduXion Manager\u00ae de Aries Systems CorporationLa evoluci\u00f3n en nuestro paciente fue buena, pero pese al curso benigno que describe, nuestro paciente present\u00f3 requerimientos de ox\u00edgeno y apneas precisando tratamiento con cafe\u00edna y ox\u00edgeno.", [["Actualmente", "TEST", 0, 11]]], ["A destacar en nuestro caso, previo a la aparici\u00f3n de la cl\u00ednica respiratoria se realiz\u00f3 una ecograf\u00eda tor\u00e1cica donde se observaba engrosamiento pleural, convergencia de l\u00edneas B y una condensaci\u00f3n subpleural, hallazgos que nos permitieron predecir el empeoramiento respiratorio de nuestro paciente.Con tecnolog\u00eda de Editorial Manager\u00ae y ProduXion Manager\u00ae de Aries Systems CorporationEste manuscrito ha sido remitido en exclusiva a Anales de Pediatr\u00eda, no ha sido publicado previamente ni est\u00e1 siendo sometido a consideraci\u00f3n en otra publicaci\u00f3n.", [["A destacar en nuestro caso", "TREATMENT", 0, 26], ["a consideraci\u00f3n en otra publicaci\u00f3n", "TREATMENT", 510, 545], ["pleural", "ANATOMY", 144, 151], ["subpleural", "ANATOMY", 197, 207]]], ["Gestaci\u00f3n controlada en madre de 26 a\u00f1os con ecograf\u00edas normales y parto eut\u00f3cico a las 39+2 semanas de gestaci\u00f3n sin factores de riesgo infecciosos perinatales (estreptococo b-hemol\u00edtico negativo y 4 horas de bolsa rota), peso al nacimiento 3,220 gramos y Apgar 10/10.", [["Gestaci\u00f3n", "TEST", 0, 9], ["perinatales", "TEST", 149, 160], ["estreptococo", "TEST", 162, 174], ["peso al nacimiento", "TREATMENT", 223, 241]]], ["Se realiz\u00f3 estudio con anal\u00edtica sangu\u00ednea, hemocultivo, orina, punci\u00f3n lumbar, aspirado nasofar\u00edngeo para adenovirus, influenza A y B, Virus Respiratorio Sincitial y RT-PCR COVID-19.", [["adenovirus", "ORGANISM", 107, 117], ["hemocultivo", "TEST", 44, 55], ["orina", "TEST", 57, 62], ["influenza", "PROBLEM", 119, 128], ["PCR COVID", "TEST", 170, 179], ["lumbar", "ANATOMY", 72, 78]]], ["Se inici\u00f3 tratamiento antibi\u00f3tico a la espera de resultados de cultivos y muestras de virus.", [["Se", "CHEMICAL", 0, 2], ["cultivos y muestras", "ORGANISM", 63, 82], ["Se inici\u00f3 tratamiento antibi\u00f3tico", "TREATMENT", 0, 33]]], ["Al ingreso presentaba los siguientes datos anal\u00edticos: hemograma con serie roja normal, leucocitos 7.4 x10e9/L, linfocitos 40,5%, monocitos 21,6%, procalcitonina 0.20 ng/ml; prote\u00edna C reactiva < 5 mg/L, la punci\u00f3n lumbar no mostr\u00f3 celularidad patol\u00f3gica y la orina fue normal.", [["roja", "TEST", 75, 79], ["leucocitos", "TEST", 88, 98], ["linfocitos", "TEST", 112, 122], ["monocitos", "TEST", 130, 139], ["procalcitonina", "TEST", 147, 161], ["prote\u00edna C reactiva", "PROBLEM", 174, 193], ["la punci\u00f3n lumbar", "TEST", 204, 221], ["lumbar", "ANATOMY", 215, 221], ["normal", "OBSERVATION", 270, 276]]], ["La RT-PCR COVID-19 fue positiva para COVID-19 y el resto de virus negativo.", [["La RT", "TEST", 0, 5], ["PCR COVID", "TEST", 6, 15]]], ["Dada la positividad de la muestra en el paciente se realiz\u00f3 el estudio de RT-PCR COVID-19 en ambos progenitores siendo positivo.Con tecnolog\u00eda de Editorial Manager\u00ae y ProduXion Manager\u00ae de Aries Systems CorporationA su ingreso el RN presentaba temperatura 36.9 \u00baC, FC 144 p/m, FR 42 r/m y saturaci\u00f3n de ox\u00edgeno 100 % aire ambiente con buen estado general, buena perfusi\u00f3n perif\u00e9rica y buena entrada de aire bilateral sin ruidos patol\u00f3gicos.", [["COVID", "TEST", 81, 86], ["temperatura", "TEST", 244, 255], ["\u00baC", "TEST", 261, 263], ["FC", "TEST", 265, 267], ["FR", "TEST", 277, 279], ["saturaci\u00f3n", "TEST", 289, 299], ["ox\u00edgeno", "TEST", 303, 310], ["bilateral", "ANATOMY_MODIFIER", 407, 416]]], ["A las 24 horas de ingreso present\u00f3 aumento de la frecuencia respiratoria hasta 60 r/m y frecuencia card\u00edaca en rango de 160-180 p/m motivo por el cual se realiz\u00f3 radiograf\u00eda de t\u00f3rax y ecocardiograf\u00eda sin hallazgos patol\u00f3gicos y ecograf\u00eda tor\u00e1cica donde se evidenci\u00f3 engrosamiento pleural, convergencia de l\u00edneas B en campos posteriores y una consolidaci\u00f3n subpleural a nivel basal posterior de hemit\u00f3rax derecho (figuras 1 y 2).", [["frecuencia respiratoria hasta 60 r/m y frecuencia card\u00edaca en rango de 160-180 p/m motivo por el cual se realiz\u00f3 radiograf\u00eda", "SPECIES", 49, 173], ["card\u00edaca", "TEST", 99, 107], ["engrosamiento pleural", "PROBLEM", 267, 288], ["pleural", "ANATOMY", 281, 288], ["subpleural", "ANATOMY_MODIFIER", 357, 367], ["basal", "ANATOMY_MODIFIER", 376, 381], ["posterior", "ANATOMY_MODIFIER", 382, 391]]], ["Posteriormente inici\u00f3 apneas y se realiz\u00f3 gasometr\u00eda capilar encontrando leve retenci\u00f3n de carb\u00f3nico (pH 7,38, pCO2 48,4, bicarbonato 26,4, lactato 1,2) por lo que se inici\u00f3 tratamiento con cafe\u00edna y administraci\u00f3n de ox\u00edgeno en incubadora con FiO2 m\u00e1xima de 0.3.", [["apneas", "PROBLEM", 22, 28], ["gasometr\u00eda", "TEST", 42, 52], ["pH", "TEST", 102, 104], ["pCO2", "TEST", 111, 115], ["bicarbonato", "TEST", 122, 133], ["lactato", "TEST", 140, 147]]], ["Se realiz\u00f3 serolog\u00eda al ingreso siendo IgM-, IgG -, mostrando seroconversi\u00f3n a los 16 d\u00edas desde el inicio de los s\u00edntomas (IgM -, IgG +).Con tecnolog\u00eda de Editorial Manager\u00ae y ProduXion Manager\u00ae de Aries Systems CorporationEn nuestro caso, se trata de una transmisi\u00f3n horizontal, el paciente conviv\u00eda con ocho personas m\u00e1s en domicilio, de los cuales tres de ellos refer\u00edan cl\u00ednica catarral de ah\u00ed el estudio de los convivientes pese a no presentar fiebre.J o u r n a l P r e -p r o o fPor otro lado, a destacar la importancia de la ecograf\u00eda tor\u00e1cica, dato no descrito anteriormente en casos pedi\u00e1tricos, ya que es m\u00e1s precoz en la valoraci\u00f3n pulmonar que la radiograf\u00eda.", [["IgM", "PROTEIN", 39, 42], ["IgM", "PROTEIN", 124, 127], ["IgG", "PROTEIN", 131, 134], ["Se realiz\u00f3 serolog\u00eda", "TEST", 0, 20], ["IgM", "TEST", 39, 42], ["IgG", "TEST", 45, 48], ["IgM", "TEST", 124, 127], ["IgG", "TEST", 131, 134], ["otro", "TEST", 491, 495], ["lado", "TEST", 496, 500]]], ["No se evidenci\u00f3 cl\u00ednica gastrointestinal descrita en otros casos 4 .", [["gastrointestinal", "ANATOMY", 24, 40]]], ["Es necesario realizar m\u00e1s estudios acerca del patr\u00f3n ecogr\u00e1fico pulmonar y de los factores que condicionan el comportamiento del COVID-19 en la poblaci\u00f3n neonatal, as\u00ed como el estudio de convivientes con cl\u00ednica catarral leve para evitar la transmisi\u00f3n en este grupo de edad.", [["COVID", "TEST", 129, 134]]], ["Es importante incluir en el estudio de neonato con fiebre el estudio de RT-PCR COVID-19 dada la pandemia actual como recomiendan los protocoles actuales 5 y tener en cuenta el papel de la carga viral en esta poblaci\u00f3n al igual que ocurre en adultos 6 .BIBLIOGRAF\u00cdAJ o u r n a l P r e -p r o o f", [["COVID", "TEST", 79, 84], ["5 y tener en cuenta el papel de la carga viral en esta poblaci\u00f3n al igual que ocurre en adultos", "TREATMENT", 153, 248]]]], "PMC7204755": [["Dear editors:Timely and accurate information is foundational to mitigating and curing the coronavirus disease 2019 (COVID-19) for both the public and the scientific community (Hua and Shaw, 2020).", [["coronavirus disease", "DISEASE", 90, 109], ["COVID-19", "CHEMICAL", 116, 124], ["coronavirus", "ORGANISM", 90, 101], ["the coronavirus disease", "PROBLEM", 86, 109], ["Hua", "ANATOMY", 176, 179]]], ["Misinformation on COVID-19, however, has also been proliferating on the Internet, especially on social media (Bastani and Bahrami, 2020).", [["COVID", "TEST", 18, 23], ["proliferating", "OBSERVATION_MODIFIER", 51, 64]]], ["Moreover, repeated media exposure to crisis-related information elevates anxiety and stress responses among people (Garfin et al., 2020).", [["anxiety", "DISEASE", 73, 80], ["people", "ORGANISM", 108, 114], ["people", "SPECIES", 108, 114], ["crisis", "PROBLEM", 37, 43], ["anxiety", "PROBLEM", 73, 80], ["stress responses", "PROBLEM", 85, 101]]], ["We were interested in the associations between the COVID-19-related information sources and people\u2019s psychological well-being.", [["people", "ORGANISM", 92, 98], ["COVID-19", "DNA", 51, 59], ["people", "SPECIES", 92, 98]]], ["We were also interested in whether the associations differed between health care workers and the public.Dear editors:The Online Survey Study on COVID-19 in Taiwan recruited participants who were \u226520 years old and lived in Taiwan through a Facebook advertisement on April 10 to April 20, 2020.", [["participants", "SPECIES", 173, 185]]], ["In the online survey, participants were asked whether they received COVID-19-related information frequently from the following sources: the Internet (including blogs, Internet news, and social media, such as Facebook, Line, Twitter, and Plurk), friends, traditional media (including television, newspapers, and radio broadcasting), formal lessons on COVID-19 (whether online or in-person), medical staff in health care settings, coworkers, and family members.", [["participants", "SPECIES", 22, 34], ["person", "SPECIES", 381, 387]]], ["We also assessed participants\u2019 level of subjective psychological well-being on a 5-point Likert scale from 1 (much worse) to 5 (much better) (Ko et al., 2006).Dear editors:In total, the data of 1904 respondents (1282 female and 622 male participants; mean age =38.0 years and standard deviation [SD] =10.8 years) were analyzed.", [["participants", "SPECIES", 17, 29], ["participants", "SPECIES", 237, 249]]], ["The mean score for psychological well-being were 3.3 (SD = 0.9).", [["The mean score", "TEST", 0, 14]]], ["The major source of information on COVID-19 was the Internet (80.6%), followed by traditional media (53.5%).", [["COVID", "TEST", 35, 40]]], ["The associations of each information source with psychological well-being were examined using multiple regression analyses to control for sex, age, education and worry about COVID-19.", [["multiple regression analyses", "TREATMENT", 94, 122], ["COVID", "TEST", 174, 179]]], ["For health care workers, receiving COVID-19 information from formal lessons was significantly positively related with psychological well-being.Dear editors:This study found that approximately 80% of participants received COVID-19 information online.", [["participants", "ORGANISM", 199, 211], ["participants", "SPECIES", 199, 211], ["COVID", "TREATMENT", 35, 40], ["This study", "TEST", 156, 166], ["COVID", "TREATMENT", 221, 226]]], ["Because of the cross-sectional design of the present study, this association may be directional.", [["the present study", "TEST", 41, 58], ["may be", "UNCERTAINTY", 77, 83], ["directional", "OBSERVATION_MODIFIER", 84, 95]]], ["Misinformation on COVID-19 is rife, especially on social media, despite the efforts of the WHO and Taiwan\u2019s Ministry of Health and Welfare in dispelling such misinformation (Bastani and Bahrami, 2020).", [["COVID", "TEST", 18, 23]]], ["Because its recipients are unlikely to be able to adjudicate truth from falsity, misinformation results in confusion and anxiety.", [["falsity", "DISEASE", 72, 79], ["confusion", "DISEASE", 107, 116], ["anxiety", "DISEASE", 121, 128], ["recipients", "ORGANISM", 12, 22], ["confusion", "PROBLEM", 107, 116], ["anxiety", "PROBLEM", 121, 128]]], ["Furthermore, poor mental health may limit some from searching for information from a variety of sources, and they may obsessively search for COVID-19 information to alleviate their anxiety.", [["anxiety", "DISEASE", 181, 188], ["their anxiety", "PROBLEM", 175, 188]]], ["These results imply the importance of mental health education, not only education on COVID-19, during this pandemic.Dear editors:Because Taiwan\u2019s Ministry of Health and Welfare recommended health care workers to attend formal lessons (whether online or in-person) on COVID-19, they were more likely to receive COVID-19 information from formal lessons, which resulted in greater psychological well-being.", [["person", "SPECIES", 256, 262], ["COVID", "TEST", 85, 90]]], ["A study in China reported depression, anxiety, insomnia, and distress in a high proportion of health care workers who were ever exposed to information on COVID-19 (Lai et al., 2020).", [["depression", "DISEASE", 26, 36], ["anxiety", "DISEASE", 38, 45], ["insomnia", "DISEASE", 47, 55], ["A study", "TEST", 0, 7], ["depression", "PROBLEM", 26, 36], ["anxiety", "PROBLEM", 38, 45], ["insomnia", "PROBLEM", 47, 55], ["distress", "PROBLEM", 61, 69], ["depression", "OBSERVATION", 26, 36]]], ["It was the uncertainty surrounding COVID-19, in addition to physical and psychological exhaustion, that resulted in such mental health problems (Neto et al., 2020).", [["COVID", "TEST", 35, 40], ["physical and psychological exhaustion", "PROBLEM", 60, 97], ["such mental health problems", "PROBLEM", 116, 143]]], ["Thus, our study and previous studies have demonstrated the necessity of providing timely and transparent formal lessons on COVID-19 for health care workers.Dear editors:We found that the non-health care workers receiving COVID-19 from medical staff in health care settings had better psychological well-being.", [["our study", "TEST", 6, 15], ["previous studies", "TEST", 20, 36]]], ["People, especially older adults, may receive COVID-19 information from the physicians on their regular or emergent visits for their existing chronic illnesses.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["their existing chronic illnesses", "PROBLEM", 126, 158], ["chronic", "OBSERVATION_MODIFIER", 141, 148], ["illnesses", "OBSERVATION", 149, 158]]], ["Research demonstrated that COVID-19 affects older adults more as well as people with comorbidities, such as hypertension, cardiovascular disease, diabetes, chronic respiratory disease, and chronic kidney disease (Shahid et al., 2020).", [["cardiovascular", "ANATOMY", 122, 136], ["respiratory", "ANATOMY", 164, 175], ["kidney", "ANATOMY", 197, 203], ["hypertension", "DISEASE", 108, 120], ["cardiovascular disease", "DISEASE", 122, 144], ["diabetes", "DISEASE", 146, 154], ["chronic respiratory disease", "DISEASE", 156, 183], ["chronic kidney disease", "DISEASE", 189, 211], ["people", "ORGANISM", 73, 79], ["kidney", "ORGAN", 197, 203], ["people", "SPECIES", 73, 79], ["comorbidities", "PROBLEM", 85, 98], ["hypertension", "PROBLEM", 108, 120], ["cardiovascular disease", "PROBLEM", 122, 144], ["diabetes", "PROBLEM", 146, 154], ["chronic respiratory disease", "PROBLEM", 156, 183], ["chronic kidney disease", "PROBLEM", 189, 211], ["hypertension", "OBSERVATION", 108, 120], ["cardiovascular", "ANATOMY", 122, 136], ["disease", "OBSERVATION", 137, 144], ["diabetes", "OBSERVATION", 146, 154], ["chronic", "OBSERVATION_MODIFIER", 156, 163], ["respiratory disease", "OBSERVATION", 164, 183], ["chronic", "OBSERVATION_MODIFIER", 189, 196], ["kidney", "ANATOMY", 197, 203], ["disease", "OBSERVATION", 204, 211]]], ["These groups of people have a greater need for health information.", [["people", "ORGANISM", 16, 22], ["people", "SPECIES", 16, 22]]], ["Thus, we suggested that all medical staff, not only frontline staff, must have complete and accurate information on COVID-19 to educate the public; the Internet and television are practical vehicles for public health education during this pandemic.", [["public health education", "TREATMENT", 203, 226]]]], "PMC7432596": [], "PMC6319316": [["IntroductionCardiovascular disease is the most common cause of death, accounting for more than 800,000 deaths in the United States and 17.3 million deaths globally.1 Elevated low-density lipoprotein cholesterol (LDL-C) has been found to be one of the major contributors to atherosclerosis and cardiovascular heart disease (CHD).2, 3, 4 Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by elevated total cholesterol that is primarily LDL-C.", [["Cardiovascular", "ANATOMY", 12, 26], ["cardiovascular heart", "ANATOMY", 293, 313], ["Cardiovascular disease", "DISEASE", 12, 34], ["death", "DISEASE", 63, 68], ["deaths", "DISEASE", 103, 109], ["deaths", "DISEASE", 148, 154], ["cholesterol", "CHEMICAL", 199, 210], ["LDL-C", "CHEMICAL", 212, 217], ["atherosclerosis", "DISEASE", 273, 288], ["cardiovascular heart disease", "DISEASE", 293, 321], ["CHD", "DISEASE", 323, 326], ["Familial hypercholesterolemia", "DISEASE", 336, 365], ["FH", "DISEASE", 367, 369], ["autosomal dominant disorder", "DISEASE", 377, 404], ["cholesterol", "CHEMICAL", 437, 448], ["cholesterol", "CHEMICAL", 199, 210], ["cholesterol", "CHEMICAL", 437, 448], ["low-density lipoprotein cholesterol", "SIMPLE_CHEMICAL", 175, 210], ["LDL-C", "SIMPLE_CHEMICAL", 212, 217], ["heart", "ORGAN", 308, 313], ["cholesterol", "SIMPLE_CHEMICAL", 437, 448], ["LDL", "PROTEIN", 212, 215], ["LDL", "PROTEIN", 467, 470], ["Cardiovascular disease", "PROBLEM", 12, 34], ["death", "PROBLEM", 63, 68], ["Elevated low-density lipoprotein cholesterol", "PROBLEM", 166, 210], ["LDL", "TEST", 212, 215], ["atherosclerosis", "PROBLEM", 273, 288], ["cardiovascular heart disease (CHD)", "PROBLEM", 293, 327], ["Familial hypercholesterolemia", "PROBLEM", 336, 365], ["an autosomal dominant disorder", "PROBLEM", 374, 404], ["elevated total cholesterol", "PROBLEM", 422, 448], ["LDL", "TEST", 467, 470], ["disease", "OBSERVATION", 27, 34], ["most common", "OBSERVATION_MODIFIER", 42, 53], ["Elevated", "OBSERVATION_MODIFIER", 166, 174], ["low-density", "OBSERVATION_MODIFIER", 175, 186], ["lipoprotein cholesterol", "OBSERVATION", 187, 210], ["atherosclerosis", "OBSERVATION", 273, 288], ["heart", "ANATOMY", 308, 313], ["disease", "OBSERVATION", 314, 321], ["hypercholesterolemia", "OBSERVATION", 345, 365], ["autosomal", "OBSERVATION_MODIFIER", 377, 386], ["dominant disorder", "OBSERVATION", 387, 404], ["elevated", "OBSERVATION_MODIFIER", 422, 430], ["total cholesterol", "OBSERVATION", 431, 448]]], ["It has been associated with premature cardiovascular disease, often resulting in death at a young age.", [["cardiovascular", "ANATOMY", 38, 52], ["premature cardiovascular disease", "DISEASE", 28, 60], ["death", "DISEASE", 81, 86], ["premature cardiovascular disease", "PROBLEM", 28, 60], ["death", "PROBLEM", 81, 86], ["associated with", "UNCERTAINTY", 12, 27], ["premature", "OBSERVATION_MODIFIER", 28, 37], ["cardiovascular disease", "OBSERVATION", 38, 60]]], ["Lipid-lowering medications and LDL apheresis, especially for statin-intolerant patients, have been used for the management of familial hypercholesterolemia.5, 6 Better pharmacological therapeutics are needed to achieve and maintain the desired target LDL-C levels.IntroductionProprotein convertases are secretory mammalian serine proteases that induce site-specific proteolytic cleavage in proteins.", [["statin", "CHEMICAL", 61, 67], ["serine", "CHEMICAL", 323, 329], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["LDL", "SIMPLE_CHEMICAL", 31, 34], ["statin", "SIMPLE_CHEMICAL", 61, 67], ["patients", "ORGANISM", 79, 87], ["LDL-C", "SIMPLE_CHEMICAL", 251, 256], ["LDL", "PROTEIN", 251, 254], ["Proprotein convertases", "PROTEIN", 276, 298], ["secretory mammalian serine proteases", "PROTEIN", 303, 339], ["patients", "SPECIES", 79, 87], ["Lipid-lowering medications", "TREATMENT", 0, 26], ["LDL apheresis", "TREATMENT", 31, 44], ["statin", "TREATMENT", 61, 67], ["the management", "TREATMENT", 108, 122], ["familial hypercholesterolemia.", "PROBLEM", 126, 156], ["IntroductionProprotein convertases", "TREATMENT", 264, 298], ["secretory mammalian serine proteases", "PROBLEM", 303, 339], ["specific proteolytic cleavage in proteins", "PROBLEM", 357, 398]]], ["This is a form of irreversible post-translational modification, which can lead to the activation or inactivation of proteins, such as growth factors, receptors, hormones, transcription factors, bacterial toxins, and viral glycoproteins.", [["growth factors", "PROTEIN", 134, 148], ["transcription factors", "PROTEIN", 171, 192], ["bacterial toxins", "PROTEIN", 194, 210], ["viral glycoproteins", "PROTEIN", 216, 235], ["irreversible post-translational modification", "PROBLEM", 18, 62], ["inactivation of proteins", "PROBLEM", 100, 124], ["growth factors", "PROBLEM", 134, 148], ["transcription factors", "PROBLEM", 171, 192], ["bacterial toxins", "PROBLEM", 194, 210], ["viral glycoproteins", "PROBLEM", 216, 235], ["irreversible", "OBSERVATION_MODIFIER", 18, 30], ["translational modification", "OBSERVATION", 36, 62], ["viral glycoproteins", "OBSERVATION", 216, 235]]], ["They have major implications in health and for disease due to their broad biological roles.7 Several modulators and inhibitors of proprotein convertases are being developed for hypercholesterolemia (proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors8, 9, 10, 11, 12, 13, 14, 15), viral infections (Furin, PACE4, and SKI-1 inhibitors16, 17, 18, 19, 20, 21, 22, 23, 24), and cancer immunotherapy (Furin and PACE4 inhibitors25, 26, 27, 28, 29, 30), as well as for use as a non-steroidal male contraceptive (PC4 inhibitors31, 32).IntroductionPCSK9 is a serine protease that belongs to the family of mammalian proprotein convertases.", [["cancer", "ANATOMY", 387, 393], ["hypercholesterolemia", "DISEASE", 177, 197], ["viral infections", "DISEASE", 294, 310], ["cancer", "DISEASE", 387, 393], ["serine", "CHEMICAL", 563, 569], ["proprotein convertase subtilisin/kexin type 9", "GENE_OR_GENE_PRODUCT", 199, 244], ["PCSK9", "GENE_OR_GENE_PRODUCT", 246, 251], ["Furin", "SIMPLE_CHEMICAL", 312, 317], ["PACE4", "GENE_OR_GENE_PRODUCT", 319, 324], ["SKI-1", "GENE_OR_GENE_PRODUCT", 330, 335], ["cancer", "CANCER", 387, 393], ["Furin", "SIMPLE_CHEMICAL", 409, 414], ["PACE4", "SIMPLE_CHEMICAL", 419, 424], ["proprotein convertases", "PROTEIN", 130, 152], ["PCSK9", "PROTEIN", 246, 251], ["IntroductionPCSK9", "PROTEIN", 540, 557], ["serine protease", "PROTEIN", 563, 578], ["mammalian proprotein convertases", "PROTEIN", 609, 641], ["disease", "PROBLEM", 47, 54], ["Several modulators", "TREATMENT", 93, 111], ["inhibitors of proprotein convertases", "TREATMENT", 116, 152], ["hypercholesterolemia", "PROBLEM", 177, 197], ["proprotein convertase subtilisin/kexin type", "TREATMENT", 199, 242], ["viral infections", "PROBLEM", 294, 310], ["Furin", "TEST", 312, 317], ["PACE4", "TEST", 319, 324], ["SKI", "TEST", 330, 333], ["cancer immunotherapy", "TREATMENT", 387, 407], ["Furin and PACE4 inhibitors25", "TEST", 409, 437], ["a non-steroidal male contraceptive (PC4 inhibitors31", "TREATMENT", 482, 534], ["a serine protease", "TREATMENT", 561, 578], ["mammalian proprotein convertases", "TREATMENT", 609, 641], ["viral infections", "OBSERVATION", 294, 310], ["cancer", "OBSERVATION", 387, 393]]], ["PCSK9 cleaves itself to form the catalytically inactive PCSK9 protein and a prosegment, which remains associated as a complex.", [["PCSK9", "GENE_OR_GENE_PRODUCT", 0, 5], ["PCSK9", "GENE_OR_GENE_PRODUCT", 56, 61], ["PCSK9", "PROTEIN", 0, 5], ["catalytically inactive PCSK9 protein", "PROTEIN", 33, 69], ["inactive", "OBSERVATION_MODIFIER", 47, 55], ["PCSK9", "OBSERVATION", 56, 61]]], ["The PCSK9-prosegment complex interacts with low-density lipoprotein receptor (LDLR), leading to its internalization and degradation.", [["PCSK9", "GENE_OR_GENE_PRODUCT", 4, 9], ["low-density lipoprotein receptor", "GENE_OR_GENE_PRODUCT", 44, 76], ["LDLR", "GENE_OR_GENE_PRODUCT", 78, 82], ["PCSK9", "PROTEIN", 4, 9], ["prosegment complex", "PROTEIN", 10, 28], ["low-density lipoprotein receptor", "PROTEIN", 44, 76], ["LDLR", "PROTEIN", 78, 82], ["The PCSK9", "TEST", 0, 9], ["PCSK9", "OBSERVATION", 4, 9], ["low-density", "OBSERVATION_MODIFIER", 44, 55], ["internalization", "OBSERVATION_MODIFIER", 100, 115]]], ["This decrease of LDLR on the hepatocyte surface results in decreased clearance of LDL particles from the circulation.33, 34, 35, 36, 37 Gain-of-function (GOF) mutations in PCSK9 leading to higher LDL-C levels have been reported to be associated with hypercholesterolemia and with an increased risk of CHD.34, 38, 39 Loss-of-function (LOF) mutations, on the other hand, have been correlated with decreased LDL-C and reduced CHD risk.", [["hepatocyte surface", "ANATOMY", 29, 47], ["hypercholesterolemia", "DISEASE", 250, 270], ["CHD", "DISEASE", 301, 304], ["CHD", "DISEASE", 423, 426], ["LDLR", "GENE_OR_GENE_PRODUCT", 17, 21], ["hepatocyte surface", "CELLULAR_COMPONENT", 29, 47], ["LDL", "SIMPLE_CHEMICAL", 82, 85], ["PCSK9", "GENE_OR_GENE_PRODUCT", 172, 177], ["LDL-C", "GENE_OR_GENE_PRODUCT", 196, 201], ["LDL-C", "GENE_OR_GENE_PRODUCT", 405, 410], ["LDLR", "PROTEIN", 17, 21], ["PCSK9", "PROTEIN", 172, 177], ["LDL", "PROTEIN", 196, 199], ["LDL", "PROTEIN", 405, 408], ["This decrease of LDLR", "PROBLEM", 0, 21], ["the hepatocyte surface", "TEST", 25, 47], ["decreased clearance of LDL particles", "PROBLEM", 59, 95], ["mutations in PCSK9", "PROBLEM", 159, 177], ["higher LDL-C levels", "PROBLEM", 189, 208], ["hypercholesterolemia", "PROBLEM", 250, 270], ["an increased risk of CHD", "PROBLEM", 280, 304], ["LOF) mutations", "PROBLEM", 334, 348], ["decreased LDL-C", "PROBLEM", 395, 410], ["reduced CHD risk", "PROBLEM", 415, 431], ["decrease", "OBSERVATION_MODIFIER", 5, 13], ["LDLR", "OBSERVATION", 17, 21], ["hepatocyte", "ANATOMY", 29, 39], ["surface", "OBSERVATION_MODIFIER", 40, 47], ["decreased", "OBSERVATION_MODIFIER", 59, 68], ["clearance", "OBSERVATION_MODIFIER", 69, 78], ["LDL particles", "OBSERVATION", 82, 95], ["circulation", "OBSERVATION_MODIFIER", 105, 116], ["hypercholesterolemia", "OBSERVATION", 250, 270], ["increased", "OBSERVATION_MODIFIER", 283, 292]]], ["In rare cases, severe LOF mutations that produce no detectable PCSK9 protein have been reported, exhibiting LDL-C levels around 15 mg/dL, and, interestingly, such individuals are identified without negative effects.7, 40, 41 Such individuals validate PCSK9 as a therapeutic target for pharmacological intervention.IntroductionPCSK9 inhibitors have emerged as a novel approach for the treatment of dyslipidemia.", [["dyslipidemia", "DISEASE", 397, 409], ["PCSK9", "GENE_OR_GENE_PRODUCT", 63, 68], ["LDL-C", "GENE_OR_GENE_PRODUCT", 108, 113], ["individuals", "ORGANISM", 230, 241], ["PCSK9", "GENE_OR_GENE_PRODUCT", 251, 256], ["PCSK9 protein", "PROTEIN", 63, 76], ["LDL", "PROTEIN", 108, 111], ["PCSK9", "PROTEIN", 251, 256], ["severe LOF mutations", "PROBLEM", 15, 35], ["detectable PCSK9 protein", "PROBLEM", 52, 76], ["LDL", "TEST", 108, 111], ["C levels", "TEST", 112, 120], ["pharmacological intervention", "TREATMENT", 285, 313], ["IntroductionPCSK9 inhibitors", "TREATMENT", 314, 342], ["a novel approach", "TREATMENT", 359, 375], ["dyslipidemia", "PROBLEM", 397, 409], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["LOF mutations", "OBSERVATION", 22, 35], ["dyslipidemia", "OBSERVATION", 397, 409]]], ["They are primarily being used for high-risk cardiovascular patients, including familial hypercholesterolemia cases, those who have managed LDL-C but are at high risk of plaque progression, and people who are statin intolerant.", [["cardiovascular", "ANATOMY", 44, 58], ["plaque", "ANATOMY", 169, 175], ["hypercholesterolemia", "DISEASE", 88, 108], ["plaque", "DISEASE", 169, 175], ["statin", "CHEMICAL", 208, 214], ["statin", "CHEMICAL", 208, 214], ["patients", "ORGANISM", 59, 67], ["LDL-C", "GENE_OR_GENE_PRODUCT", 139, 144], ["plaque", "PATHOLOGICAL_FORMATION", 169, 175], ["people", "ORGANISM", 193, 199], ["LDL", "PROTEIN", 139, 142], ["patients", "SPECIES", 59, 67], ["people", "SPECIES", 193, 199], ["familial hypercholesterolemia cases", "PROBLEM", 79, 114], ["plaque progression", "PROBLEM", 169, 187], ["statin intolerant", "PROBLEM", 208, 225], ["hypercholesterolemia", "OBSERVATION", 88, 108], ["plaque", "OBSERVATION", 169, 175]]], ["Around 5%\u201310% of patients treated with statins exhibit adverse side effects, such as muscle pain, weakness, and rhabdomyolysis.42, 43, 44, 45 Some approaches for PCSK9 inhibition involve monoclonal antibodies,46, 47, 48, 49, 50, 51 small interfering RNAs (siRNAs),13, 52 anti-sense oligonucleotides,53, 54 adnectins,55 small molecules,56, 57, 58, 59 peptide mimetics,60, 61, 62 and vaccines.63, 64, 65IntroductionCurrently there are two US Food and Drug Administration (FDA)-approved PCSK9 inhibitors, alirocumab (Regeneron and Sanofi) and evolocumab (Amgen), both of which are fully human monoclonal antibodies (mAbs) targeting PCSK9.", [["muscle", "ANATOMY", 85, 91], ["statins", "CHEMICAL", 39, 46], ["muscle pain", "DISEASE", 85, 96], ["weakness", "DISEASE", 98, 106], ["rhabdomyolysis", "DISEASE", 112, 126], ["alirocumab", "CHEMICAL", 502, 512], ["Regeneron", "CHEMICAL", 514, 523], ["Sanofi", "CHEMICAL", 528, 534], ["evolocumab", "CHEMICAL", 540, 550], ["statins", "CHEMICAL", 39, 46], ["alirocumab", "CHEMICAL", 502, 512], ["Regeneron", "CHEMICAL", 514, 523], ["evolocumab", "CHEMICAL", 540, 550], ["patients", "ORGANISM", 17, 25], ["muscle", "ORGAN", 85, 91], ["PCSK9", "GENE_OR_GENE_PRODUCT", 162, 167], ["adnectins", "GENE_OR_GENE_PRODUCT", 306, 315], ["PCSK9", "GENE_OR_GENE_PRODUCT", 484, 489], ["alirocumab", "SIMPLE_CHEMICAL", 502, 512], ["Regeneron", "SIMPLE_CHEMICAL", 514, 523], ["Sanofi", "SIMPLE_CHEMICAL", 528, 534], ["evolocumab", "SIMPLE_CHEMICAL", 540, 550], ["human", "ORGANISM", 584, 589], ["PCSK9", "GENE_OR_GENE_PRODUCT", 629, 634], ["PCSK9", "PROTEIN", 162, 167], ["monoclonal antibodies", "PROTEIN", 187, 208], ["46, 47, 48, 49, 50, 51 small interfering RNAs", "RNA", 209, 254], ["human monoclonal antibodies", "PROTEIN", 584, 611], ["mAbs", "PROTEIN", 613, 617], ["PCSK9", "PROTEIN", 629, 634], ["patients", "SPECIES", 17, 25], ["human", "SPECIES", 584, 589], ["human", "SPECIES", 584, 589], ["statins", "TREATMENT", 39, 46], ["adverse side effects", "PROBLEM", 55, 75], ["muscle pain", "PROBLEM", 85, 96], ["weakness", "PROBLEM", 98, 106], ["rhabdomyolysis", "PROBLEM", 112, 126], ["PCSK9 inhibition", "TEST", 162, 178], ["monoclonal antibodies", "TEST", 187, 208], ["small interfering RNAs", "PROBLEM", 232, 254], ["siRNAs", "TEST", 256, 262], ["anti-sense oligonucleotides", "TEST", 271, 298], ["peptide mimetics", "TEST", 350, 366], ["vaccines", "TREATMENT", 382, 390], ["Drug Administration", "TREATMENT", 449, 468], ["PCSK9 inhibitors", "TREATMENT", 484, 500], ["alirocumab", "TREATMENT", 502, 512], ["Regeneron", "TREATMENT", 514, 523], ["Sanofi", "TREATMENT", 528, 534], ["evolocumab (Amgen)", "TREATMENT", 540, 558], ["muscle", "ANATOMY", 85, 91], ["weakness", "OBSERVATION", 98, 106], ["rhabdomyolysis", "OBSERVATION", 112, 126]]], ["Clinical trials on high-risk cardiovascular patients have demonstrated their efficacy in reducing LDL-C.", [["cardiovascular", "ANATOMY", 29, 43], ["patients", "ORGANISM", 44, 52], ["LDL", "PROTEIN", 98, 101], ["patients", "SPECIES", 44, 52], ["Clinical trials", "TEST", 0, 15]]], ["In the RUTHERFORD-2 clinical trial on heterozygous familial hypercholesterolemia patients, treatment with evolocumab (140 mg/2 weeks or 420 mg/month) resulted in a 60%\u201365% decrease in LDL-C levels.", [["familial hypercholesterolemia", "DISEASE", 51, 80], ["evolocumab", "CHEMICAL", 106, 116], ["evolocumab", "CHEMICAL", 106, 116], ["patients", "ORGANISM", 81, 89], ["evolocumab", "SIMPLE_CHEMICAL", 106, 116], ["LDL-C", "SIMPLE_CHEMICAL", 184, 189], ["LDL", "PROTEIN", 184, 187], ["patients", "SPECIES", 81, 89], ["heterozygous familial hypercholesterolemia", "PROBLEM", 38, 80], ["evolocumab", "TREATMENT", 106, 116], ["LDL", "TEST", 184, 187], ["familial", "OBSERVATION_MODIFIER", 51, 59], ["hypercholesterolemia", "OBSERVATION", 60, 80]]], ["More than 60% of the patients were able to reach their LDL-C goal of 70 mg/dL.66 In the ODYSSEY HIGH clinical trial on familial hypercholesterolemia patients treated with alirocumab (75/150 mg every 2 weeks), 57% of those with difficult-to-treat severe familial hypercholesterolemia were able to reach their LDL-C goal of 100 mg/dL.67 Moreover, when alirocumab was administered to statin-treated patients, they achieved significantly greater reductions in LDL-C than those who doubled their dose of statin or received the addition of ezetimibe.67, 68, 69, 70IntroductionCost is a major limitation in the clinical management of high-risk cardiovascular patients.", [["cardiovascular", "ANATOMY", 637, 651], ["hypercholesterolemia", "DISEASE", 128, 148], ["alirocumab", "CHEMICAL", 171, 181], ["hypercholesterolemia", "DISEASE", 262, 282], ["alirocumab", "CHEMICAL", 350, 360], ["statin", "CHEMICAL", 381, 387], ["statin", "CHEMICAL", 499, 505], ["ezetimibe", "CHEMICAL", 534, 543], ["alirocumab", "CHEMICAL", 171, 181], ["alirocumab", "CHEMICAL", 350, 360], ["statin", "CHEMICAL", 381, 387], ["statin", "CHEMICAL", 499, 505], ["ezetimibe", "CHEMICAL", 534, 543], ["patients", "ORGANISM", 21, 29], ["LDL-C", "SIMPLE_CHEMICAL", 55, 60], ["patients", "ORGANISM", 149, 157], ["alirocumab", "SIMPLE_CHEMICAL", 171, 181], ["LDL-C", "SIMPLE_CHEMICAL", 308, 313], ["alirocumab", "SIMPLE_CHEMICAL", 350, 360], ["statin", "SIMPLE_CHEMICAL", 381, 387], ["patients", "ORGANISM", 396, 404], ["LDL-C", "SIMPLE_CHEMICAL", 456, 461], ["statin", "SIMPLE_CHEMICAL", 499, 505], ["ezetimibe", "SIMPLE_CHEMICAL", 534, 543], ["patients", "ORGANISM", 652, 660], ["LDL", "PROTEIN", 55, 58], ["LDL", "PROTEIN", 308, 311], ["LDL", "PROTEIN", 456, 459], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 396, 404], ["patients", "SPECIES", 652, 660], ["LDL", "TEST", 55, 58], ["familial hypercholesterolemia", "PROBLEM", 119, 148], ["alirocumab", "TREATMENT", 171, 181], ["severe familial hypercholesterolemia", "PROBLEM", 246, 282], ["alirocumab", "TREATMENT", 350, 360], ["statin", "TREATMENT", 381, 387], ["statin", "TREATMENT", 499, 505], ["ezetimibe", "TREATMENT", 534, 543], ["the clinical management", "TREATMENT", 600, 623], ["hypercholesterolemia", "OBSERVATION", 262, 282], ["cardiovascular", "ANATOMY", 637, 651]]], ["Biological products such as recombinant mAbs are complex and expensive to manufacture.", [["mAbs", "GENE_OR_GENE_PRODUCT", 40, 44], ["recombinant mAbs", "PROTEIN", 28, 44], ["Biological products", "TREATMENT", 0, 19], ["recombinant mAbs", "TREATMENT", 28, 44]]], ["Evolocumab and alirocumab are projected to cost around $14,350 per year per patient.71 A recent analysis on the cost-effectiveness of PCSK9 inhibitors for use in atherosclerotic cardiovascular disease (ASCVD) patients found that these inhibitors are poorly cost-effective and that a 71% reduction in price is needed to reach the patient willingness-to-pay threshold of $100,000/quality-adjusted life-year (QALY).72 In addition to the high cost, current anti-PCSK9 recombinant antibodies require frequent administration, such as injections every 2 weeks.", [["atherosclerotic cardiovascular", "ANATOMY", 162, 192], ["Evolocumab", "CHEMICAL", 0, 10], ["alirocumab", "CHEMICAL", 15, 25], ["atherosclerotic cardiovascular disease", "DISEASE", 162, 200], ["ASCVD", "DISEASE", 202, 207], ["Evolocumab", "CHEMICAL", 0, 10], ["alirocumab", "CHEMICAL", 15, 25], ["Evolocumab", "SIMPLE_CHEMICAL", 0, 10], ["alirocumab", "SIMPLE_CHEMICAL", 15, 25], ["patient", "ORGANISM", 76, 83], ["PCSK9", "GENE_OR_GENE_PRODUCT", 134, 139], ["cardiovascular", "ANATOMICAL_SYSTEM", 178, 192], ["patients", "ORGANISM", 209, 217], ["patient", "ORGANISM", 329, 336], ["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 453, 463], ["PCSK9", "PROTEIN", 134, 139], ["anti-PCSK9 recombinant antibodies", "PROTEIN", 453, 486], ["patient", "SPECIES", 76, 83], ["patients", "SPECIES", 209, 217], ["patient", "SPECIES", 329, 336], ["Evolocumab and alirocumab", "TREATMENT", 0, 25], ["A recent analysis", "TEST", 87, 104], ["PCSK9 inhibitors", "TREATMENT", 134, 150], ["atherosclerotic cardiovascular disease", "PROBLEM", 162, 200], ["these inhibitors", "PROBLEM", 229, 245], ["a 71% reduction in price", "TREATMENT", 281, 305], ["the high cost", "PROBLEM", 430, 443], ["current anti-PCSK9 recombinant antibodies", "TREATMENT", 445, 486], ["frequent administration", "TREATMENT", 495, 518], ["alirocumab", "OBSERVATION", 15, 25], ["atherosclerotic", "OBSERVATION_MODIFIER", 162, 177], ["cardiovascular disease", "OBSERVATION", 178, 200]]], ["Development of more cost-effective, longer-lived, and potent pharmacologic interventions would provide an avenue for making such therapeutics more widely available for high-risk cardiovascular patients.IntroductionCompared to other therapeutic approaches, with in vivo electroporation technology, the plasmid DNA is delivered transiently and is not integrated, therefore allowing for repeat administration without any adverse consequences.", [["cardiovascular", "ANATOMY", 178, 192], ["plasmid", "ANATOMY", 301, 308], ["patients", "ORGANISM", 193, 201], ["DNA", "CELLULAR_COMPONENT", 309, 312], ["plasmid DNA", "DNA", 301, 312], ["patients", "SPECIES", 193, 201], ["potent pharmacologic interventions", "TREATMENT", 54, 88], ["vivo electroporation technology", "TREATMENT", 264, 295], ["the plasmid DNA", "TREATMENT", 297, 312], ["repeat administration", "TREATMENT", 384, 405], ["any adverse consequences", "PROBLEM", 414, 438], ["more", "OBSERVATION_MODIFIER", 15, 19], ["cost-effective", "OBSERVATION_MODIFIER", 20, 34]]], ["Furthermore, with the recombinant protein therapy approach, numerous repeat administrations are required, which generally come at a high financial cost to the patient.", [["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["the recombinant protein therapy approach", "TREATMENT", 18, 58], ["numerous repeat administrations", "TREATMENT", 60, 91]]], ["With the DNA-encoded mAb (DMAb) platform it is possible to administer therapeutics repeatedly without facing challenges such as pre-existing immunity, difficult manufacturing processes, or high cost.", [["DNA", "CELLULAR_COMPONENT", 9, 12], ["mAb", "GENE_OR_GENE_PRODUCT", 21, 24], ["DNA-encoded mAb", "PROTEIN", 9, 24], ["DMAb", "PROTEIN", 26, 30], ["the DNA", "TREATMENT", 5, 12], ["therapeutics", "TREATMENT", 70, 82], ["facing challenges", "TREATMENT", 102, 119]]], ["DMAb technology represents a new approach for a direct in vivo production of biologically active immunoglobulins in a patient in a non-permanent fashion.", [["immunoglobulins", "GENE_OR_GENE_PRODUCT", 97, 112], ["patient", "ORGANISM", 118, 125], ["immunoglobulins", "PROTEIN", 97, 112], ["patient", "SPECIES", 118, 125], ["a new approach", "TREATMENT", 27, 41], ["biologically active immunoglobulins", "TREATMENT", 77, 112]]], ["Low-voltage electropermeabilization allows for robust plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence can now drive transcription and in vivo translation of the desired protein.", [["plasmid", "ANATOMY", 54, 61], ["tissue", "ANATOMY", 80, 86], ["plasmid", "ANATOMY", 107, 114], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["tissue", "TISSUE", 80, 86], ["delivered plasmid", "DNA", 97, 114], ["encoded antibody sequence", "DNA", 129, 154], ["Low-voltage electropermeabilization", "TREATMENT", 0, 35], ["robust plasmid DNA delivery", "TREATMENT", 47, 74], ["the delivered plasmid", "TREATMENT", 93, 114], ["an encoded antibody sequence", "TREATMENT", 126, 154]]], ["While there have been a few recent reports describing adaptations of this technology as an approach to specific infectious diseases or cancer targets,73, 74, 75, 76, 77 there have not been reports of utilizing this approach for in vivo chronic disease therapy.IntroductionHere we developed a DMAb approach (Figure 1A) targeting PCSK9 based on engineering a plasmid DNA to encode a novel anti-PCSK9 mAb as a single insert expression cassette, named daPCSK9 (labeled HdaPCSK9 [human] or MdaPCSK9 [mouse], respectively bearing human or mouse Fc regions).", [["cancer", "ANATOMY", 135, 141], ["plasmid", "ANATOMY", 357, 364], ["infectious diseases", "DISEASE", 112, 131], ["cancer", "DISEASE", 135, 141], ["chronic disease", "DISEASE", 236, 251], ["cancer", "CANCER", 135, 141], ["PCSK9", "GENE_OR_GENE_PRODUCT", 328, 333], ["DNA", "CELLULAR_COMPONENT", 365, 368], ["anti-PCSK9 mAb", "GENE_OR_GENE_PRODUCT", 387, 401], ["daPCSK9", "GENE_OR_GENE_PRODUCT", 448, 455], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 465, 473], ["human", "ORGANISM", 475, 480], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 485, 493], ["mouse", "ORGANISM", 495, 500], ["human", "ORGANISM", 524, 529], ["mouse", "ORGANISM", 533, 538], ["Fc", "GENE_OR_GENE_PRODUCT", 539, 541], ["PCSK9", "PROTEIN", 328, 333], ["plasmid DNA", "DNA", 357, 368], ["anti-PCSK9 mAb", "PROTEIN", 387, 401], ["single insert expression cassette", "DNA", 407, 440], ["daPCSK9", "PROTEIN", 448, 455], ["HdaPCSK9", "PROTEIN", 465, 473], ["MdaPCSK9", "PROTEIN", 485, 493], ["human or mouse Fc regions", "DNA", 524, 549], ["human", "SPECIES", 475, 480], ["mouse", "SPECIES", 495, 500], ["human", "SPECIES", 524, 529], ["mouse", "SPECIES", 533, 538], ["human", "SPECIES", 475, 480], ["mouse", "SPECIES", 495, 500], ["human", "SPECIES", 524, 529], ["mouse", "SPECIES", 533, 538], ["this technology", "TREATMENT", 69, 84], ["specific infectious diseases", "PROBLEM", 103, 131], ["cancer targets", "PROBLEM", 135, 149], ["this approach", "TREATMENT", 210, 223], ["vivo chronic disease therapy", "TREATMENT", 231, 259], ["a DMAb approach", "TREATMENT", 290, 305], ["PCSK9", "TREATMENT", 328, 333], ["a plasmid DNA", "TREATMENT", 355, 368], ["a novel anti-PCSK9 mAb", "TREATMENT", 379, 401], ["a single insert expression cassette", "TREATMENT", 405, 440], ["few", "OBSERVATION_MODIFIER", 24, 27], ["infectious", "OBSERVATION_MODIFIER", 112, 122], ["chronic", "OBSERVATION_MODIFIER", 236, 243], ["disease", "OBSERVATION", 244, 251]]], ["In vivo daPCSK9 plasmid administration using electroporation-enhanced intramuscular injection was performed to evaluate anti-PCSK9 DMAb production kinetics and the efficacy of PCSK9 inhibition on lipid reduction in vivo.", [["plasmid", "ANATOMY", 16, 23], ["intramuscular", "ANATOMY", 70, 83], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 83], ["DMAb", "SIMPLE_CHEMICAL", 131, 135], ["PCSK9", "GENE_OR_GENE_PRODUCT", 176, 181], ["lipid", "SIMPLE_CHEMICAL", 196, 201], ["daPCSK9 plasmid", "DNA", 8, 23], ["DMAb", "PROTEIN", 131, 135], ["PCSK9", "PROTEIN", 176, 181], ["vivo daPCSK9 plasmid administration", "TREATMENT", 3, 38], ["electroporation-enhanced intramuscular injection", "TREATMENT", 45, 93], ["anti-PCSK9", "TREATMENT", 120, 130], ["DMAb production kinetics", "PROBLEM", 131, 155], ["PCSK9 inhibition", "TREATMENT", 176, 192], ["lipid reduction", "TREATMENT", 196, 211]]], ["Robust production of anti-PCSK9 DMAb began within days of administration, with peak levels of antibody achieved by 1 week post-injection.", [["anti-PCSK9 DMAb", "SIMPLE_CHEMICAL", 21, 36], ["anti-PCSK9 DMAb", "PROTEIN", 21, 36], ["anti-PCSK9 DMAb", "TREATMENT", 21, 36], ["peak levels", "TEST", 79, 90], ["antibody", "TEST", 94, 102]]], ["PCSK9 DMAb could be detected in sera for up to 2 months, and levels could be boosted with additional administrations.", [["sera", "ANATOMY", 32, 36], ["PCSK9", "GENE_OR_GENE_PRODUCT", 0, 5], ["sera", "ORGANISM_SUBSTANCE", 32, 36], ["PCSK9 DMAb", "PROTEIN", 0, 10], ["PCSK9 DMAb", "TREATMENT", 0, 10], ["sera", "TEST", 32, 36]]], ["In vivo-produced anti-PCSK9 DMAb retained its ability to bind to its target.", [["DMAb", "CHEMICAL", 28, 32], ["anti-PCSK9 DMAb", "SIMPLE_CHEMICAL", 17, 32], ["anti-PCSK9 DMAb", "PROTEIN", 17, 32], ["anti-PCSK9 DMAb", "TREATMENT", 17, 32]]], ["An increase in LDLR was detected upon in vivo administration and expression of daPCSK9.", [["LDLR", "GENE_OR_GENE_PRODUCT", 15, 19], ["daPCSK9", "GENE_OR_GENE_PRODUCT", 79, 86], ["LDLR", "PROTEIN", 15, 19], ["daPCSK9", "PROTEIN", 79, 86], ["An increase in LDLR", "PROBLEM", 0, 19], ["vivo administration", "TREATMENT", 41, 60], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["LDLR", "OBSERVATION", 15, 19]]], ["This was accompanied by significant reductions in non-high-density lipoprotein cholesterol (non-HDL-C) and total cholesterol levels in both C57BL/6 and nude mice studies.", [["cholesterol", "CHEMICAL", 79, 90], ["cholesterol", "CHEMICAL", 113, 124], ["cholesterol", "CHEMICAL", 79, 90], ["cholesterol", "CHEMICAL", 113, 124], ["non-high-density lipoprotein cholesterol", "SIMPLE_CHEMICAL", 50, 90], ["non-HDL-C", "SIMPLE_CHEMICAL", 92, 101], ["cholesterol", "SIMPLE_CHEMICAL", 113, 124], ["C57BL/6", "ORGANISM", 140, 147], ["nude mice", "ORGANISM", 152, 161], ["HDL", "PROTEIN", 96, 99], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 157, 161], ["significant reductions", "PROBLEM", 24, 46], ["non-high-density lipoprotein cholesterol", "TEST", 50, 90], ["HDL", "TEST", 96, 99], ["total cholesterol levels", "TEST", 107, 131], ["nude mice studies", "TEST", 152, 169], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["reductions", "OBSERVATION_MODIFIER", 36, 46]]], ["These observations support an exciting proof of principle for further study utilizing daPCSK9 DMAb approaches for the treatment of dyslipidemic disorders.Construction of Mouse Anti-PCSK9 DMAb Plasmids and In\u00a0Vitro Characterization ::: ResultsThe mouse anti-PCSK9 (IgG2a) was designed in a single linked heavy- and light-chain cassette to be expressed from a single open reading frame, with the heavy- and light-chain genes separated by a previously developed furin/P2A cleavage site (Figure 1B) to provide efficient protein processing necessary for immunoglobulin G (IgG) production in vivo.", [["dyslipidemic disorders", "DISEASE", 131, 153], ["daPCSK9 DMAb", "SIMPLE_CHEMICAL", 86, 98], ["Mouse", "ORGANISM", 170, 175], ["mouse", "ORGANISM", 246, 251], ["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 252, 262], ["IgG2a", "GENE_OR_GENE_PRODUCT", 264, 269], ["furin", "GENE_OR_GENE_PRODUCT", 459, 464], ["P2A", "GENE_OR_GENE_PRODUCT", 465, 468], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 549, 565], ["IgG", "GENE_OR_GENE_PRODUCT", 567, 570], ["mouse anti-PCSK9", "PROTEIN", 246, 262], ["IgG2a", "PROTEIN", 264, 269], ["heavy- and light-chain cassette", "DNA", 303, 334], ["open reading frame", "DNA", 365, 383], ["heavy- and light-chain genes", "DNA", 394, 422], ["furin/P2A cleavage site", "DNA", 459, 482], ["immunoglobulin G", "PROTEIN", 549, 565], ["IgG", "PROTEIN", 567, 570], ["Mouse", "SPECIES", 170, 175], ["mouse", "SPECIES", 246, 251], ["mouse", "SPECIES", 246, 251], ["further study", "TEST", 62, 75], ["daPCSK9 DMAb approaches", "TREATMENT", 86, 109], ["dyslipidemic disorders", "PROBLEM", 131, 153], ["Mouse Anti-PCSK9 DMAb Plasmids", "TREATMENT", 170, 200], ["light-chain cassette", "TREATMENT", 314, 334], ["furin/P2A cleavage site", "TREATMENT", 459, 482], ["efficient protein processing", "TREATMENT", 506, 534], ["immunoglobulin G (IgG)", "TREATMENT", 549, 571], ["dyslipidemic", "OBSERVATION", 131, 143]]], ["A cytomegalovirus (CMV) promoter in the pVax-1 vector was used to drive the expression of the antibodies, and the final construct was designated MdaPCSK9.", [["cytomegalovirus", "ORGANISM", 2, 17], ["CMV", "ORGANISM", 19, 22], ["pVax-1", "GENE_OR_GENE_PRODUCT", 40, 46], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 145, 153], ["cytomegalovirus (CMV) promoter", "DNA", 2, 32], ["pVax-1 vector", "DNA", 40, 53], ["antibodies", "PROTEIN", 94, 104], ["MdaPCSK9", "DNA", 145, 153], ["CMV", "SPECIES", 19, 22], ["A cytomegalovirus (CMV) promoter", "TREATMENT", 0, 32], ["cytomegalovirus", "OBSERVATION", 2, 17]]], ["At 72 hr after plasmid transfection into HEK293T cells, secreted antibody expression in supernatants was determined to be 831 ng/mL for MdaPCSK9 (Figure 2A).", [["plasmid", "ANATOMY", 15, 22], ["HEK293T cells", "ANATOMY", 41, 54], ["supernatants", "ANATOMY", 88, 100], ["HEK293T cells", "CELL", 41, 54], ["HEK293T cells", "CELL_LINE", 41, 54], ["MdaPCSK9", "PROTEIN", 136, 144], ["plasmid transfection into HEK293T cells", "TREATMENT", 15, 54], ["secreted antibody expression in supernatants", "PROBLEM", 56, 100]]], ["Western blot-binding studies, using supernatants from MdaPCSK9 DMAb-transfected cells, showed specific binding to both human and mouse recombinant PCSK9 antigens, with greater binding detected to human PCSK9 (Figure 2B).", [["supernatants", "ANATOMY", 36, 48], ["cells", "ANATOMY", 80, 85], ["MdaPCSK9 DMAb", "CELL", 54, 67], ["cells", "CELL", 80, 85], ["human", "ORGANISM", 119, 124], ["mouse", "ORGANISM", 129, 134], ["PCSK9", "GENE_OR_GENE_PRODUCT", 147, 152], ["human", "ORGANISM", 196, 201], ["PCSK9", "GENE_OR_GENE_PRODUCT", 202, 207], ["MdaPCSK9 DMAb", "CELL_LINE", 54, 67], ["transfected cells", "CELL_LINE", 68, 85], ["human and mouse recombinant PCSK9 antigens", "PROTEIN", 119, 161], ["human PCSK9", "PROTEIN", 196, 207], ["Figure 2B", "PROTEIN", 209, 218], ["human", "SPECIES", 119, 124], ["mouse", "SPECIES", 129, 134], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 119, 124], ["mouse", "SPECIES", 129, 134], ["human", "SPECIES", 196, 201], ["blot-binding studies", "TEST", 8, 28], ["transfected cells", "PROBLEM", 68, 85], ["specific binding", "PROBLEM", 94, 110], ["greater binding", "PROBLEM", 168, 183]]], ["This showed proper binding activity of MdaPCSK9 against the PCSK9 antigen.", [["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 39, 47], ["PCSK9 antigen", "GENE_OR_GENE_PRODUCT", 60, 73], ["MdaPCSK9", "PROTEIN", 39, 47], ["PCSK9 antigen", "PROTEIN", 60, 73], ["binding activity", "OBSERVATION", 19, 35]]], ["Fluorescence microscopy was also used to demonstrate MdaPCSK9 expression in Hepa1-6 cells (Figure 2C), and it showed a strong expression of MdaPCSK9 in DMAb plasmid-transfected, but not control, pVax1-transfected cells.In\u00a0Vivo Expression and Kinetics of MdaPCSK9 ::: ResultsThe expression level and duration of the daPCSK9 DMAbs were evaluated in C57BL/6J wild-type and nude B6.Cg-foxn1nu/J mice (Jackson Laboratory) (Figure 3).", [["Hepa1-6 cells", "ANATOMY", 76, 89], ["cells", "ANATOMY", 213, 218], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 53, 61], ["Hepa1-6 cells", "CELL", 76, 89], ["Figure 2C", "CELL", 91, 100], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 140, 148], ["DMAb", "GENE_OR_GENE_PRODUCT", 152, 156], ["pVax1", "GENE_OR_GENE_PRODUCT", 195, 200], ["cells", "CELL", 213, 218], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 254, 262], ["daPCSK9", "GENE_OR_GENE_PRODUCT", 315, 322], ["C57BL/6J wild-type", "ORGANISM", 347, 365], ["nude B6", "ORGANISM", 370, 377], ["Cg-foxn1nu", "GENE_OR_GENE_PRODUCT", 378, 388], ["MdaPCSK9", "PROTEIN", 53, 61], ["Hepa1-6 cells", "CELL_LINE", 76, 89], ["MdaPCSK9", "PROTEIN", 140, 148], ["DMAb plasmid", "DNA", 152, 164], ["pVax1-transfected cells", "CELL_LINE", 195, 218], ["MdaPCSK9", "PROTEIN", 254, 262], ["daPCSK9 DMAbs", "PROTEIN", 315, 328], ["mice", "SPECIES", 391, 395], ["Fluorescence microscopy", "TEST", 0, 23], ["Hepa1", "TEST", 76, 81], ["MdaPCSK9 in DMAb plasmid", "TREATMENT", 140, 164], ["pVax1", "TEST", 195, 200], ["the daPCSK9 DMAbs", "TEST", 311, 328], ["Cg", "TEST", 378, 380], ["transfected cells", "OBSERVATION", 201, 218]]], ["Plasmid DNA (100 or 300 \u03bcg) was injected intramuscularly into the tibialis anterior muscle, followed by electroporation (IM-EP). daPCSK9 with a mouse backbone demonstrated high expression with a long duration.", [["Plasmid", "ANATOMY", 0, 7], ["intramuscularly", "ANATOMY", 41, 56], ["tibialis anterior muscle", "ANATOMY", 66, 90], ["Plasmid DNA", "CELLULAR_COMPONENT", 0, 11], ["tibialis anterior muscle", "TISSUE", 66, 90], ["daPCSK9", "GENE_OR_GENE_PRODUCT", 129, 136], ["mouse", "ORGANISM", 144, 149], ["daPCSK9", "PROTEIN", 129, 136], ["mouse", "SPECIES", 144, 149], ["mouse", "SPECIES", 144, 149], ["Plasmid DNA", "TREATMENT", 0, 11], ["a mouse backbone", "TREATMENT", 142, 158], ["tibialis", "ANATOMY", 66, 74], ["anterior", "ANATOMY_MODIFIER", 75, 83], ["muscle", "ANATOMY", 84, 90], ["high expression", "OBSERVATION", 172, 187]]], ["MdaPCSK9 levels reached a maximum mean of 2,902 ng/mL at day 14, and they persisted for over 6 weeks, with blood levels at 1,649 ng/mL on day 42.", [["blood", "ANATOMY", 107, 112], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["MdaPCSK9", "PROTEIN", 0, 8], ["MdaPCSK9 levels", "TEST", 0, 15], ["a maximum mean", "TEST", 24, 38], ["blood levels", "TEST", 107, 119]]], ["In nude mice, the MdaPCSK9 expression was higher, reaching a maximum mean of 4,923 ng/mL at day 21, and expression persisted through the last bleed at day 42.", [["nude mice", "ORGANISM", 3, 12], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 18, 26], ["MdaPCSK9", "PROTEIN", 18, 26], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["the last bleed", "PROBLEM", 133, 147], ["higher", "OBSERVATION_MODIFIER", 42, 48]]], ["Sequential administration of mouse DMAbs at days 0, 21, and 42 resulted in continuous increases in DMAb expression, with MdaPCSK9 levels reaching 7,521 ng/mL (3 \u00d7 100 \u03bcg doses) on day 62 (Figure 3C).", [["DMAbs", "CHEMICAL", 35, 40], ["mouse", "ORGANISM", 29, 34], ["DMAb", "GENE_OR_GENE_PRODUCT", 99, 103], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 121, 129], ["DMAb", "PROTEIN", 99, 103], ["MdaPCSK9", "PROTEIN", 121, 129], ["mouse", "SPECIES", 29, 34], ["mouse", "SPECIES", 29, 34], ["mouse DMAbs", "TREATMENT", 29, 40], ["continuous increases in DMAb expression", "PROBLEM", 75, 114], ["MdaPCSK9 levels", "TEST", 121, 136], ["increases", "OBSERVATION_MODIFIER", 86, 95], ["DMAb", "OBSERVATION", 99, 103]]], ["This highlights the sustainability of DMAb expression over long periods.", [["DMAb", "GENE_OR_GENE_PRODUCT", 38, 42], ["DMAb", "PROTEIN", 38, 42], ["DMAb expression", "PROBLEM", 38, 53], ["sustainability", "OBSERVATION_MODIFIER", 20, 34], ["DMAb", "OBSERVATION", 38, 42]]], ["Improved MdaPCSK9 expression was observed when doses were spread out over several-week periods, simplifying administration.PCSK9 Protein Binding and Inhibition by DMAbs ::: ResultsPCSK9 inhibition was determined using western blot analysis of LDLR expression levels in mouse liver sections (Figure 4A).", [["liver sections", "ANATOMY", 275, 289], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 9, 17], ["PCSK9", "GENE_OR_GENE_PRODUCT", 123, 128], ["DMAbs", "SIMPLE_CHEMICAL", 163, 168], ["ResultsPCSK9", "GENE_OR_GENE_PRODUCT", 173, 185], ["LDLR", "GENE_OR_GENE_PRODUCT", 243, 247], ["mouse", "ORGANISM", 269, 274], ["liver sections", "MULTI-TISSUE_STRUCTURE", 275, 289], ["MdaPCSK9", "DNA", 9, 17], ["PCSK9", "PROTEIN", 123, 128], ["ResultsPCSK9", "PROTEIN", 173, 185], ["LDLR", "PROTEIN", 243, 247], ["mouse", "SPECIES", 269, 274], ["mouse", "SPECIES", 269, 274], ["western blot analysis", "TEST", 218, 239], ["LDLR expression levels", "TEST", 243, 265], ["liver", "ANATOMY", 275, 280]]], ["Mouse livers were harvested at day 5, and the LDLR expression was evaluated by comparing the human and MdaPCSK9-treated mice to pVax-1 control mice.", [["livers", "ANATOMY", 6, 12], ["Mouse", "ORGANISM", 0, 5], ["livers", "ORGAN", 6, 12], ["LDLR", "GENE_OR_GENE_PRODUCT", 46, 50], ["human", "ORGANISM", 93, 98], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 103, 111], ["mice", "ORGANISM", 120, 124], ["pVax-1", "GENE_OR_GENE_PRODUCT", 128, 134], ["mice", "ORGANISM", 143, 147], ["LDLR", "PROTEIN", 46, 50], ["MdaPCSK9", "PROTEIN", 103, 111], ["Mouse", "SPECIES", 0, 5], ["human", "SPECIES", 93, 98], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 143, 147], ["Mouse", "SPECIES", 0, 5], ["human", "SPECIES", 93, 98], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 143, 147], ["MdaPCSK9", "TEST", 103, 111], ["pVax", "TREATMENT", 128, 132], ["livers", "ANATOMY", 6, 12], ["harvested", "OBSERVATION", 18, 27]]], ["Western blot analysis showed that LDLR expression levels were significantly higher for PCSK9 DMAb-treated mice than control mice.", [["DMAb", "CHEMICAL", 93, 97], ["LDLR", "GENE_OR_GENE_PRODUCT", 34, 38], ["PCSK9", "GENE_OR_GENE_PRODUCT", 87, 92], ["DMAb", "GENE_OR_GENE_PRODUCT", 93, 97], ["mice", "ORGANISM", 106, 110], ["mice", "ORGANISM", 124, 128], ["LDLR", "PROTEIN", 34, 38], ["PCSK9", "PROTEIN", 87, 92], ["DMAb", "PROTEIN", 93, 97], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 124, 128], ["Western blot analysis", "TEST", 0, 21], ["LDLR expression levels", "TEST", 34, 56], ["PCSK9 DMAb", "TREATMENT", 87, 97]]], ["ELISA protein quantification was used to detect the presence of DMAbs in the livers of treated mice.", [["livers", "ANATOMY", 77, 83], ["DMAbs", "SIMPLE_CHEMICAL", 64, 69], ["livers", "ORGAN", 77, 83], ["mice", "ORGANISM", 95, 99], ["DMAbs", "PROTEIN", 64, 69], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["ELISA protein quantification", "TEST", 0, 28], ["DMAbs", "PROBLEM", 64, 69], ["livers", "ANATOMY", 77, 83]]], ["DMAb levels were 185 ng/mg tissue for MdaPCSK9 (Figure 4B).", [["tissue", "ANATOMY", 27, 33], ["DMAb", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissue", "TISSUE", 27, 33], ["DMAb", "PROTEIN", 0, 4], ["MdaPCSK9", "PROTEIN", 38, 46], ["DMAb levels", "TEST", 0, 11], ["MdaPCSK9", "TEST", 38, 46]]], ["Binding western blot analysis was used to evaluate the binding of DMAbs from serum samples of DMAb-treated and untreated mice to human and mouse PCSK9 protein (Figure 4C).", [["serum samples", "ANATOMY", 77, 90], ["DMAb", "CHEMICAL", 94, 98], ["DMAbs", "CHEMICAL", 66, 71], ["DMAb", "CHEMICAL", 94, 98], ["DMAbs", "SIMPLE_CHEMICAL", 66, 71], ["serum samples", "ORGANISM_SUBSTANCE", 77, 90], ["DMAb", "SIMPLE_CHEMICAL", 94, 98], ["mice", "ORGANISM", 121, 125], ["human", "ORGANISM", 129, 134], ["mouse", "ORGANISM", 139, 144], ["PCSK9", "GENE_OR_GENE_PRODUCT", 145, 150], ["DMAbs", "PROTEIN", 66, 71], ["DMAb", "PROTEIN", 94, 98], ["human and mouse PCSK9 protein", "PROTEIN", 129, 158], ["mice", "SPECIES", 121, 125], ["human", "SPECIES", 129, 134], ["mouse", "SPECIES", 139, 144], ["mice", "SPECIES", 121, 125], ["human", "SPECIES", 129, 134], ["mouse", "SPECIES", 139, 144], ["Binding western blot analysis", "TEST", 0, 29], ["DMAbs", "PROBLEM", 66, 71], ["serum samples", "TEST", 77, 90], ["DMAb", "TREATMENT", 94, 98]]], ["After incubation of the serum samples with blots containing the recombinant mouse or human PCSK9 proteins, the sera of DMAb-treated mice reacted with the PCSK9 protein, but sera from the pVax-1-treated mice did not.", [["serum samples", "ANATOMY", 24, 37], ["sera", "ANATOMY", 111, 115], ["sera", "ANATOMY", 173, 177], ["DMAb", "CHEMICAL", 119, 123], ["pVax-1", "CHEMICAL", 187, 193], ["serum samples", "ORGANISM_SUBSTANCE", 24, 37], ["mouse", "ORGANISM", 76, 81], ["human", "ORGANISM", 85, 90], ["PCSK9", "GENE_OR_GENE_PRODUCT", 91, 96], ["sera", "ORGANISM_SUBSTANCE", 111, 115], ["DMAb", "SIMPLE_CHEMICAL", 119, 123], ["mice", "ORGANISM", 132, 136], ["PCSK9", "GENE_OR_GENE_PRODUCT", 154, 159], ["sera", "ORGANISM_SUBSTANCE", 173, 177], ["pVax-1", "GENE_OR_GENE_PRODUCT", 187, 193], ["mice", "ORGANISM", 202, 206], ["recombinant mouse or human PCSK9 proteins", "PROTEIN", 64, 105], ["DMAb", "PROTEIN", 119, 123], ["PCSK9 protein", "PROTEIN", 154, 167], ["mouse", "SPECIES", 76, 81], ["human", "SPECIES", 85, 90], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 202, 206], ["mouse", "SPECIES", 76, 81], ["human", "SPECIES", 85, 90], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 202, 206], ["the serum samples", "TEST", 20, 37], ["blots", "TREATMENT", 43, 48], ["human PCSK9 proteins", "TREATMENT", 85, 105], ["the sera of DMAb", "TREATMENT", 107, 123], ["the PCSK9 protein", "TEST", 150, 167], ["sera", "TEST", 173, 177], ["the pVax", "TEST", 183, 191]]], ["Furthermore, MdaPCSK9 were evaluated on a human liver cell line, Huh7; 72 hr after transfection, cells were harvested and analyzed by flow cytometry (Figure 4D).", [["liver cell line", "ANATOMY", 48, 63], ["Huh7", "ANATOMY", 65, 69], ["cells", "ANATOMY", 97, 102], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 13, 21], ["human", "ORGANISM", 42, 47], ["liver cell line", "CELL", 48, 63], ["Huh7", "CELL", 65, 69], ["cells", "CELL", 97, 102], ["MdaPCSK9", "PROTEIN", 13, 21], ["human liver cell line", "CELL_LINE", 42, 63], ["Huh7", "CELL_LINE", 65, 69], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["a human liver cell line", "TREATMENT", 40, 63], ["Huh7", "TEST", 65, 69], ["cells", "TEST", 97, 102], ["flow cytometry", "TEST", 134, 148], ["liver", "ANATOMY", 48, 53], ["cell line", "OBSERVATION", 54, 63]]], ["There were significant increases in LDLR levels in the MdaPCSK9-treated group, with mean fluorescence intensity (MFI) increasing from 1,573 in the control group to 11,166 in the DMAb-treated group.", [["MdaPCSK9", "CHEMICAL", 55, 63], ["DMAb", "CHEMICAL", 178, 182], ["DMAb", "CHEMICAL", 178, 182], ["LDLR", "GENE_OR_GENE_PRODUCT", 36, 40], ["MdaPCSK9", "SIMPLE_CHEMICAL", 55, 63], ["DMAb", "SIMPLE_CHEMICAL", 178, 182], ["LDLR", "PROTEIN", 36, 40], ["MdaPCSK9", "PROTEIN", 55, 63], ["significant increases in LDLR levels", "PROBLEM", 11, 47], ["mean fluorescence intensity", "PROBLEM", 84, 111], ["the DMAb", "TREATMENT", 174, 182], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["increases", "OBSERVATION_MODIFIER", 23, 32], ["LDLR", "OBSERVATION_MODIFIER", 36, 40], ["levels", "OBSERVATION_MODIFIER", 41, 47]]], ["The results demonstrate the functional efficacy of daPCSK9 at inhibiting PCSK9 protein from inducing LDLR degradation in hepatocytes.Lipid-Lowering Capability of Mouse Anti-PCSK9 DMAb ::: ResultsThe lipid-lowering capability of daPCSK9 was evaluated in C57BL/6J wild-type and B6.Cg-foxn1nu/J nude mice (Figure 5).", [["hepatocytes", "ANATOMY", 121, 132], ["daPCSK9", "CHEMICAL", 51, 58], ["daPCSK9", "SIMPLE_CHEMICAL", 51, 58], ["PCSK9", "GENE_OR_GENE_PRODUCT", 73, 78], ["LDLR", "GENE_OR_GENE_PRODUCT", 101, 105], ["hepatocytes", "CELL", 121, 132], ["Lipid", "SIMPLE_CHEMICAL", 133, 138], ["Mouse", "ORGANISM", 162, 167], ["lipid", "SIMPLE_CHEMICAL", 199, 204], ["daPCSK9", "GENE_OR_GENE_PRODUCT", 228, 235], ["C57BL/6J wild-type", "ORGANISM", 253, 271], ["B6", "CELL", 276, 278], ["Cg-foxn1nu", "GENE_OR_GENE_PRODUCT", 279, 289], ["J nude mice", "ORGANISM", 290, 301], ["daPCSK9", "PROTEIN", 51, 58], ["PCSK9 protein", "PROTEIN", 73, 86], ["LDLR", "PROTEIN", 101, 105], ["hepatocytes", "CELL_TYPE", 121, 132], ["daPCSK9", "PROTEIN", 228, 235], ["Mouse", "SPECIES", 162, 167], ["mice", "SPECIES", 297, 301], ["Mouse", "SPECIES", 162, 167], ["mice", "SPECIES", 297, 301], ["daPCSK9", "PROBLEM", 51, 58], ["PCSK9 protein", "TEST", 73, 86], ["LDLR degradation in hepatocytes", "PROBLEM", 101, 132], ["Lipid", "TREATMENT", 133, 138], ["The lipid-lowering capability of daPCSK9", "TREATMENT", 195, 235], ["Cg", "TEST", 279, 281], ["foxn1nu/J nude mice", "TREATMENT", 282, 301], ["LDLR", "OBSERVATION_MODIFIER", 101, 105], ["hepatocytes", "ANATOMY", 121, 132]]], ["For accurate calculations of lipid reductions in the treated group, percentage decreases were analyzed against the control group for each day.", [["lipid", "SIMPLE_CHEMICAL", 29, 34], ["lipid reductions", "TREATMENT", 29, 45], ["lipid", "OBSERVATION_MODIFIER", 29, 34], ["reductions", "OBSERVATION_MODIFIER", 35, 45]]], ["In C57BL/6J mice, a significant 28.6% decrease in non-HDL-C was detected on day 7 for the MdaPCSK9 group.", [["C57BL/6J mice", "ORGANISM", 3, 16], ["non-HDL-C", "SIMPLE_CHEMICAL", 50, 59], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 90, 98], ["non-HDL", "PROTEIN", 50, 57], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["a significant 28.6% decrease in non-HDL-C", "PROBLEM", 18, 59], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["decrease", "OBSERVATION_MODIFIER", 38, 46]]], ["By day 14, there was a 30% decrease in non-HDL-C for the MdaPCSK9 group.", [["non-HDL-C", "SIMPLE_CHEMICAL", 39, 48], ["MdaPCSK9", "CANCER", 57, 65], ["non-HDL", "TEST", 39, 46], ["the MdaPCSK9 group", "TREATMENT", 53, 71]]], ["Total cholesterol reductions were also observed for the MdaPCSK9 group, with a 14% decrease on day 14.", [["cholesterol", "CHEMICAL", 6, 17], ["cholesterol", "CHEMICAL", 6, 17], ["cholesterol", "SIMPLE_CHEMICAL", 6, 17], ["Total cholesterol reductions", "TEST", 0, 28]]], ["In nude mice, there was a significant 32.5% reduction in non-HDL-C on day 14 for those treated with MdaPCSK9.", [["MdaPCSK9", "CHEMICAL", 100, 108], ["MdaPCSK9", "CHEMICAL", 100, 108], ["nude mice", "ORGANISM", 3, 12], ["non-HDL-C", "SIMPLE_CHEMICAL", 57, 66], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 100, 108], ["MdaPCSK9", "PROTEIN", 100, 108], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["non-HDL", "TEST", 57, 64], ["MdaPCSK9", "TREATMENT", 100, 108], ["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["This reduction persisted until day 21.", [["This reduction", "TREATMENT", 0, 14]]], ["There were similar reductions in total cholesterol that persisted to day 21, with a 14.3% decrease.", [["cholesterol", "CHEMICAL", 39, 50], ["cholesterol", "CHEMICAL", 39, 50], ["cholesterol", "SIMPLE_CHEMICAL", 39, 50], ["total cholesterol", "TEST", 33, 50], ["similar", "OBSERVATION_MODIFIER", 11, 18], ["reductions", "OBSERVATION_MODIFIER", 19, 29], ["total cholesterol", "OBSERVATION", 33, 50]]], ["The persistent reduction of non-HDL-C and total cholesterol in the mouse models correlates with the DMAb expression in the circulation.", [["non-HDL-C", "CHEMICAL", 28, 37], ["cholesterol", "CHEMICAL", 48, 59], ["cholesterol", "CHEMICAL", 48, 59], ["non-HDL-C", "SIMPLE_CHEMICAL", 28, 37], ["cholesterol", "SIMPLE_CHEMICAL", 48, 59], ["mouse", "ORGANISM", 67, 72], ["DMAb", "GENE_OR_GENE_PRODUCT", 100, 104], ["non-HDL", "PROTEIN", 28, 35], ["DMAb", "PROTEIN", 100, 104], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 67, 72], ["non-HDL", "TEST", 28, 35], ["total cholesterol", "TEST", 42, 59], ["persistent", "OBSERVATION_MODIFIER", 4, 14], ["reduction", "OBSERVATION_MODIFIER", 15, 24], ["DMAb", "OBSERVATION", 100, 104], ["circulation", "ANATOMY", 123, 134]]], ["Repeated administrations of MdaPCSK9 led to increasing DMAb expression kinetics over a period of 62 days, with reductions in non-HDL-C of 20.9% from pooled sera on days 56 and 62 (Figures 5E and 5F).Construction and Evaluation of Human Anti-PCSK9 DMAb ::: ResultsdaPCSK9 plasmid engineered to express either human or mouse Fc regions (labeled HdaPCSK9 and MdaPCSK9, respectively) were designed to evaluate the effect on expression levels and kinetics in vivo.", [["sera", "ANATOMY", 156, 160], ["plasmid", "ANATOMY", 271, 278], ["MdaPCSK9", "CHEMICAL", 28, 36], ["MdaPCSK9", "SIMPLE_CHEMICAL", 28, 36], ["DMAb", "SIMPLE_CHEMICAL", 55, 59], ["non-HDL-C", "SIMPLE_CHEMICAL", 125, 134], ["sera", "ORGANISM_SUBSTANCE", 156, 160], ["Human", "ORGANISM", 230, 235], ["ResultsdaPCSK9", "GENE_OR_GENE_PRODUCT", 256, 270], ["human", "ORGANISM", 308, 313], ["mouse", "ORGANISM", 317, 322], ["Fc", "GENE_OR_GENE_PRODUCT", 323, 325], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 343, 351], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 356, 364], ["MdaPCSK9", "PROTEIN", 28, 36], ["DMAb", "PROTEIN", 55, 59], ["ResultsdaPCSK9 plasmid", "DNA", 256, 278], ["human or mouse Fc regions", "DNA", 308, 333], ["HdaPCSK9", "PROTEIN", 343, 351], ["MdaPCSK9", "DNA", 356, 364], ["Human", "SPECIES", 230, 235], ["human", "SPECIES", 308, 313], ["mouse", "SPECIES", 317, 322], ["Human", "SPECIES", 230, 235], ["human", "SPECIES", 308, 313], ["mouse", "SPECIES", 317, 322], ["MdaPCSK9", "TREATMENT", 28, 36], ["increasing DMAb expression kinetics", "PROBLEM", 44, 79], ["non-HDL", "TEST", 125, 132], ["pooled sera", "TEST", 149, 160], ["expression levels", "TEST", 420, 437], ["increasing", "OBSERVATION_MODIFIER", 44, 54], ["DMAb", "OBSERVATION", 55, 59]]], ["Evaluation of HdaPCSK9 in HEK293T cells showed the DMAb expression levels at 1,349 ng/mL (Figure S1).", [["HEK293T cells", "ANATOMY", 26, 39], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 14, 22], ["HEK293T cells", "CELL", 26, 39], ["DMAb", "GENE_OR_GENE_PRODUCT", 51, 55], ["HdaPCSK9", "PROTEIN", 14, 22], ["HEK293T cells", "CELL_LINE", 26, 39], ["DMAb", "PROTEIN", 51, 55], ["Evaluation of HdaPCSK9 in HEK293T cells", "TEST", 0, 39], ["the DMAb expression levels", "TEST", 47, 73]]], ["Strong expression for HdaPCSK9 was also confirmed in Hepa1-6 cells by using fluorescence microscopy after intracellular staining with anti-human IgG-fluorescein isothiocyanate (FITC).", [["Hepa1-6 cells", "ANATOMY", 53, 66], ["intracellular", "ANATOMY", 106, 119], ["fluorescein isothiocyanate", "CHEMICAL", 149, 175], ["fluorescein isothiocyanate", "CHEMICAL", 149, 175], ["FITC", "CHEMICAL", 177, 181], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 22, 30], ["Hepa1-6 cells", "CELL", 53, 66], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 119], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 149, 175], ["FITC", "SIMPLE_CHEMICAL", 177, 181], ["HdaPCSK9", "PROTEIN", 22, 30], ["Hepa1-6 cells", "CELL_LINE", 53, 66], ["anti-human IgG", "PROTEIN", 134, 148], ["HdaPCSK9", "TEST", 22, 30], ["Hepa1", "TEST", 53, 58], ["fluorescence microscopy", "TEST", 76, 99], ["intracellular staining", "TEST", 106, 128], ["anti-human IgG", "TEST", 134, 148], ["fluorescein isothiocyanate (FITC)", "TREATMENT", 149, 182]]], ["Western blot-binding studies with the HdaPCSK9 demonstrated binding to both recombinant human and mouse PCSK9 proteins.Construction and Evaluation of Human Anti-PCSK9 DMAb ::: ResultsHdaPCSK9 expression levels and kinetics were analyzed in vivo in wild-type C57BL/6J and nude B6.Cg-foxn1nu/J mice (Figures 6A and 6B).", [["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 38, 46], ["human", "ORGANISM", 88, 93], ["mouse", "ORGANISM", 98, 103], ["PCSK9", "GENE_OR_GENE_PRODUCT", 104, 109], ["Human", "ORGANISM", 150, 155], ["ResultsHdaPCSK9", "GENE_OR_GENE_PRODUCT", 176, 191], ["C57BL/6J", "ORGANISM", 258, 266], ["nude B6", "ORGANISM", 271, 278], ["Cg-foxn1nu", "GENE_OR_GENE_PRODUCT", 279, 289], ["HdaPCSK9", "PROTEIN", 38, 46], ["recombinant human and mouse PCSK9 proteins", "PROTEIN", 76, 118], ["ResultsHdaPCSK9", "PROTEIN", 176, 191], ["human", "SPECIES", 88, 93], ["mouse", "SPECIES", 98, 103], ["Human", "SPECIES", 150, 155], ["mice", "SPECIES", 292, 296], ["human", "SPECIES", 88, 93], ["mouse", "SPECIES", 98, 103], ["Human", "SPECIES", 150, 155], ["blot-binding studies", "TEST", 8, 28], ["expression levels", "TEST", 192, 209], ["kinetics", "TEST", 214, 222], ["nude B6", "TREATMENT", 271, 278], ["Cg", "TEST", 279, 281]]], ["After a single intramuscular administration of 300 \u03bcg plasmid DNA, the HdaPCSK9 reached a maximum mean of 2,224 ng/mL protein mAbs at day 14 in nude mice.", [["intramuscular", "ANATOMY", 15, 28], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 28], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 71, 79], ["nude mice", "ORGANISM", 144, 153], ["300 \u03bcg plasmid DNA", "DNA", 47, 65], ["HdaPCSK9", "PROTEIN", 71, 79], ["protein mAbs", "PROTEIN", 118, 130], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 149, 153], ["a single intramuscular administration", "TREATMENT", 6, 43], ["300 \u03bcg plasmid DNA", "TREATMENT", 47, 65], ["the HdaPCSK9", "TREATMENT", 67, 79]]], ["In wild-type mice, there was an acute immune reaction to the DMAbs containing human Fc, resulting in drops in DMAb expression by day 7.", [["mice", "ORGANISM", 13, 17], ["DMAbs", "SIMPLE_CHEMICAL", 61, 66], ["human", "ORGANISM", 78, 83], ["Fc", "GENE_OR_GENE_PRODUCT", 84, 86], ["DMAb", "GENE_OR_GENE_PRODUCT", 110, 114], ["DMAbs", "PROTEIN", 61, 66], ["human Fc", "PROTEIN", 78, 86], ["DMAb", "PROTEIN", 110, 114], ["mice", "SPECIES", 13, 17], ["human", "SPECIES", 78, 83], ["mice", "SPECIES", 13, 17], ["human", "SPECIES", 78, 83], ["an acute immune reaction", "PROBLEM", 29, 53], ["human Fc", "TREATMENT", 78, 86], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["immune reaction", "OBSERVATION", 38, 53]]], ["Maximum expression was observed at day 5, with a mean of around 2,485 ng/mL for the 300 \u03bcg dose of HdaPCSK9.", [["HdaPCSK9", "CHEMICAL", 99, 107], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 99, 107], ["HdaPCSK9", "PROTEIN", 99, 107], ["HdaPCSK9", "TREATMENT", 99, 107]]], ["The results of human DMAb studies in wild-type mice demonstrate the importance of considering intraspecies differences in antibody evaluation and how this may impact translation to other models.", [["human", "ORGANISM", 15, 20], ["DMAb", "GENE_OR_GENE_PRODUCT", 21, 25], ["mice", "ORGANISM", 47, 51], ["human", "SPECIES", 15, 20], ["mice", "SPECIES", 47, 51], ["human", "SPECIES", 15, 20], ["human DMAb studies", "TEST", 15, 33], ["antibody evaluation", "TEST", 122, 141]]], ["The reason for the resulting drop in expression of human PCSK9 DMAb is interesting.", [["human", "ORGANISM", 51, 56], ["PCSK9", "GENE_OR_GENE_PRODUCT", 57, 62], ["human PCSK9 DMAb", "PROTEIN", 51, 67], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["the resulting drop", "PROBLEM", 15, 33], ["human PCSK9 DMAb", "TREATMENT", 51, 67], ["drop", "OBSERVATION", 29, 33]]], ["The functional activity of sera DMAbs was confirmed by binding western blot analysis, showing binding to both recombinant mouse and human PCSK9 proteins (Figure 6C).Construction and Evaluation of Human Anti-PCSK9 DMAb ::: ResultsAnti-PCSK9 DMAb expression was also confirmed in vivo by immunohistochemistry analysis of mouse muscle tissue at day 5.", [["sera", "ANATOMY", 27, 31], ["muscle tissue", "ANATOMY", 325, 338], ["sera", "ORGANISM_SUBSTANCE", 27, 31], ["DMAbs", "SIMPLE_CHEMICAL", 32, 37], ["mouse", "ORGANISM", 122, 127], ["human", "ORGANISM", 132, 137], ["PCSK9", "GENE_OR_GENE_PRODUCT", 138, 143], ["Human", "ORGANISM", 196, 201], ["DMAb", "GENE_OR_GENE_PRODUCT", 240, 244], ["mouse", "ORGANISM", 319, 324], ["muscle tissue", "TISSUE", 325, 338], ["sera DMAbs", "PROTEIN", 27, 37], ["recombinant mouse and human PCSK9 proteins", "PROTEIN", 110, 152], ["Figure 6C", "PROTEIN", 154, 163], ["DMAb", "PROTEIN", 240, 244], ["mouse", "SPECIES", 122, 127], ["human", "SPECIES", 132, 137], ["Human", "SPECIES", 196, 201], ["mouse", "SPECIES", 319, 324], ["mouse", "SPECIES", 122, 127], ["human", "SPECIES", 132, 137], ["Human", "SPECIES", 196, 201], ["mouse", "SPECIES", 319, 324], ["sera DMAbs", "TEST", 27, 37], ["blot analysis", "TEST", 71, 84], ["mouse muscle tissue", "PROBLEM", 319, 338], ["mouse muscle tissue", "OBSERVATION", 319, 338]]], ["As shown in Figure 6D, immunohistochemistry using HdaPCSK9 immunostained with anti-human IgG-horseradish peroxidase (HRP) indicates positive browning in the mouse tibialis anterior muscle section, compared to no browning in the control pVax-1 muscle sections.", [["tibialis anterior muscle section", "ANATOMY", 163, 195], ["pVax-1 muscle sections", "ANATOMY", 236, 258], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 50, 58], ["IgG-horseradish peroxidase", "GENE_OR_GENE_PRODUCT", 89, 115], ["HRP", "GENE_OR_GENE_PRODUCT", 117, 120], ["mouse", "ORGANISM", 157, 162], ["tibialis anterior muscle", "ORGAN", 163, 187], ["muscle sections", "MULTI-TISSUE_STRUCTURE", 243, 258], ["HdaPCSK9", "PROTEIN", 50, 58], ["anti-human IgG", "PROTEIN", 78, 92], ["horseradish peroxidase", "PROTEIN", 93, 115], ["HRP", "PROTEIN", 117, 120], ["horseradish", "SPECIES", 93, 104], ["mouse", "SPECIES", 157, 162], ["mouse", "SPECIES", 157, 162], ["immunohistochemistry", "TEST", 23, 43], ["HdaPCSK9", "TEST", 50, 58], ["anti-human IgG", "TEST", 78, 92], ["positive browning in the mouse tibialis anterior muscle section", "PROBLEM", 132, 195], ["browning", "PROBLEM", 212, 220], ["positive browning", "OBSERVATION", 132, 149], ["mouse tibialis", "ANATOMY", 157, 171], ["anterior", "ANATOMY_MODIFIER", 172, 180], ["muscle", "ANATOMY", 181, 187], ["muscle", "ANATOMY", 243, 249]]], ["H&E staining of the DMAb-treated and control groups showed no signs of tissue damage.", [["tissue", "ANATOMY", 71, 77], ["DMAb", "CHEMICAL", 20, 24], ["tissue damage", "DISEASE", 71, 84], ["DMAb", "CHEMICAL", 20, 24], ["DMAb", "SIMPLE_CHEMICAL", 20, 24], ["tissue", "TISSUE", 71, 77], ["the DMAb", "TREATMENT", 16, 24], ["tissue damage", "PROBLEM", 71, 84], ["DMAb", "OBSERVATION", 20, 24], ["no signs of", "UNCERTAINTY", 59, 70], ["tissue", "ANATOMY", 71, 77], ["damage", "OBSERVATION", 78, 84]]], ["This confirms the expression of anti-PCSK9 DMAbs and the lack of tissue damage caused by their administration.Lipid-Lowering Capability of Human Anti-PCSK9 DMAbs ::: ResultsThe HdaPCSK9 performed similarly to MdaPCSK9 in its capacity at lipid reduction in C57BL/6J wild-type and B6.Cg-foxn1nu/J nude mice (Figure S2).", [["tissue", "ANATOMY", 65, 71], ["tissue damage", "DISEASE", 65, 78], ["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 32, 42], ["tissue", "TISSUE", 65, 71], ["Lipid", "SIMPLE_CHEMICAL", 110, 115], ["Human", "ORGANISM", 139, 144], ["Anti-PCSK9 DMAbs", "SIMPLE_CHEMICAL", 145, 161], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 177, 185], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 209, 217], ["lipid", "SIMPLE_CHEMICAL", 237, 242], ["C57BL/6J wild-type", "ORGANISM", 256, 274], ["B6", "CELL", 279, 281], ["Cg-foxn1nu", "GENE_OR_GENE_PRODUCT", 282, 292], ["J nude mice", "ORGANISM", 293, 304], ["anti-PCSK9 DMAbs", "PROTEIN", 32, 48], ["HdaPCSK9", "PROTEIN", 177, 185], ["MdaPCSK9", "PROTEIN", 209, 217], ["Human", "SPECIES", 139, 144], ["mice", "SPECIES", 300, 304], ["mice", "SPECIES", 300, 304], ["anti-PCSK9 DMAbs", "PROBLEM", 32, 48], ["tissue damage", "PROBLEM", 65, 78], ["Lipid", "TEST", 110, 115], ["The HdaPCSK9", "TEST", 173, 185], ["lipid reduction", "TREATMENT", 237, 252], ["Cg", "TEST", 282, 284], ["foxn1nu/J nude mice", "TREATMENT", 285, 304], ["damage", "OBSERVATION", 72, 78]]], ["In wild-type mice, there was a significant 23.8% decrease in non-HDL-C detected on day 7 for the HdaPCSK9 group and a 30% reduction by day 14.", [["mice", "ORGANISM", 13, 17], ["non-HDL-C", "SIMPLE_CHEMICAL", 61, 70], ["HdaPCSK9", "CANCER", 97, 105], ["non-HDL", "PROTEIN", 61, 68], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["non-HDL", "TEST", 61, 68], ["the HdaPCSK9 group", "TREATMENT", 93, 111], ["a 30% reduction", "TREATMENT", 116, 131], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["decrease", "OBSERVATION_MODIFIER", 49, 57]]], ["Total cholesterol reduction was also observed, with a 14% decrease on day 14.", [["cholesterol", "CHEMICAL", 6, 17], ["cholesterol", "CHEMICAL", 6, 17], ["cholesterol", "SIMPLE_CHEMICAL", 6, 17], ["Total cholesterol reduction", "TREATMENT", 0, 27], ["cholesterol reduction", "OBSERVATION", 6, 27]]], ["Compared to HdaPCSK9, MdaPCSK9 demonstrated better reductions of both non-HDL-C and total cholesterol, which correlates with its superior expression levels and duration in the circulation in the matched species.", [["MdaPCSK9", "CHEMICAL", 22, 30], ["cholesterol", "CHEMICAL", 90, 101], ["cholesterol", "CHEMICAL", 90, 101], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 12, 20], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 22, 30], ["non-HDL-C", "SIMPLE_CHEMICAL", 70, 79], ["cholesterol", "SIMPLE_CHEMICAL", 90, 101], ["HdaPCSK9", "PROTEIN", 12, 20], ["MdaPCSK9", "PROTEIN", 22, 30], ["HdaPCSK9", "TEST", 12, 20], ["MdaPCSK9", "TEST", 22, 30], ["non-HDL", "TEST", 70, 77], ["total cholesterol", "TEST", 84, 101], ["better", "OBSERVATION_MODIFIER", 44, 50], ["reductions", "OBSERVATION_MODIFIER", 51, 61], ["total cholesterol", "OBSERVATION_MODIFIER", 84, 101], ["superior", "OBSERVATION_MODIFIER", 129, 137], ["expression", "OBSERVATION", 138, 148], ["circulation", "ANATOMY", 176, 187]]], ["In nude mice, there were significant reductions in non-HDL-C on day 14 for both species\u2019 antibodies, with 28.6% for human and 32.5% for mouse anti-PCSK9 DMAb groups.", [["nude mice", "ORGANISM", 3, 12], ["non-HDL-C", "SIMPLE_CHEMICAL", 51, 60], ["human", "ORGANISM", 116, 121], ["mouse", "ORGANISM", 136, 141], ["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 142, 152], ["non-HDL", "PROTEIN", 51, 58], ["mice", "SPECIES", 8, 12], ["human", "SPECIES", 116, 121], ["mouse", "SPECIES", 136, 141], ["mice", "SPECIES", 8, 12], ["human", "SPECIES", 116, 121], ["mouse", "SPECIES", 136, 141], ["non-HDL", "TEST", 51, 58], ["both species\u2019 antibodies", "TEST", 75, 99], ["human", "TEST", 116, 121], ["mouse anti-PCSK9 DMAb groups", "TREATMENT", 136, 164], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["reductions", "OBSERVATION_MODIFIER", 37, 47]]], ["This reduction persisted until the final endpoint at day 21.", [["This reduction", "TREATMENT", 0, 14]]], ["There were similar reductions in total cholesterol that persisted until day 21, with a 15.2% decrease for the HdaPCSK9.", [["cholesterol", "CHEMICAL", 39, 50], ["cholesterol", "CHEMICAL", 39, 50], ["cholesterol", "SIMPLE_CHEMICAL", 39, 50], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 110, 118], ["HdaPCSK9", "PROTEIN", 110, 118], ["similar reductions in total cholesterol", "PROBLEM", 11, 50], ["the HdaPCSK9", "TREATMENT", 106, 118], ["similar", "OBSERVATION_MODIFIER", 11, 18], ["reductions", "OBSERVATION_MODIFIER", 19, 29], ["total cholesterol", "OBSERVATION", 33, 50]]], ["Although they were not expressed as well in mouse as MdaPCSK9, the human DMAb performed well at lipid reduction in this short-term study supporting potential application of the human Fc DMAbs in a matched species setting.DiscussionIndividuals with elevated LDL-C or those afflicted with hereditary familial hypercholesterolemia are at increased risk for CHD.", [["hereditary familial hypercholesterolemia", "DISEASE", 287, 327], ["CHD", "DISEASE", 354, 357], ["mouse", "ORGANISM", 44, 49], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 53, 61], ["human", "ORGANISM", 67, 72], ["DMAb", "GENE_OR_GENE_PRODUCT", 73, 77], ["lipid", "SIMPLE_CHEMICAL", 96, 101], ["human", "ORGANISM", 177, 182], ["Fc DMAbs", "GENE_OR_GENE_PRODUCT", 183, 191], ["LDL-C", "GENE_OR_GENE_PRODUCT", 257, 262], ["MdaPCSK9", "PROTEIN", 53, 61], ["human DMAb", "PROTEIN", 67, 77], ["human Fc DMAbs", "PROTEIN", 177, 191], ["LDL", "PROTEIN", 257, 260], ["mouse", "SPECIES", 44, 49], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 177, 182], ["mouse", "SPECIES", 44, 49], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 177, 182], ["the human DMAb", "TREATMENT", 63, 77], ["lipid reduction", "TREATMENT", 96, 111], ["this short-term study", "TREATMENT", 115, 136], ["the human Fc DMAbs", "TREATMENT", 173, 191], ["elevated LDL", "PROBLEM", 248, 260], ["hereditary familial hypercholesterolemia", "PROBLEM", 287, 327], ["CHD", "PROBLEM", 354, 357], ["hypercholesterolemia", "OBSERVATION", 307, 327]]], ["LDL-C reduction therapy with 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, such as statins, has been a standard treatment for reducing the risk of CHD, but intolerable musculoskeletal symptoms can prevent their use.78 Alternative therapies are needed when the gold standard for reducing high LDL-C causes such adverse effects.", [["musculoskeletal", "ANATOMY", 193, 208], ["LDL-C", "CHEMICAL", 0, 5], ["3-hydroxy-3-methyl-glutaryl-coenzyme A", "CHEMICAL", 29, 67], ["statins", "CHEMICAL", 108, 115], ["CHD", "DISEASE", 172, 175], ["3-hydroxy-3-methyl-glutaryl-coenzyme A", "CHEMICAL", 29, 67], ["HMG-CoA", "CHEMICAL", 69, 76], ["statins", "CHEMICAL", 108, 115], ["LDL-C", "SIMPLE_CHEMICAL", 0, 5], ["3-hydroxy-3-methyl-glutaryl-coenzyme A", "SIMPLE_CHEMICAL", 29, 67], ["HMG-CoA) reductase", "GENE_OR_GENE_PRODUCT", 69, 87], ["LDL-C", "SIMPLE_CHEMICAL", 317, 322], ["LDL", "PROTEIN", 317, 320], ["LDL", "TEST", 0, 3], ["C reduction therapy", "TREATMENT", 4, 23], ["hydroxy", "TREATMENT", 31, 38], ["methyl-glutaryl", "TREATMENT", 41, 56], ["coenzyme A (HMG-CoA) reductase inhibitors", "TREATMENT", 57, 98], ["statins", "TREATMENT", 108, 115], ["a standard treatment", "TREATMENT", 126, 146], ["CHD", "PROBLEM", 172, 175], ["intolerable musculoskeletal symptoms", "PROBLEM", 181, 217], ["Alternative therapies", "TREATMENT", 243, 264], ["such adverse effects", "PROBLEM", 330, 350]]], ["PCSK9 inhibitors are emerging as a potent important new approach for reducing LDL-C by increasing its hepatic clearance via the LDLR.DiscussionSeveral strategies have been taken to inhibit PCSK9, with mAbs achieving recent success.", [["hepatic", "ANATOMY", 102, 109], ["PCSK9", "GENE_OR_GENE_PRODUCT", 0, 5], ["LDL-C", "SIMPLE_CHEMICAL", 78, 83], ["hepatic", "ORGAN", 102, 109], ["LDLR", "GENE_OR_GENE_PRODUCT", 128, 132], ["PCSK9", "GENE_OR_GENE_PRODUCT", 189, 194], ["PCSK9", "PROTEIN", 0, 5], ["LDL", "PROTEIN", 78, 81], ["LDLR", "PROTEIN", 128, 132], ["PCSK9", "PROTEIN", 189, 194], ["mAbs", "PROTEIN", 201, 205], ["PCSK9 inhibitors", "TREATMENT", 0, 16], ["reducing LDL", "TREATMENT", 69, 81], ["DiscussionSeveral strategies", "TREATMENT", 133, 161], ["hepatic", "ANATOMY", 102, 109]]], ["Evolocumab and alirocumab are two FDA-approved anti-PCSK9 recombinant mAbs that have shown significant LDL-C reduction.", [["Evolocumab", "CHEMICAL", 0, 10], ["alirocumab", "CHEMICAL", 15, 25], ["Evolocumab", "CHEMICAL", 0, 10], ["alirocumab", "CHEMICAL", 15, 25], ["Evolocumab", "SIMPLE_CHEMICAL", 0, 10], ["alirocumab", "SIMPLE_CHEMICAL", 15, 25], ["LDL-C", "SIMPLE_CHEMICAL", 103, 108], ["anti-PCSK9 recombinant mAbs", "PROTEIN", 47, 74], ["LDL", "PROTEIN", 103, 106], ["Evolocumab and alirocumab", "TREATMENT", 0, 25], ["anti-PCSK9 recombinant mAbs", "TREATMENT", 47, 74], ["C reduction", "TREATMENT", 107, 118], ["alirocumab", "OBSERVATION", 15, 25], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["LDL", "OBSERVATION", 103, 106], ["reduction", "OBSERVATION_MODIFIER", 109, 118]]], ["Various recombinant anti-PCSK9 antibodies have been investigated in mice for their lipid-lowering capabilities.", [["anti-PCSK9 antibodies", "GENE_OR_GENE_PRODUCT", 20, 41], ["mice", "ORGANISM", 68, 72], ["lipid", "SIMPLE_CHEMICAL", 83, 88], ["recombinant anti-PCSK9 antibodies", "PROTEIN", 8, 41], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["Various recombinant anti-PCSK9 antibodies", "TREATMENT", 0, 41]]], ["Zhang et al.9 developed a transgenic cholesteryl ester transfer protein (CETP)/LDLR-hemi mouse model that expressed human CETP transgene and one copy of the LDLR, to mimic healthy human lipid levels in mice.", [["cholesteryl ester", "CHEMICAL", 37, 54], ["cholesteryl ester", "CHEMICAL", 37, 54], ["cholesteryl ester transfer protein", "GENE_OR_GENE_PRODUCT", 37, 71], ["CETP", "GENE_OR_GENE_PRODUCT", 73, 77], ["LDLR", "GENE_OR_GENE_PRODUCT", 79, 83], ["mouse", "ORGANISM", 89, 94], ["human", "ORGANISM", 116, 121], ["CETP", "GENE_OR_GENE_PRODUCT", 122, 126], ["LDLR", "GENE_OR_GENE_PRODUCT", 157, 161], ["human", "ORGANISM", 180, 185], ["lipid", "SIMPLE_CHEMICAL", 186, 191], ["mice", "ORGANISM", 202, 206], ["transgenic cholesteryl ester transfer protein", "PROTEIN", 26, 71], ["CETP", "PROTEIN", 73, 77], ["LDLR", "PROTEIN", 79, 83], ["human CETP transgene", "DNA", 116, 136], ["LDLR", "PROTEIN", 157, 161], ["mouse", "SPECIES", 89, 94], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 180, 185], ["mice", "SPECIES", 202, 206], ["mouse", "SPECIES", 89, 94], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 180, 185], ["mice", "SPECIES", 202, 206], ["a transgenic cholesteryl ester transfer protein", "TREATMENT", 24, 71], ["LDLR", "PROBLEM", 79, 83], ["hemi mouse model", "PROBLEM", 84, 100], ["human CETP transgene", "TREATMENT", 116, 136], ["LDLR", "ANATOMY", 79, 83]]], ["After 48 hr of a single intravenous administration of the anti-PCSK9 antibody at 1.1 mg/kg, there was a 29% reduction from the baseline in LDL-C, with serum antibody levels of 3.5 \u03bcg/mL.", [["intravenous", "ANATOMY", 24, 35], ["serum", "ANATOMY", 151, 156], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 35], ["anti-PCSK9 antibody", "GENE_OR_GENE_PRODUCT", 58, 77], ["LDL-C", "SIMPLE_CHEMICAL", 139, 144], ["serum", "ORGANISM_SUBSTANCE", 151, 156], ["anti-PCSK9 antibody", "PROTEIN", 58, 77], ["LDL", "PROTEIN", 139, 142], ["serum antibody", "PROTEIN", 151, 165], ["a single intravenous administration", "TREATMENT", 15, 50], ["the anti-PCSK9 antibody", "TREATMENT", 54, 77], ["a 29% reduction", "PROBLEM", 102, 117], ["LDL", "TEST", 139, 142], ["serum antibody levels", "TEST", 151, 172]]], ["This correlates with expression levels and the lipid reduction capability observed with the DMAbs.", [["lipid", "SIMPLE_CHEMICAL", 47, 52], ["DMAbs", "SIMPLE_CHEMICAL", 92, 97], ["DMAbs", "PROTEIN", 92, 97], ["expression levels", "TEST", 21, 38], ["the lipid reduction capability", "TREATMENT", 43, 73]]], ["There was even a significant 50%\u201370% reduction in LDL-C at higher administered recombinant antibody doses of 3 mg/kg and 10 mg/kg.9 Chan et al. evaluated an anti-PCSK9 antibody in wild-type mice and LDLR-knockout mice, and they observed a 36% reduction in total cholesterol 3 days after administration to the wild-type mice, while detecting no change in the LDLR-knockout mice.8 Another group examined the effect of an anti-PCSK9 antibody on humanized hyperlipidemic Pcsk9hum/hum Ldlr\u2212/+ mice on a carbohydrate-rich diet.", [["cholesterol", "CHEMICAL", 262, 273], ["cholesterol", "CHEMICAL", 262, 273], ["carbohydrate", "CHEMICAL", 498, 510], ["LDL-C", "SIMPLE_CHEMICAL", 50, 55], ["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 157, 167], ["mice", "ORGANISM", 190, 194], ["LDLR", "GENE_OR_GENE_PRODUCT", 199, 203], ["mice", "ORGANISM", 213, 217], ["cholesterol", "SIMPLE_CHEMICAL", 262, 273], ["mice", "ORGANISM", 319, 323], ["LDLR", "GENE_OR_GENE_PRODUCT", 358, 362], ["mice", "ORGANISM", 372, 376], ["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 419, 429], ["Pcsk9hum", "ORGANISM", 467, 475], ["hum", "ORGANISM", 476, 479], ["Ldlr\u2212", "GENE_OR_GENE_PRODUCT", 480, 485], ["LDL", "PROTEIN", 50, 53], ["recombinant antibody", "PROTEIN", 79, 99], ["anti-PCSK9 antibody", "PROTEIN", 157, 176], ["LDLR", "PROTEIN", 199, 203], ["LDLR", "PROTEIN", 358, 362], ["anti-PCSK9 antibody", "PROTEIN", 419, 438], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 213, 217], ["mice", "SPECIES", 319, 323], ["mice", "SPECIES", 372, 376], ["mice", "SPECIES", 488, 492], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 213, 217], ["mice", "SPECIES", 488, 492], ["LDL", "TEST", 50, 53], ["administered recombinant antibody doses", "TREATMENT", 66, 105], ["an anti-PCSK9 antibody", "TEST", 154, 176], ["LDLR", "TEST", 199, 203], ["an anti-PCSK9 antibody", "TREATMENT", 416, 438], ["humanized hyperlipidemic", "TREATMENT", 442, 466], ["a carbohydrate-rich diet", "TREATMENT", 496, 520], ["significant", "OBSERVATION_MODIFIER", 17, 28]]], ["The anti-PCSK9 antibody REGN727 reduced LDL-C to a pre-diet level within 24 hr.", [["REGN727", "CHEMICAL", 24, 31], ["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 4, 14], ["REGN727", "SIMPLE_CHEMICAL", 24, 31], ["LDL-C", "SIMPLE_CHEMICAL", 40, 45], ["anti-PCSK9 antibody REGN727", "PROTEIN", 4, 31], ["LDL", "PROTEIN", 40, 43], ["The anti-PCSK9 antibody", "TEST", 0, 23], ["LDL", "TEST", 40, 43]]], ["It was also found to be effective in cynomolgus monkeys, with up to a 75% reduction in LDL-C for over 20 days after a single intravenous administration.79DiscussionRecombinant anti-PCSK9 mAbs have shown success, but a major limiting factor to their use is their high cost.", [["intravenous", "ANATOMY", 125, 136], ["cynomolgus", "ORGANISM", 37, 47], ["monkeys", "ORGANISM", 48, 55], ["LDL-C", "SIMPLE_CHEMICAL", 87, 92], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 136], ["anti-PCSK9 mAbs", "GENE_OR_GENE_PRODUCT", 176, 191], ["LDL", "PROTEIN", 87, 90], ["Recombinant anti-PCSK9 mAbs", "PROTEIN", 164, 191], ["cynomolgus monkeys", "SPECIES", 37, 55], ["cynomolgus monkeys", "SPECIES", 37, 55], ["LDL", "TEST", 87, 90], ["a single intravenous administration", "TREATMENT", 116, 151], ["effective", "OBSERVATION_MODIFIER", 24, 33]]], ["Moreover, they require frequent dosing, such as every 2 weeks used for recombinant anti-PCSK9 antibody therapeutics.", [["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 83, 93], ["recombinant anti-PCSK9 antibody", "PROTEIN", 71, 102], ["frequent dosing", "TREATMENT", 23, 38], ["recombinant anti-PCSK9 antibody therapeutics", "TREATMENT", 71, 115]]], ["Here we developed a novel approach to inhibit PCSK9 using DMAb technology.", [["PCSK9", "GENE_OR_GENE_PRODUCT", 46, 51], ["DMAb", "SIMPLE_CHEMICAL", 58, 62], ["PCSK9", "PROTEIN", 46, 51], ["DMAb", "PROTEIN", 58, 62], ["DMAb technology", "TREATMENT", 58, 73]]], ["DMAbs have several advantages that make them an important new technology for the development of protein-based therapeutics, such as cost-effectiveness, ease of manufacturing, stability, and no requirement for a cold chain and rapid development and engineering.", [["DMAbs", "SIMPLE_CHEMICAL", 0, 5], ["protein-based therapeutics", "TREATMENT", 96, 122], ["a cold chain", "PROBLEM", 209, 221]]], ["DMAbs can be delivered via intramuscular or intradermal routes via in vivo electroporation of plasmid DNA.", [["intramuscular", "ANATOMY", 27, 40], ["plasmid", "ANATOMY", 94, 101], ["DMAbs", "CHEMICAL", 0, 5], ["DMAbs", "SIMPLE_CHEMICAL", 0, 5], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 40], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["plasmid DNA", "DNA", 94, 105], ["intramuscular or intradermal routes", "TREATMENT", 27, 62], ["plasmid DNA", "PROBLEM", 94, 105], ["plasmid DNA", "OBSERVATION", 94, 105]]], ["Low-voltage electroporation leads to consistent intracellular delivery of the injected plasmid DNA.", [["intracellular", "ANATOMY", 48, 61], ["plasmid", "ANATOMY", 87, 94], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 61], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["injected plasmid DNA", "DNA", 78, 98], ["Low-voltage electroporation", "TREATMENT", 0, 27], ["intracellular delivery", "TREATMENT", 48, 70], ["the injected plasmid DNA", "TREATMENT", 74, 98], ["intracellular delivery", "OBSERVATION", 48, 70]]], ["Our DMAb platform has shown protective efficacy against several viral pathogens, including HIV, Middle East Respiratory Syndrome (MERS), and Zika among others, and it is currently under evaluation for immunotherapeutics against cancers.73, 74, 75, 76, 77DiscussionIn this study, we used a CELLECTRA in vivo electroporation device, which utilizes an adaptive constant current electroporation system that can measure tissue resistance and adjust in real time to prevent any tissue damage and enhance DNA uptake.", [["cancers", "ANATOMY", 228, 235], ["tissue", "ANATOMY", 415, 421], ["tissue", "ANATOMY", 472, 478], ["DMAb", "CHEMICAL", 4, 8], ["viral pathogens", "DISEASE", 64, 79], ["Middle East Respiratory Syndrome", "DISEASE", 96, 128], ["MERS", "DISEASE", 130, 134], ["cancers", "DISEASE", 228, 235], ["cancers", "CANCER", 228, 235], ["tissue", "TISSUE", 415, 421], ["tissue", "TISSUE", 472, 478], ["DNA", "CELLULAR_COMPONENT", 498, 501], ["HIV", "SPECIES", 91, 94], ["HIV", "SPECIES", 91, 94], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 96, 135], ["Our DMAb platform", "TEST", 0, 17], ["several viral pathogens", "PROBLEM", 56, 79], ["HIV", "PROBLEM", 91, 94], ["Middle East Respiratory Syndrome", "PROBLEM", 96, 128], ["evaluation", "TEST", 186, 196], ["immunotherapeutics", "TREATMENT", 201, 219], ["cancers", "PROBLEM", 228, 235], ["this study", "TEST", 267, 277], ["a CELLECTRA in vivo electroporation device", "TREATMENT", 287, 329], ["an adaptive constant current electroporation system", "TREATMENT", 346, 397], ["any tissue damage", "PROBLEM", 468, 485], ["DNA uptake", "PROBLEM", 498, 508], ["protective efficacy", "OBSERVATION_MODIFIER", 28, 47], ["viral", "OBSERVATION_MODIFIER", 64, 69], ["pathogens", "OBSERVATION", 70, 79], ["Middle", "ANATOMY_MODIFIER", 96, 102], ["Respiratory Syndrome", "OBSERVATION", 108, 128], ["tissue", "ANATOMY", 472, 478], ["damage", "OBSERVATION", 479, 485]]], ["For DNA delivery, electroporation has been able to allow 1,000-fold enhancement in gene expression in vivo.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA delivery", "TREATMENT", 4, 16], ["electroporation", "TREATMENT", 18, 33]]], ["There have been several impactful clinical studies performed using this in vivo electroporation technology.", [["clinical studies", "TEST", 34, 50], ["this in vivo electroporation technology", "TREATMENT", 67, 106]]], ["One example is the human papilloma virus (HPV) VGX-3100 DNA vaccine, which showed efficacy in phase IIb clinical trials, demonstrating robust antigen-specific T cell response, as well as inducing clearance of the HPV virus and lesions.80 Another example is the development of the Zika virus DNA vaccine reported in the New England Journal of Medicine in 2017.81 In a phase I clinical trial evaluating the safety and immunogenicity of DNA vaccine GLS-5700, healthy adults demonstrated development of both binding and neutralizing antibodies, associated with protection in animal models.81DiscussionIn our study, the mouse PCSK9 DMAb was capable of expression for over 42 days in wild-type mice.", [["T cell", "ANATOMY", 159, 165], ["lesions", "ANATOMY", 227, 234], ["human papilloma virus", "DISEASE", 19, 40], ["VGX-3100", "CHEMICAL", 47, 55], ["GLS-5700", "CHEMICAL", 446, 454], ["human papilloma virus", "ORGANISM", 19, 40], ["HPV", "ORGANISM", 42, 45], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["T cell", "CELL", 159, 165], ["HPV virus", "ORGANISM", 213, 222], ["lesions", "PATHOLOGICAL_FORMATION", 227, 234], ["Zika virus", "ORGANISM", 280, 290], ["DNA", "CELLULAR_COMPONENT", 291, 294], ["DNA", "CELLULAR_COMPONENT", 434, 437], ["adults", "ORGANISM", 464, 470], ["mouse", "ORGANISM", 615, 620], ["PCSK9", "GENE_OR_GENE_PRODUCT", 621, 626], ["mice", "ORGANISM", 688, 692], ["neutralizing antibodies", "PROTEIN", 516, 539], ["mouse PCSK9 DMAb", "PROTEIN", 615, 631], ["human", "SPECIES", 19, 24], ["papilloma virus", "SPECIES", 25, 40], ["mouse", "SPECIES", 615, 620], ["mice", "SPECIES", 688, 692], ["human papilloma virus", "SPECIES", 19, 40], ["HPV", "SPECIES", 42, 45], ["HPV virus", "SPECIES", 213, 222], ["Zika virus", "SPECIES", 280, 290], ["mouse", "SPECIES", 615, 620], ["the human papilloma virus", "PROBLEM", 15, 40], ["VGX", "TEST", 47, 50], ["DNA vaccine", "TREATMENT", 56, 67], ["robust antigen", "PROBLEM", 135, 149], ["the HPV virus", "PROBLEM", 209, 222], ["lesions", "PROBLEM", 227, 234], ["the Zika virus DNA vaccine", "TREATMENT", 276, 302], ["DNA vaccine GLS", "TEST", 434, 449], ["both binding and neutralizing antibodies", "PROBLEM", 499, 539], ["the mouse PCSK9 DMAb", "TREATMENT", 611, 631], ["papilloma virus", "OBSERVATION", 25, 40], ["HPV virus", "OBSERVATION", 213, 222], ["lesions", "OBSERVATION", 227, 234], ["both binding", "OBSERVATION", 499, 511], ["neutralizing antibodies", "OBSERVATION", 516, 539]]], ["Expression for several months has been demonstrated with several DMAbs, such as Anti-Dengue,73 Anit-Ebola (A.P., unpublished data), and the immunoadhesin eCD4-Ig.82 These studies support the potential of DMAbs, some lasting several months, to be administered as a possible treatment for atherosclerotic cardiovascular disease.", [["cardiovascular", "ANATOMY", 303, 317], ["Dengue", "DISEASE", 85, 91], ["DMAbs", "CHEMICAL", 204, 209], ["atherosclerotic cardiovascular disease", "DISEASE", 287, 325], ["DMAbs", "CHEMICAL", 204, 209], ["Anit-Ebola", "ORGANISM", 95, 105], ["DMAbs", "SIMPLE_CHEMICAL", 204, 209], ["cardiovascular", "ANATOMICAL_SYSTEM", 303, 317], ["immunoadhesin", "PROTEIN", 140, 153], ["eCD4", "PROTEIN", 154, 158], ["Ig", "PROTEIN", 159, 161], ["These studies", "TEST", 165, 178], ["DMAbs", "PROBLEM", 204, 209], ["treatment", "TREATMENT", 273, 282], ["atherosclerotic cardiovascular disease", "PROBLEM", 287, 325], ["atherosclerotic", "OBSERVATION_MODIFIER", 287, 302], ["cardiovascular", "ANATOMY", 303, 317], ["disease", "OBSERVATION", 318, 325]]], ["Here we evaluated the efficacy of the anti-PCSK9 DMAb platform for its ability to express anti-PCSK9 antibodies directly in vivo and to exhibit lipid-lowering properties in mice.", [["anti-PCSK9 antibodies", "GENE_OR_GENE_PRODUCT", 90, 111], ["lipid", "SIMPLE_CHEMICAL", 144, 149], ["mice", "ORGANISM", 173, 177], ["DMAb", "PROTEIN", 49, 53], ["anti-PCSK9 antibodies", "PROTEIN", 90, 111], ["mice", "SPECIES", 173, 177], ["mice", "SPECIES", 173, 177], ["the anti-PCSK9 DMAb platform", "TREATMENT", 34, 62], ["anti-PCSK9 antibodies", "TREATMENT", 90, 111], ["lipid-lowering properties", "TREATMENT", 144, 169]]], ["An anti-PCSK9 DMAb (MdaPCSK9) that used a mouse-matched backbone was found to express for at least 6 weeks in vivo at reasonable levels.", [["anti-PCSK9 DMAb", "GENE_OR_GENE_PRODUCT", 3, 18], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 20, 28], ["mouse", "ORGANISM", 42, 47], ["anti-PCSK9 DMAb", "PROTEIN", 3, 18], ["MdaPCSK9", "PROTEIN", 20, 28], ["mouse", "SPECIES", 42, 47], ["mouse", "SPECIES", 42, 47], ["An anti-PCSK9 DMAb", "TREATMENT", 0, 18], ["a mouse-matched backbone", "TREATMENT", 40, 64], ["DMAb", "OBSERVATION", 14, 18]]], ["Importantly, inhibition of PCSK9 was observed in vivo, showing elevated liver LDLR expression 5 days after treatment.", [["liver", "ANATOMY", 72, 77], ["PCSK9", "GENE_OR_GENE_PRODUCT", 27, 32], ["liver", "ORGAN", 72, 77], ["LDLR", "GENE_OR_GENE_PRODUCT", 78, 82], ["PCSK9", "PROTEIN", 27, 32], ["LDLR", "PROTEIN", 78, 82], ["PCSK9", "TEST", 27, 32], ["elevated liver LDLR expression", "PROBLEM", 63, 93], ["treatment", "TREATMENT", 107, 116], ["elevated", "OBSERVATION_MODIFIER", 63, 71], ["liver", "ANATOMY", 72, 77], ["LDLR", "OBSERVATION", 78, 82]]], ["With a single intramuscular administration of anti-PCSK9 DMAbs (300 \u03bcg plasmid DNA), we observed reductions in non-HDL-C and total cholesterol with both mouse and human anti-PCSK9 antibodies.", [["intramuscular", "ANATOMY", 14, 27], ["anti-PCSK9 DMAbs", "CHEMICAL", 46, 62], ["cholesterol", "CHEMICAL", 131, 142], ["cholesterol", "CHEMICAL", 131, 142], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["anti-PCSK9 DMAbs", "SIMPLE_CHEMICAL", 46, 62], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["non-HDL-C", "SIMPLE_CHEMICAL", 111, 120], ["cholesterol", "SIMPLE_CHEMICAL", 131, 142], ["mouse", "ORGANISM", 153, 158], ["human", "ORGANISM", 163, 168], ["anti-PCSK9 antibodies", "GENE_OR_GENE_PRODUCT", 169, 190], ["anti-PCSK9 DMAbs", "PROTEIN", 46, 62], ["non-HDL", "PROTEIN", 111, 118], ["mouse and human anti-PCSK9 antibodies", "PROTEIN", 153, 190], ["mouse", "SPECIES", 153, 158], ["human", "SPECIES", 163, 168], ["mouse", "SPECIES", 153, 158], ["human", "SPECIES", 163, 168], ["a single intramuscular administration", "TREATMENT", 5, 42], ["anti-PCSK9 DMAbs", "TREATMENT", 46, 62], ["non-HDL", "TEST", 111, 118], ["total cholesterol", "TEST", 125, 142], ["human anti-PCSK9 antibodies", "TREATMENT", 163, 190]]], ["Significant reductions in non-HDL-C were observed with MdaPCSK9 as early as day 7 post-administration in wild-type and nude mice.", [["MdaPCSK9", "CHEMICAL", 55, 63], ["non-HDL-C", "SIMPLE_CHEMICAL", 26, 35], ["MdaPCSK9", "SIMPLE_CHEMICAL", 55, 63], ["nude mice", "ORGANISM", 119, 128], ["non-HDL", "PROTEIN", 26, 33], ["MdaPCSK9", "PROTEIN", 55, 63], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 124, 128], ["Significant reductions", "PROBLEM", 0, 22], ["non-HDL", "TEST", 26, 33], ["MdaPCSK9", "TREATMENT", 55, 63], ["reductions", "OBSERVATION_MODIFIER", 12, 22]]], ["Compared to wild-type pVax-1 negative controls, there was a 28.6% reduction on day 7 for the MdaPCSK9 group.", [["pVax-1", "GENE_OR_GENE_PRODUCT", 22, 28], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 93, 101], ["wild-type pVax-1 negative controls", "CELL_LINE", 12, 46]]], ["Both human and mouse anti-PCSK9 DMAbs led to 30% decreases in non-HDL-C and 14% reductions in total cholesterol by day 14.", [["DMAbs", "CHEMICAL", 32, 37], ["cholesterol", "CHEMICAL", 100, 111], ["cholesterol", "CHEMICAL", 100, 111], ["human", "ORGANISM", 5, 10], ["mouse", "ORGANISM", 15, 20], ["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 21, 31], ["non-HDL-C", "SIMPLE_CHEMICAL", 62, 71], ["cholesterol", "SIMPLE_CHEMICAL", 100, 111], ["human", "SPECIES", 5, 10], ["mouse", "SPECIES", 15, 20], ["human", "SPECIES", 5, 10], ["mouse", "SPECIES", 15, 20], ["non-HDL", "TEST", 62, 69], ["total cholesterol", "TEST", 94, 111]]], ["Wild-type mice, which are normocholesterolemic, were used in the current study, and it is difficult to observe significant decreases in LDL levels in these mice as compared to transgenic hypercholesterolemic mice.", [["hypercholesterolemic", "DISEASE", 187, 207], ["mice", "ORGANISM", 10, 14], ["LDL", "SIMPLE_CHEMICAL", 136, 139], ["mice", "ORGANISM", 156, 160], ["transgenic hypercholesterolemic mice", "ORGANISM", 176, 212], ["LDL", "PROTEIN", 136, 139], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 208, 212], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 208, 212], ["the current study", "TEST", 61, 78], ["significant decreases in LDL levels", "PROBLEM", 111, 146], ["transgenic hypercholesterolemic mice", "TREATMENT", 176, 212], ["type mice", "OBSERVATION_MODIFIER", 5, 14], ["decreases", "OBSERVATION_MODIFIER", 123, 132], ["hypercholesterolemic", "OBSERVATION", 187, 207]]], ["Future studies with transgenic hypercholesterolemic mice are important for evaluation of the PCSK9 DMAbs.DiscussionIn conclusion, these results demonstrate the efficacy of highly novel anti-PCSK9 DMAbs at reducing non-HDL-C and total cholesterol, and they suggest the potential of this new technology in the treatment of atherosclerotic cardiovascular disease and familial hypercholesterolemia patients.", [["cardiovascular", "ANATOMY", 337, 351], ["DMAbs", "CHEMICAL", 196, 201], ["non-HDL-C", "CHEMICAL", 214, 223], ["cholesterol", "CHEMICAL", 234, 245], ["atherosclerotic cardiovascular disease", "DISEASE", 321, 359], ["hypercholesterolemia", "DISEASE", 373, 393], ["cholesterol", "CHEMICAL", 234, 245], ["transgenic hypercholesterolemic mice", "ORGANISM", 20, 56], ["PCSK9", "GENE_OR_GENE_PRODUCT", 93, 98], ["anti-PCSK9", "SIMPLE_CHEMICAL", 185, 195], ["DMAbs", "SIMPLE_CHEMICAL", 196, 201], ["non-HDL-C", "SIMPLE_CHEMICAL", 214, 223], ["cholesterol", "SIMPLE_CHEMICAL", 234, 245], ["cardiovascular", "ANATOMICAL_SYSTEM", 337, 351], ["patients", "ORGANISM", 394, 402], ["PCSK9 DMAbs", "PROTEIN", 93, 104], ["mice", "SPECIES", 52, 56], ["patients", "SPECIES", 394, 402], ["mice", "SPECIES", 52, 56], ["Future studies", "TEST", 0, 14], ["transgenic hypercholesterolemic mice", "TREATMENT", 20, 56], ["evaluation", "TEST", 75, 85], ["the PCSK9 DMAbs", "PROBLEM", 89, 104], ["highly novel anti-PCSK9 DMAbs", "PROBLEM", 172, 201], ["non-HDL", "TEST", 214, 221], ["total cholesterol", "TEST", 228, 245], ["atherosclerotic cardiovascular disease", "PROBLEM", 321, 359], ["familial hypercholesterolemia patients", "PROBLEM", 364, 402], ["atherosclerotic", "OBSERVATION_MODIFIER", 321, 336], ["cardiovascular disease", "OBSERVATION", 337, 359], ["familial", "OBSERVATION_MODIFIER", 364, 372], ["hypercholesterolemia", "OBSERVATION", 373, 393]]], ["These novel DNA-produced, antibody-based therapeutics could be valuable as an alternative method of therapy of treatment for hypercholesterolemia and other cardiovascular diseases.Cell Culture ::: Materials and MethodsHEK293T, mouse hepatoma Hepa1-6, and human Huh-7 cells were maintained in DMEM (Gibco-Life Technologies) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 \u03bcg/mL streptomycin (Life Technologies).Anti-PCSK9 DMAb Plasmid Design and Construction ::: Materials and MethodsDMAb plasmids were designed to encode human or mouse anti-PCSK9 mAbs.", [["cardiovascular", "ANATOMY", 156, 170], ["Cell", "ANATOMY", 180, 184], ["hepatoma Hepa1-6", "ANATOMY", 233, 249], ["Huh-7 cells", "ANATOMY", 261, 272], ["fetal bovine serum", "ANATOMY", 345, 363], ["FBS", "ANATOMY", 365, 368], ["hypercholesterolemia", "DISEASE", 125, 145], ["cardiovascular diseases", "DISEASE", 156, 179], ["penicillin", "CHEMICAL", 380, 390], ["streptomycin", "CHEMICAL", 406, 418], ["penicillin", "CHEMICAL", 380, 390], ["streptomycin", "CHEMICAL", 406, 418], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["cardiovascular", "ANATOMICAL_SYSTEM", 156, 170], ["Cell", "CELL", 180, 184], ["mouse", "ORGANISM", 227, 232], ["hepatoma Hepa1-6", "CELL", 233, 249], ["human", "ORGANISM", 255, 260], ["Huh-7 cells", "CELL", 261, 272], ["bovine", "ORGANISM", 351, 357], ["serum", "ORGANISM_SUBSTANCE", 358, 363], ["FBS", "ORGANISM_SUBSTANCE", 365, 368], ["penicillin", "SIMPLE_CHEMICAL", 380, 390], ["streptomycin", "SIMPLE_CHEMICAL", 406, 418], ["human", "ORGANISM", 550, 555], ["mouse", "ORGANISM", 559, 564], ["anti-PCSK9 mAbs", "GENE_OR_GENE_PRODUCT", 565, 580], ["MethodsHEK293T", "CELL_LINE", 211, 225], ["mouse hepatoma Hepa1-6", "CELL_LINE", 227, 249], ["human Huh-7 cells", "CELL_LINE", 255, 272], ["MethodsDMAb plasmids", "DNA", 505, 525], ["human or mouse anti-PCSK9 mAbs", "PROTEIN", 550, 580], ["mouse", "SPECIES", 227, 232], ["human", "SPECIES", 255, 260], ["bovine", "SPECIES", 351, 357], ["human", "SPECIES", 550, 555], ["mouse", "SPECIES", 559, 564], ["mouse", "SPECIES", 227, 232], ["human", "SPECIES", 255, 260], ["human", "SPECIES", 550, 555], ["mouse", "SPECIES", 559, 564], ["These novel DNA", "TEST", 0, 15], ["antibody", "TEST", 26, 34], ["an alternative method of therapy", "TREATMENT", 75, 107], ["treatment", "TREATMENT", 111, 120], ["hypercholesterolemia", "PROBLEM", 125, 145], ["other cardiovascular diseases", "PROBLEM", 150, 179], ["Cell Culture", "TEST", 180, 192], ["Materials", "TEST", 197, 206], ["MethodsHEK293T", "TEST", 211, 225], ["mouse hepatoma Hepa1", "TEST", 227, 247], ["human Huh-7 cells", "TREATMENT", 255, 272], ["10% fetal bovine serum (FBS", "TREATMENT", 341, 368], ["penicillin", "TREATMENT", 380, 390], ["streptomycin", "TREATMENT", 406, 418], ["Materials", "TREATMENT", 491, 500], ["MethodsDMAb plasmids", "TREATMENT", 505, 525], ["mouse anti-PCSK9 mAbs", "TREATMENT", 559, 580], ["cardiovascular diseases", "OBSERVATION", 156, 179]]], ["DMAb transgenes were designed in a single open reading frame, with the variable and constant heavy chains separated from variable and constant light chains by a furin/P2A cleavage site.", [["DMAb", "GENE_OR_GENE_PRODUCT", 0, 4], ["furin", "GENE_OR_GENE_PRODUCT", 161, 166], ["P2A", "GENE_OR_GENE_PRODUCT", 167, 170], ["DMAb transgenes", "DNA", 0, 15], ["open reading frame", "DNA", 42, 60], ["furin", "PROTEIN", 161, 166], ["P2A", "PROTEIN", 167, 170], ["DMAb transgenes", "TREATMENT", 0, 15], ["the variable and constant heavy chains", "PROBLEM", 67, 105], ["constant light chains", "TREATMENT", 134, 155], ["a furin/P2A cleavage site", "TREATMENT", 159, 184]]], ["Two constructs were developed: a human anti-PCSK9 DMAb (HdaPCSK9) on an IgG1 backbone, and a mouse anti-PCSK9 DMAb (MdaPCSK9) on an IgG2a backbone.", [["human", "ORGANISM", 33, 38], ["anti-PCSK9 DMAb", "GENE_OR_GENE_PRODUCT", 39, 54], ["HdaPCSK9", "GENE_OR_GENE_PRODUCT", 56, 64], ["IgG1", "GENE_OR_GENE_PRODUCT", 72, 76], ["mouse", "ORGANISM", 93, 98], ["anti-PCSK9 DMAb", "GENE_OR_GENE_PRODUCT", 99, 114], ["MdaPCSK9", "GENE_OR_GENE_PRODUCT", 116, 124], ["IgG2a", "GENE_OR_GENE_PRODUCT", 132, 137], ["human anti-PCSK9 DMAb", "PROTEIN", 33, 54], ["HdaPCSK9", "PROTEIN", 56, 64], ["IgG1 backbone", "PROTEIN", 72, 85], ["mouse anti-PCSK9 DMAb", "PROTEIN", 93, 114], ["MdaPCSK9", "PROTEIN", 116, 124], ["IgG2a backbone", "PROTEIN", 132, 146], ["human", "SPECIES", 33, 38], ["mouse", "SPECIES", 93, 98], ["human", "SPECIES", 33, 38], ["mouse", "SPECIES", 93, 98], ["a human anti-PCSK9 DMAb", "TREATMENT", 31, 54], ["an IgG1 backbone", "TREATMENT", 69, 85], ["a mouse anti-PCSK9 DMAb", "TREATMENT", 91, 114], ["an IgG2a backbone", "TREATMENT", 129, 146]]], ["DMAb transgenes were flanked with BamHI and XhoI restriction enzyme sites and synthesized by GenScript for subcloning into the corresponding restriction enzyme sites in a pVax-1 mammalian expression vector.", [["DMAb", "GENE_OR_GENE_PRODUCT", 0, 4], ["BamHI", "GENE_OR_GENE_PRODUCT", 34, 39], ["XhoI", "GENE_OR_GENE_PRODUCT", 44, 48], ["pVax-1", "GENE_OR_GENE_PRODUCT", 171, 177], ["DMAb transgenes", "DNA", 0, 15], ["BamHI and XhoI restriction enzyme sites", "DNA", 34, 73], ["GenScript", "DNA", 93, 102], ["restriction enzyme sites", "DNA", 141, 165], ["pVax-1 mammalian expression vector", "DNA", 171, 205], ["DMAb transgenes", "TREATMENT", 0, 15], ["BamHI and XhoI restriction enzyme sites", "TREATMENT", 34, 73], ["subcloning into the corresponding restriction enzyme sites", "PROBLEM", 107, 165], ["a pVax", "TEST", 169, 175]]], ["Human CMV immediate-early promoter in the pVax-1 vector was used to drive the expression of the antibodies.In\u00a0Vitro Transfection of DMAb Plasmids ::: Materials and MethodsHEK293T, Hepa1-6, or Huh7 cells were transfected with anti-PCSK9 DMAb plasmids using lipofectamine LTX reagent and following the manufacturer\u2019s protocol.", [["Hepa1-6", "ANATOMY", 180, 187], ["Huh7 cells", "ANATOMY", 192, 202], ["lipofectamine", "CHEMICAL", 256, 269], ["Human", "ORGANISM", 0, 5], ["CMV", "ORGANISM", 6, 9], ["pVax-1", "GENE_OR_GENE_PRODUCT", 42, 48], ["Hepa1-6", "CELL", 180, 187], ["Huh7 cells", "CELL", 192, 202], ["Human CMV immediate-early promoter", "DNA", 0, 34], ["pVax-1 vector", "DNA", 42, 55], ["antibodies", "PROTEIN", 96, 106], ["DMAb Plasmids", "DNA", 132, 145], ["MethodsHEK293T, Hepa1-6", "CELL_LINE", 164, 187], ["Huh7 cells", "CELL_LINE", 192, 202], ["anti-PCSK9 DMAb plasmids", "DNA", 225, 249], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human CMV immediate", "TREATMENT", 0, 19], ["Materials", "TEST", 150, 159], ["MethodsHEK293T", "TEST", 164, 178], ["Hepa1", "TEST", 180, 185], ["Huh7 cells", "TREATMENT", 192, 202], ["anti-PCSK9 DMAb plasmids", "TREATMENT", 225, 249], ["lipofectamine LTX reagent", "TREATMENT", 256, 281], ["the manufacturer\u2019s protocol", "TREATMENT", 296, 323]]], ["Briefly, 5 \u00d7 105 cells were seeded in a 12-well plate and incubated in a 37\u00b0C incubator with 5% CO2.", [["cells", "ANATOMY", 17, 22], ["CO2", "CHEMICAL", 96, 99], ["CO2", "CHEMICAL", 96, 99], ["\u00d7 105 cells", "CELL", 11, 22], ["CO2", "SIMPLE_CHEMICAL", 96, 99], ["5 \u00d7 105 cells", "CELL_LINE", 9, 22], ["a 37\u00b0C incubator", "TREATMENT", 71, 87], ["5% CO2", "TREATMENT", 93, 99]]], ["Cells were transfected with 1 \u03bcg DMAb plasmid at 70% confluence and incubated for a maximum of 72 hr.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DMAb plasmid", "DNA", 33, 45], ["Cells", "TEST", 0, 5], ["1 \u03bcg DMAb plasmid", "TREATMENT", 28, 45]]], ["DMAb expression following transfection was analyzed by western blot, ELISA, and immunofluorescence microscopy.Western Blot and ELISA Analyses ::: Materials and MethodsA binding western blot analysis was performed to evaluate anti-PCSK9 DMAb-binding capability.", [["DMAb", "GENE_OR_GENE_PRODUCT", 0, 4], ["anti-PCSK9", "GENE_OR_GENE_PRODUCT", 225, 235], ["DMAb", "SIMPLE_CHEMICAL", 236, 240], ["DMAb", "PROTEIN", 0, 4], ["DMAb", "PROTEIN", 236, 240], ["ELISA", "TEST", 69, 74], ["immunofluorescence microscopy", "TEST", 80, 109], ["MethodsA binding western blot analysis", "TEST", 160, 198]]], ["Recombinant human or mouse PCSK9 protein (0.5\u20135 \u03bcg) was run in precast Bis-Tris gels (Invitrogen) under nonreducing conditions.", [["Bis-Tris", "CHEMICAL", 71, 79], ["Bis-Tris gels", "CHEMICAL", 71, 84], ["human", "ORGANISM", 12, 17], ["mouse", "ORGANISM", 21, 26], ["PCSK9", "GENE_OR_GENE_PRODUCT", 27, 32], ["Bis-Tris gels", "SIMPLE_CHEMICAL", 71, 84], ["Invitrogen", "SIMPLE_CHEMICAL", 86, 96], ["Recombinant human or mouse PCSK9 protein", "PROTEIN", 0, 40], ["human", "SPECIES", 12, 17], ["mouse", "SPECIES", 21, 26], ["human", "SPECIES", 12, 17], ["mouse", "SPECIES", 21, 26], ["protein", "TEST", 33, 40]]], ["Gels were transferred to Immobilon-FL polyvinylidene fluoride (PVDF) transfer membranes (Millipore).", [["FL polyvinylidene fluoride", "CHEMICAL", 35, 61], ["polyvinylidene fluoride", "CHEMICAL", 38, 61], ["PVDF", "CHEMICAL", 63, 67], ["Gels", "SIMPLE_CHEMICAL", 0, 4], ["polyvinylidene fluoride", "SIMPLE_CHEMICAL", 38, 61], ["membranes", "CELLULAR_COMPONENT", 78, 87], ["Immobilon-FL polyvinylidene fluoride (PVDF) transfer membranes (Millipore", "TREATMENT", 25, 98]]], ["The membranes were blocked in Odyssey Blocking Buffer (LI-COR Biosciences) for 1 hr, then stained overnight at 4\u00b0C with either supernatant from DMAb-transfected cells or serum from DMAb-treated mice, and compared to those of pVax-1-negative control samples.", [["membranes", "ANATOMY", 4, 13], ["supernatant", "ANATOMY", 127, 138], ["cells", "ANATOMY", 161, 166], ["serum", "ANATOMY", 170, 175], ["samples", "ANATOMY", 249, 256], ["DMAb", "CHEMICAL", 181, 185], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["DMAb", "SIMPLE_CHEMICAL", 144, 148], ["cells", "CELL", 161, 166], ["serum", "ORGANISM_SUBSTANCE", 170, 175], ["DMAb", "SIMPLE_CHEMICAL", 181, 185], ["mice", "ORGANISM", 194, 198], ["pVax-1", "GENE_OR_GENE_PRODUCT", 225, 231], ["samples", "CANCER", 249, 256], ["DMAb-transfected cells", "CELL_LINE", 144, 166], ["pVax", "PROTEIN", 225, 229], ["mice", "SPECIES", 194, 198], ["mice", "SPECIES", 194, 198], ["Odyssey Blocking Buffer", "TREATMENT", 30, 53], ["DMAb", "TREATMENT", 144, 148], ["transfected cells", "PROBLEM", 149, 166], ["serum", "TEST", 170, 175], ["DMAb", "TREATMENT", 181, 185], ["pVax", "TEST", 225, 229]]], ["Membranes were washed with PBST (PBS with 0.05% Tween 20).", [["Membranes", "ANATOMY", 0, 9], ["Tween 20", "CHEMICAL", 48, 56], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["PBS", "TEST", 33, 36]]], ["Subsequently, membranes were stained with either anti-human or anti-mouse IgG 680RD antibody (LI-COR Biosciences) for 1 hr at room temperature (RT) and washed in PBST.", [["membranes", "ANATOMY", 14, 23], ["membranes", "CELLULAR_COMPONENT", 14, 23], ["anti-mouse IgG 680RD antibody", "PROTEIN", 63, 92], ["LI", "PROTEIN", 94, 96], ["COR Biosciences", "PROTEIN", 97, 112], ["anti-human", "TREATMENT", 49, 59], ["anti-mouse IgG", "TEST", 63, 77]]], ["Membranes were scanned on a LI-COR Odyssey CLx imager.", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9]]], ["50 \u03bcg total sample protein was loaded in gels and run as described above for the analysis of liver lysates for LDLR expression.", [["sample", "ANATOMY", 12, 18], ["liver lysates", "ANATOMY", 93, 106], ["liver lysates", "ORGANISM_SUBSTANCE", 93, 106], ["LDLR", "GENE_OR_GENE_PRODUCT", 111, 115], ["50 \u03bcg total sample protein", "PROTEIN", 0, 26], ["LDLR", "PROTEIN", 111, 115], ["total sample protein", "TREATMENT", 6, 26], ["the analysis", "TEST", 77, 89], ["liver lysates", "TEST", 93, 106], ["LDLR expression", "PROBLEM", 111, 126], ["liver", "ANATOMY", 93, 98]]], ["Membranes were stained with an anti-mLDLR primary antibody (AF2255; R&D Systems).", [["Membranes", "ANATOMY", 0, 9], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["anti-mLDLR primary antibody", "PROTEIN", 31, 58], ["AF2255", "PROTEIN", 60, 66], ["R&D", "PROTEIN", 68, 71], ["an anti-mLDLR primary antibody", "TEST", 28, 58]]], ["Actin was stained using an anti-actin primary antibody (ab198991; Abcam) and an anti-rabbit IgG-HRP secondary antibody.Western Blot and ELISA Analyses ::: Materials and MethodsDMAbs with human backbones were quantified by an ELISA for total human IgG.", [["Actin", "GENE_OR_GENE_PRODUCT", 0, 5], ["Abcam", "GENE_OR_GENE_PRODUCT", 66, 71], ["HRP", "GENE_OR_GENE_PRODUCT", 96, 99], ["MethodsDMAbs", "SIMPLE_CHEMICAL", 169, 181], ["human", "ORGANISM", 187, 192], ["human", "ORGANISM", 241, 246], ["IgG", "GENE_OR_GENE_PRODUCT", 247, 250], ["Actin", "PROTEIN", 0, 5], ["anti-actin primary antibody", "PROTEIN", 27, 54], ["ab198991", "PROTEIN", 56, 64], ["Abcam", "PROTEIN", 66, 71], ["anti-rabbit IgG", "PROTEIN", 80, 95], ["HRP secondary antibody", "PROTEIN", 96, 118], ["human IgG", "PROTEIN", 241, 250], ["anti-rabbit", "SPECIES", 80, 91], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 241, 246], ["anti-rabbit", "SPECIES", 80, 91], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 241, 246], ["an anti-actin primary antibody", "TEST", 24, 54], ["Abcam", "TEST", 66, 71], ["an anti-rabbit IgG", "TEST", 77, 95], ["human backbones", "TREATMENT", 187, 202], ["an ELISA", "TEST", 222, 230], ["total human IgG", "TREATMENT", 235, 250]]], ["ELISA MaxiSorp plates were coated with 1 \u03bcg/well anti-human IgG-Fc fragment antibody (A80-104A; Bethyl Laboratories) overnight at 4\u00b0C. Plates were blocked in 10% FBS in PBS for 1 hr at RT.", [["FBS", "ANATOMY", 162, 165], ["A80-104A", "CHEMICAL", 86, 94], ["FBS", "ORGANISM_SUBSTANCE", 162, 165], ["anti-human IgG", "PROTEIN", 49, 63], ["Fc fragment antibody", "PROTEIN", 64, 84], ["A80", "PROTEIN", 86, 89], ["104A", "PROTEIN", 90, 94], ["ELISA MaxiSorp plates", "TREATMENT", 0, 21], ["anti-human IgG", "TEST", 49, 63], ["Fc fragment antibody", "TEST", 64, 84], ["A80", "TEST", 86, 89], ["Bethyl Laboratories", "TEST", 96, 115], ["Plates", "TEST", 135, 141], ["blocked", "OBSERVATION_MODIFIER", 147, 154]]], ["Samples and recombinant human IgG standards were added to the plate for 1 hr at RT.", [["Samples", "ANATOMY", 0, 7], ["human", "ORGANISM", 24, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 30, 33], ["recombinant human IgG", "PROTEIN", 12, 33], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["Samples", "TEST", 0, 7], ["recombinant human IgG standards", "TREATMENT", 12, 43]]], ["After washing the plates, anti-human IgG-Fc fragment antibody-HRP (A80-104P; Bethyl Laboratories) was added for 1 hr at RT.", [["A80-104P", "CHEMICAL", 67, 75], ["HRP", "SIMPLE_CHEMICAL", 62, 65], ["Bethyl", "GENE_OR_GENE_PRODUCT", 77, 83], ["anti-human IgG", "PROTEIN", 26, 40], ["Fc fragment antibody", "PROTEIN", 41, 61], ["HRP", "PROTEIN", 62, 65], ["A80", "PROTEIN", 67, 70], ["104P", "PROTEIN", 71, 75], ["the plates", "TEST", 14, 24], ["anti-human IgG", "TEST", 26, 40], ["Fc fragment antibody", "TEST", 41, 61], ["HRP", "TEST", 62, 65], ["A80", "TEST", 67, 70]]], ["SigmaFast OPD (Sigma-Aldrich) substrate solution was used for sample detection.", [["sample", "ANATOMY", 62, 68], ["SigmaFast OPD", "SIMPLE_CHEMICAL", 0, 13], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 15, 28], ["SigmaFast OPD (Sigma-Aldrich) substrate solution", "TREATMENT", 0, 48], ["sample detection", "TEST", 62, 78]]], ["Optical density was measured at 450 nm using a GloMax 96 Microplate Luminometer (Promega).", [["Optical density", "PROBLEM", 0, 15], ["a GloMax 96 Microplate Luminometer (Promega)", "TREATMENT", 45, 89], ["density", "OBSERVATION", 8, 15]]], ["For quantification of DMAbs with mouse backbones from cell supernatants, plates were coated with anti-mouse IgG-Fc fragment antibody (A90-131A; Bethyl Laboratories).", [["cell supernatants", "ANATOMY", 54, 71], ["DMAbs", "SIMPLE_CHEMICAL", 22, 27], ["mouse", "ORGANISM", 33, 38], ["cell", "CELL", 54, 58], ["Bethyl", "GENE_OR_GENE_PRODUCT", 144, 150], ["DMAbs", "PROTEIN", 22, 27], ["anti-mouse IgG", "PROTEIN", 97, 111], ["Fc fragment antibody", "PROTEIN", 112, 132], ["A90", "PROTEIN", 134, 137], ["131A", "PROTEIN", 138, 142], ["Bethyl Laboratories", "PROTEIN", 144, 163], ["mouse", "SPECIES", 33, 38], ["mouse", "SPECIES", 33, 38], ["DMAbs", "PROBLEM", 22, 27], ["mouse backbones from cell supernatants", "PROBLEM", 33, 71], ["plates", "TEST", 73, 79], ["anti-mouse IgG", "TEST", 97, 111], ["Fc fragment antibody", "TEST", 112, 132], ["A90", "TEST", 134, 137]]], ["Anti-mouse IgG-HRP (62-6520; Invitrogen) was used for detection.", [["IgG-HRP", "GENE_OR_GENE_PRODUCT", 11, 18], ["Anti-mouse IgG", "PROTEIN", 0, 14], ["HRP", "PROTEIN", 15, 18], ["Anti-mouse IgG", "TEST", 0, 14]]], ["Serum samples of DMAbs with a mouse backbone were differentiated from background mouse IgGs by coating ELISA plates with recombinant PCSK9 protein.", [["Serum samples", "ANATOMY", 0, 13], ["DMAbs", "ANATOMY", 17, 22], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["DMAbs", "SIMPLE_CHEMICAL", 17, 22], ["mouse", "ORGANISM", 30, 35], ["mouse", "ORGANISM", 81, 86], ["IgGs", "GENE_OR_GENE_PRODUCT", 87, 91], ["PCSK9", "GENE_OR_GENE_PRODUCT", 133, 138], ["mouse IgGs", "PROTEIN", 81, 91], ["recombinant PCSK9 protein", "PROTEIN", 121, 146], ["mouse", "SPECIES", 30, 35], ["mouse", "SPECIES", 81, 86], ["mouse", "SPECIES", 30, 35], ["mouse", "SPECIES", 81, 86], ["Serum samples", "TEST", 0, 13], ["DMAbs", "TEST", 17, 22], ["a mouse backbone", "TREATMENT", 28, 44], ["background mouse IgGs", "TREATMENT", 70, 91], ["coating ELISA plates", "TEST", 95, 115]]], ["Purified recombinant anti-PCSK9 mAb was used as the standard.", [["anti-PCSK9 mAb", "GENE_OR_GENE_PRODUCT", 21, 35], ["Purified recombinant anti-PCSK9 mAb", "PROTEIN", 0, 35], ["Purified recombinant anti-PCSK9 mAb", "TREATMENT", 0, 35]]], ["Quantitative ELISA data are expressed as \u00b1 SEM (n = 3).Immunofluorescence Analysis ::: Materials and MethodsHepa1-6 cells were transfected with anti-PCSK9 DMAbs using lipofectamine LTX reagent as described above.", [["Hepa1-6 cells", "ANATOMY", 108, 121], ["lipofectamine", "CHEMICAL", 167, 180], ["Hepa1-6 cells", "CELL", 108, 121], ["anti-PCSK9 DMAbs", "SIMPLE_CHEMICAL", 144, 160], ["Hepa1-6 cells", "CELL_LINE", 108, 121], ["anti-PCSK9 DMAbs", "PROTEIN", 144, 160], ["Quantitative ELISA data", "TEST", 0, 23], ["Immunofluorescence Analysis", "TEST", 55, 82], ["MethodsHepa1", "TEST", 101, 113], ["anti-PCSK9 DMAbs", "TREATMENT", 144, 160], ["lipofectamine LTX reagent", "TREATMENT", 167, 192]]], ["48 hr after transfection, cells were washed in PBS and fixed in 4% paraformaldehyde for 10 min at RT.", [["cells", "ANATOMY", 26, 31], ["paraformaldehyde", "CHEMICAL", 67, 83], ["cells", "CELL", 26, 31], ["paraformaldehyde", "SIMPLE_CHEMICAL", 67, 83], ["PBS", "TREATMENT", 47, 50], ["4% paraformaldehyde", "TREATMENT", 64, 83]]], ["Cells were then washed and incubated with anti-human IgG-FITC (A80-319F; Bethyl Laboratories) for 1 hr.", [["Cells", "ANATOMY", 0, 5], ["A80-319F", "CHEMICAL", 63, 71], ["FITC", "CHEMICAL", 57, 61], ["Cells", "CELL", 0, 5], ["FITC", "SIMPLE_CHEMICAL", 57, 61], ["anti-human IgG", "PROTEIN", 42, 56], ["FITC", "PROTEIN", 57, 61], ["A80", "PROTEIN", 63, 66], ["319F", "PROTEIN", 67, 71], ["anti-human IgG", "TEST", 42, 56]]], ["After washing, cells were stained with DAPI nuclear stain and imaged on an EVOS FL Imaging System.Flow Cytometry Analysis ::: Materials and MethodsFlow cytometry was used for the detection of LDLR on Huh7 cells transfected with control pVax-1 or anti-PCSK9 DMAb plasmids.", [["cells", "ANATOMY", 15, 20], ["nuclear", "ANATOMY", 44, 51], ["Huh7 cells", "ANATOMY", 200, 210], ["plasmids", "ANATOMY", 262, 270], ["DAPI", "CHEMICAL", 39, 43], ["cells", "CELL", 15, 20], ["DAPI", "SIMPLE_CHEMICAL", 39, 43], ["LDLR", "GENE_OR_GENE_PRODUCT", 192, 196], ["Huh7 cells", "CELL", 200, 210], ["pVax-1", "GENE_OR_GENE_PRODUCT", 236, 242], ["anti-PCSK9", "ORGANISM", 246, 256], ["DMAb", "GENE_OR_GENE_PRODUCT", 257, 261], ["LDLR", "PROTEIN", 192, 196], ["Huh7 cells", "CELL_LINE", 200, 210], ["pVax-1 or anti-PCSK9 DMAb plasmids", "DNA", 236, 270], ["DAPI nuclear stain", "TEST", 39, 57], ["an EVOS FL Imaging System", "TEST", 72, 97], ["Flow Cytometry Analysis", "TEST", 98, 121], ["MethodsFlow cytometry", "TEST", 140, 161], ["the detection", "TEST", 175, 188], ["LDLR", "PROBLEM", 192, 196], ["Huh7 cells", "TREATMENT", 200, 210], ["control pVax", "TREATMENT", 228, 240], ["anti-PCSK9 DMAb plasmids", "TREATMENT", 246, 270], ["Huh7 cells", "OBSERVATION", 200, 210]]], ["72 hr post-transfection, cells were washed with fluorescence-activated cell sorting (FACS) buffer (3% FBS in PBS) and stained with anti-LDLR primary antibody (ab52818; Abcam) for 1 hr at 4\u00b0C, followed by anti-rabbit IgG-FITC secondary antibody (ab6717; Abcam) for 1 hr at 4\u00b0C. Cells were washed 3 times in FACS buffer and fixed in 2% paraformaldehyde.", [["cells", "ANATOMY", 25, 30], ["cell", "ANATOMY", 71, 75], ["FBS", "ANATOMY", 102, 105], ["Cells", "ANATOMY", 277, 282], ["FITC", "CHEMICAL", 220, 224], ["paraformaldehyde", "CHEMICAL", 334, 350], ["cells", "CELL", 25, 30], ["cell", "CELL", 71, 75], ["FBS", "ORGANISM_SUBSTANCE", 102, 105], ["Abcam", "GENE_OR_GENE_PRODUCT", 168, 173], ["FITC", "GENE_OR_GENE_PRODUCT", 220, 224], ["Abcam", "GENE_OR_GENE_PRODUCT", 253, 258], ["Cells", "CELL", 277, 282], ["paraformaldehyde", "SIMPLE_CHEMICAL", 334, 350], ["anti-LDLR primary antibody", "PROTEIN", 131, 157], ["ab52818", "PROTEIN", 159, 166], ["Abcam", "PROTEIN", 168, 173], ["anti-rabbit IgG", "PROTEIN", 204, 219], ["FITC secondary antibody", "PROTEIN", 220, 243], ["ab6717", "PROTEIN", 245, 251], ["Abcam", "PROTEIN", 253, 258], ["anti-rabbit", "SPECIES", 204, 215], ["anti-rabbit", "SPECIES", 204, 215], ["fluorescence", "TEST", 48, 60], ["FBS in PBS", "TEST", 102, 112], ["anti-LDLR primary antibody", "TEST", 131, 157], ["Abcam", "TEST", 168, 173], ["anti-rabbit IgG", "TEST", 204, 219], ["FITC secondary antibody", "TEST", 220, 243], ["Abcam", "TEST", 253, 258], ["2% paraformaldehyde", "TREATMENT", 331, 350]]], ["Cells were analyzed on an LSR18 flow cytometer (BD Biosciences).Immunohistochemistry of Mouse Muscle ::: Materials and MethodsImmunohistochemistry was performed by The Wistar Institute Histotechnology Facility.", [["Cells", "ANATOMY", 0, 5], ["Muscle", "ANATOMY", 94, 100], ["Cells", "CELL", 0, 5], ["Mouse", "ORGANISM", 88, 93], ["Mouse", "SPECIES", 88, 93], ["an LSR18 flow cytometer", "TEST", 23, 46], ["MethodsImmunohistochemistry", "TEST", 119, 146], ["Mouse Muscle", "ANATOMY", 88, 100]]], ["Briefly, mouse anterior tibialis muscle sections were resected and embedded in paraffin.", [["anterior tibialis muscle sections", "ANATOMY", 15, 48], ["paraffin", "CHEMICAL", 79, 87], ["mouse", "ORGANISM", 9, 14], ["anterior tibialis muscle sections", "MULTI-TISSUE_STRUCTURE", 15, 48], ["mouse", "SPECIES", 9, 14], ["mouse", "SPECIES", 9, 14], ["mouse anterior tibialis muscle sections", "TREATMENT", 9, 48], ["anterior", "ANATOMY_MODIFIER", 15, 23], ["tibialis muscle", "ANATOMY", 24, 39], ["resected", "OBSERVATION", 54, 62]]], ["Paraffin-embedded samples were treated with antigen retrieval reagent and deparaffinized.", [["samples", "ANATOMY", 18, 25], ["antigen retrieval reagent", "TREATMENT", 44, 69], ["deparaffinized", "TREATMENT", 74, 88]]], ["Slides were then fixed with acetone and washed with PBS, followed by blocking and staining the sections with anti-human IgG antibody-HRP.In\u00a0Vivo DMAb Plasmid Administration ::: Materials and MethodsEvaluation of DMAbs was carried out in 6- to 8-week-old C57BL/6J wild-type and nude B6.Cg-foxn1nu/J mice.", [["sections", "ANATOMY", 95, 103], ["acetone", "CHEMICAL", 28, 35], ["acetone", "CHEMICAL", 28, 35], ["acetone", "SIMPLE_CHEMICAL", 28, 35], ["DMAbs", "SIMPLE_CHEMICAL", 212, 217], ["C57BL/6J wild-type", "ORGANISM", 254, 272], ["nude B6", "ORGANISM", 277, 284], ["Cg-foxn1nu", "GENE_OR_GENE_PRODUCT", 285, 295], ["anti-human IgG antibody", "PROTEIN", 109, 132], ["mice", "SPECIES", 298, 302], ["acetone", "TREATMENT", 28, 35], ["PBS", "TREATMENT", 52, 55], ["staining the sections", "TEST", 82, 103], ["anti-human IgG antibody", "TREATMENT", 109, 132], ["DMAbs", "TEST", 212, 217], ["Cg", "TEST", 285, 287], ["DMAb", "OBSERVATION", 145, 149]]], ["Animal experiments were carried out in accordance with the guidelines of the NIH and The Wistar Institute Institutional Animal Care and Use Committee (IACUC).", [["Animal experiments", "TEST", 0, 18]]], ["Mice were injected with plasmid DNA in the tibialis anterior or quadricep muscles.", [["plasmid", "ANATOMY", 24, 31], ["tibialis anterior", "ANATOMY", 43, 60], ["quadricep muscles", "ANATOMY", 64, 81], ["Mice", "ORGANISM", 0, 4], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["tibialis anterior", "MULTI-TISSUE_STRUCTURE", 43, 60], ["quadricep muscles", "TISSUE", 64, 81], ["plasmid DNA", "DNA", 24, 35], ["Mice", "SPECIES", 0, 4], ["plasmid DNA", "TREATMENT", 24, 35], ["plasmid DNA", "OBSERVATION", 24, 35], ["tibialis", "ANATOMY", 43, 51], ["anterior", "ANATOMY_MODIFIER", 52, 60], ["quadricep muscles", "ANATOMY", 64, 81]]], ["In vivo electroporation was performed using a CELLECTRA adaptive constant-current EP device (Inovio Pharmaceuticals).", [["vivo electroporation", "TREATMENT", 3, 23], ["a CELLECTRA adaptive constant", "TREATMENT", 44, 73], ["current EP device (Inovio Pharmaceuticals", "TREATMENT", 74, 115]]], ["Triangular 3-electrode arrays consisting of 26G solid stainless steel electrodes were used to deliver square-wave pulses.", [["Triangular 3-electrode arrays", "TREATMENT", 0, 29], ["26G solid stainless steel electrodes", "TREATMENT", 44, 80], ["square-wave pulses", "TEST", 102, 120], ["solid stainless", "OBSERVATION", 48, 63], ["steel electrodes", "OBSERVATION", 64, 80], ["wave pulses", "OBSERVATION", 109, 120]]], ["Mice were given either 100 or 300 \u03bcg plasmid DNA resuspended in water.", [["Mice", "ORGANISM", 0, 4], ["DNA", "CELLULAR_COMPONENT", 45, 48], ["Mice", "SPECIES", 0, 4]]], ["The plasmids were co-formulated with recombinant hyaluronidase to enhance their intramuscular distribution.", [["plasmids", "ANATOMY", 4, 12], ["intramuscular", "ANATOMY", 80, 93], ["hyaluronidase", "GENE_OR_GENE_PRODUCT", 49, 62], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["plasmids", "DNA", 4, 12], ["recombinant hyaluronidase", "PROTEIN", 37, 62], ["The plasmids", "TREATMENT", 0, 12], ["recombinant hyaluronidase", "TREATMENT", 37, 62], ["plasmids", "OBSERVATION", 4, 12], ["intramuscular", "ANATOMY", 80, 93]]], ["A maximum of 30 \u03bcL volume was used at each injection site. pVax-1 empty vector was used as a negative control for DMAbs.", [["pVax-1", "GENE_OR_GENE_PRODUCT", 59, 65], ["DMAbs", "SIMPLE_CHEMICAL", 114, 119], ["pVax-1 empty vector", "DNA", 59, 78], ["DMAbs", "PROTEIN", 114, 119], ["A maximum of 30 \u03bcL volume", "TREATMENT", 0, 25], ["pVax", "TEST", 59, 63], ["1 empty vector", "TREATMENT", 64, 78], ["DMAbs", "PROBLEM", 114, 119], ["maximum", "OBSERVATION_MODIFIER", 2, 9]]], ["Blood was collected by submandibular bleeding for DMAb quantification and lipid panel analysis.", [["Blood", "ANATOMY", 0, 5], ["submandibular", "ANATOMY", 23, 36], ["submandibular bleeding", "DISEASE", 23, 45], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["submandibular", "ORGAN", 23, 36], ["DMAb", "SIMPLE_CHEMICAL", 50, 54], ["Blood", "TEST", 0, 5], ["submandibular bleeding", "PROBLEM", 23, 45], ["DMAb quantification", "TEST", 50, 69], ["lipid panel analysis", "TEST", 74, 94], ["submandibular", "ANATOMY", 23, 36], ["bleeding", "OBSERVATION", 37, 45]]], ["Samples were collected until day 42 or 62.Mouse Lipid Panel Analysis ::: Materials and MethodsLipid panel analysis was carried out using a VITROS 350 Clinical Chemistry Analyzer.", [["Samples", "ANATOMY", 0, 7], ["Mouse", "ORGANISM", 42, 47], ["Mouse", "SPECIES", 42, 47], ["Mouse", "SPECIES", 42, 47], ["Samples", "TEST", 0, 7], ["MethodsLipid panel analysis", "TEST", 87, 114], ["a VITROS", "TEST", 137, 145]]], ["Mice were fasted for 4 hr and bled by submandibular bleeding.", [["submandibular", "ANATOMY", 38, 51], ["submandibular bleeding", "DISEASE", 38, 60], ["Mice", "ORGANISM", 0, 4], ["submandibular", "ORGAN", 38, 51], ["Mice", "SPECIES", 0, 4], ["submandibular bleeding", "PROBLEM", 38, 60], ["submandibular", "ANATOMY", 38, 51], ["bleeding", "OBSERVATION", 52, 60]]], ["Serum samples collected from whole blood were used for the lipid panel analysis.", [["Serum samples", "ANATOMY", 0, 13], ["whole blood", "ANATOMY", 29, 40], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["Serum samples", "TEST", 0, 13], ["whole blood", "TEST", 29, 40], ["the lipid panel analysis", "TEST", 55, 79]]], ["Mouse non-HDL-C levels were calculated by subtracting HDL-C from total cholesterol.Statistics ::: Materials and MethodsExperimental data were analyzed using two-way ANOVA tests.", [["cholesterol", "CHEMICAL", 71, 82], ["cholesterol", "CHEMICAL", 71, 82], ["Mouse", "ORGANISM", 0, 5], ["non-HDL-C", "SIMPLE_CHEMICAL", 6, 15], ["HDL-C", "SIMPLE_CHEMICAL", 54, 59], ["cholesterol", "SIMPLE_CHEMICAL", 71, 82], ["HDL", "PROTEIN", 54, 57], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse non-HDL", "TEST", 0, 13], ["C levels", "TEST", 14, 22], ["HDL", "TEST", 54, 57], ["total cholesterol", "TEST", 65, 82], ["MethodsExperimental data", "TEST", 112, 136], ["ANOVA tests", "TEST", 165, 176]]], ["A.P., K.W., S.B.K., L.H., N.N.L., and D.J.R. were involved in experimental design and data analysis and contributed intellectually to the research.", [["data analysis", "TEST", 86, 99]]], ["All authors contributed to manuscript editing.Conflicts of InterestL.H. is an employee of Inovio Pharmaceuticals and as such receives salary and benefits, including ownership of stock and stock options.", [["manuscript editing", "PROBLEM", 27, 45], ["Inovio Pharmaceuticals", "TREATMENT", 90, 112], ["manuscript editing", "OBSERVATION", 27, 45]]], ["D.B.W. discloses grant funding, industry collaborations, speaking honoraria, and fees or stock for consulting.", [["honoraria", "ORGANISM", 66, 75], ["grant funding", "OBSERVATION", 17, 30]]], ["Remuneration includes direct payments and/or stock or stock options.", [["direct payments", "TREATMENT", 22, 37]]], ["K.M. reports receiving grants from Inovio and receiving consulting fees from Inovio related to DNA vaccine development.", [["DNA", "CELLULAR_COMPONENT", 95, 98], ["Inovio", "TREATMENT", 35, 41], ["Inovio", "TREATMENT", 77, 83], ["DNA vaccine", "TREATMENT", 95, 106]]]], "ac6a3ec26ec271c0610aad78c7ae93781d78b272": [["Le rapport du s\u00e9natLa pr\u00e9paration des soci\u00e9t\u00e9s aux MIE reste une priorit\u00e9 non seulement m\u00e9dicale, mais aussi environnementale, et politique, comportant l'\u00e9volution appropri\u00e9e des syst\u00e8mes de sant\u00e9.", [["Le rapport", "TEST", 0, 10], ["comportant l'\u00e9volution", "TREATMENT", 141, 163]]], ["Savoir s'y pr\u00e9parer est un enjeu central car quels que soient les sc\u00e9narios envisag\u00e9s, il appara\u00eet quasiment impossible de pr\u00e9voir avec exactitude la r\u00e9alit\u00e9 d'un ph\u00e9nom\u00e8ne \u00e0 venir et son impact sur le terrain.", [["Savoir s", "TREATMENT", 0, 8]]], ["La tendance premi\u00e8re est alors de se prot\u00e9ger des situations les plus d\u00e9favorables et les plus alarmistes.", [["La tendance", "PROBLEM", 0, 11]]], ["En juillet 2012, Fabienne Keller, s\u00e9natrice, a propos\u00e9 10 leviers d'action dans un rapport intitul\u00e9 \u00ab Les nouvelles menaces des maladies infectieuses \u00e9mergentes \u00bb [3] .", [["a propos\u00e9", "TREATMENT", 45, 54]]], ["En janvier 2013, Fabienne Keller a pr\u00e9sent\u00e9 cette analyse aux groupes politiques au s\u00e9nat en pr\u00e9sence de Marisol Touraine, ministre des Affaires sociales et de la Sant\u00e9 [4] .Le rapport du s\u00e9natLes 10 leviers d'action propos\u00e9s pour lutter contre ces nouvelles menaces sont :Le rapport du s\u00e9nat\u2022 faire prendre conscience aux opinions publiques de la globalisation du ph\u00e9nom\u00e8ne des maladies infectieuses \u00e9mergentes et de l'importance des rapports Nord Cette mission avait pour objectif d'identifier les moyens de :Le rapport du s\u00e9nat\u2022 faire des patients des acteurs de la politique de sant\u00e9 et de la s\u00e9curit\u00e9 sanitaire, en facilitant les signalements qu'ils effectuent ; \u2022 promouvoir l'implication des professionnels de sant\u00e9 dans le signalement des \u00ab \u00e9v\u00e9nements ind\u00e9sirables \u00bb ; \u2022 pr\u00e9ciser le r\u00f4le des agences r\u00e9gionales de sant\u00e9 (ARS) dans la gestion des signaux et alertes sanitaires ; \u2022 am\u00e9liorer la coop\u00e9ration entre l'ensemble des acteurs r\u00e9gionaux et nationaux (notamment les agences nationales, au premier rang desquelles l'ANSM et l'InVS) concern\u00e9s.", [["patients", "ORGANISM", 542, 550], ["patients", "SPECIES", 542, 550], ["Marisol Touraine, ministre des", "TREATMENT", 105, 135], ["du ph\u00e9nom\u00e8ne des maladies", "TREATMENT", 362, 387], ["et de l'importance des", "TREATMENT", 412, 434]]], ["\u00c0 l'issue d'une consultation des administrations centrales, des ARS et des agences sanitaires, le rapport formule plusieurs propositions, parmi lesquelles :Le rapport du s\u00e9nat\u2022 la simplification de la d\u00e9claration des \u00e9v\u00e9nements sanitaires ind\u00e9sirables par la population et les professionnels par la cr\u00e9ation d'un portail commun de d\u00e9claration ; \u2022 l'optimisation du dispositif en r\u00e9gion autour des ARS ; \u2022 la modification de l'organisation des agences sanitaires autour de trois axes majeurs : \u00ab produits \u00bb, \u00ab prises en charge \u00bb et \u00ab pathologies \u00bb.Le rapport du s\u00e9natCes propositions seront analys\u00e9es dans le cadre de la strat\u00e9gie nationale de sant\u00e9 et serviront \u00e0 l'\u00e9laboration de la loi de Sant\u00e9 Publique de 2014.Le rapport du s\u00e9natEn perspective, ces interactions multiples doivent \u00eatre soutenues et organis\u00e9es non seulement au niveau sanitaire, local et national, mais aussi aux niveaux europ\u00e9en, international et au niveau trans-sectoriel.", [["des administrations centrales", "TREATMENT", 29, 58], ["sanitaires", "TEST", 83, 93], ["du s\u00e9nat\u2022 la simplification de la d\u00e9claration des", "TREATMENT", 167, 216], ["\u2022 la modification", "TREATMENT", 403, 420], ["et \u00ab pathologies", "PROBLEM", 528, 544], ["Le rapport du s\u00e9natCes propositions", "TREATMENT", 547, 582]]], ["Il faut favoriser les interactions \u00e0 diff\u00e9rents niveaux dont celui de la surveillance, en particulier, entre les praticiens cliniciens, v\u00e9t\u00e9rinaires, sp\u00e9cialistes de l'environnement, et des sciences humaines et sociales (SHS) et mettre en place une culture du retour d'exp\u00e9riences, trop n\u00e9glig\u00e9e aujourd'hui en France, notamment parce que ses effets attendus peuvent \u00eatre per\u00e7us par les d\u00e9cideurs voire l'ensemble des personnels comme \u00e9tant trop \u00e9loign\u00e9s de l'action et des applications qui en d\u00e9coulent.\u00c9valuation d'un signal \u00e9mergent et gestion du risque\u00c0 l'heure actuelle, diff\u00e9rents signaux, issus de la veille scientifique ou m\u00e9diatique, de la veille internationale, ou des r\u00e9seaux organis\u00e9s ou informels d'acteurs de la surveillance peuvent \u00eatre transmis \u00e0 l'Institut de veille sanitaire (InVS).", [["une culture", "TEST", 245, 256], ["trop", "TEST", 282, 286], ["trop \u00e9loign\u00e9s", "TREATMENT", 441, 454]]], ["Sur la base de cette analyse, l'alerte peut \u00eatre signal\u00e9e aux autorit\u00e9s sanitaires et la transmission des informations n\u00e9cessaires pour la gestion et la prise en charge du risque est organis\u00e9e.", [["et la transmission des", "TREATMENT", 83, 105], ["pour la gestion", "TREATMENT", 131, 146]]], ["L'appr\u00e9ciation du risque li\u00e9 \u00e0 une MIE reste une d\u00e9marche difficile, int\u00e9grant les informations disponibles sur l'agent infectieux ( Pour cela, une coordination est n\u00e9cessaire \u00e0 l'\u00e9chelon national, mais aussi europ\u00e9en.", [["L'appr\u00e9ciation", "TEST", 0, 14], ["difficile", "PROBLEM", 58, 67]]], ["Depuis 1998, 2 axes sont sous la responsabilit\u00e9 de la Commission (CE) et du Parlement europ\u00e9ens : la surveillance, confi\u00e9e \u00e0 l'European Centre for Disease Prevention and Control (ECDC), cr\u00e9\u00e9 en 2005, et la r\u00e9ponse aux \u00e9v\u00e8nements \u00e0 impact trans-frontalier.", [["Disease Prevention", "TREATMENT", 147, 165]]], ["L'int\u00e9r\u00eat de cette agence est d'assurer les partages d'information et d'avoir aussi des agents de liaison se d\u00e9pla\u00e7ant dans les agences de diff\u00e9rents pays, permettant une plus grande coh\u00e9sion \u00e0 l'\u00e9chelon europ\u00e9en.", [["l'\u00e9chelon europ\u00e9en", "TREATMENT", 194, 212]]], ["En d\u00e9finitive, apr\u00e8s partage des informations, les d\u00e9cisions rel\u00e8vent aujourd'hui des \u00e9tats membres.La recherche clinique en situation de crise sanitaireUne r\u00e9vision de la directive des essais cliniques est en cours par le Parlement Europ\u00e9en, visant \u00e0 am\u00e9liorer l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des r\u00e8gles selon les pays, la baisse des inclusions dans les essais, les co\u00fbts croissants, et une d\u00e9localisation de la recherche clinique dans certains pays.", [["La recherche clinique en situation", "TREATMENT", 100, 134], ["Une r\u00e9vision de la directive des essais", "TREATMENT", 153, 192], ["est en cours par le Parlement Europ\u00e9en", "TREATMENT", 203, 241], ["visant", "TREATMENT", 243, 249]]], ["Les 4 grands objectifs de ce projet sont de :La recherche clinique en situation de crise sanitaire\u2022 harmoniser et standardiser ; \u2022 renforcer la coop\u00e9ration entre les \u00e9tats membres ;La recherche clinique en situation de crise sanitaire\u2022 permettre une approche fond\u00e9e sur le risque (notion de d'essai \u00e0 faible risque) avec le d\u00e9veloppement d'une recherche d\u00e9di\u00e9e ; \u2022 renforcer la s\u00e9curit\u00e9 et la transparence.La recherche clinique en situation de crise sanitaireLes d\u00e9lais d'acceptation des essais seraient raccourcis, et leur mise en place serait simplifi\u00e9e gr\u00e2ce \u00e0 une soumission par le promoteur \u00e0 un portail europ\u00e9en unique.", [["La recherche clinique en situation", "TREATMENT", 181, 215], ["La recherche clinique en situation", "TREATMENT", 406, 440], ["d\u00e9lais d'acceptation des", "TREATMENT", 463, 487], ["seraient raccourcis", "TREATMENT", 495, 514]]], ["Il appara\u00eet essentiel d'avoir une r\u00e9glementation sp\u00e9cifique pour la recherche en situation d'urgence sanitaire, \u00e9tendant le champ de la directive aux essais \u00e9pid\u00e9mio-cliniques, \u00e9troitement coupl\u00e9s \u00e0 la recherche th\u00e9rapeutique, dont l'encadrement est particuli\u00e8rement important dans ce contexte.La recherche clinique en situation de crise sanitaireLes comit\u00e9s de protection des personnes (CPP) pourront en cas de pand\u00e9mie traiter en priorit\u00e9 les dossiers concern\u00e9s par l'urgence sanitaire, sans alt\u00e9rer la qualit\u00e9 des avis.", [["avoir une r\u00e9glementation", "PROBLEM", 24, 48], ["La recherche clinique en situation", "TREATMENT", 294, 328], ["pourront en cas", "TREATMENT", 393, 408]]], ["De m\u00eame, le Ministre dispose des outils l\u00e9gislatifs et juridiques pour prescrire des mesures d'exception adapt\u00e9es.", [["et juridiques pour prescrire des", "TREATMENT", 52, 84]]], ["Par contre, le financement de la recherche clinique dans le cadre des MIE, n'entrant pas dans le cadre du PHRC ni de l'ANR, a \u00e9t\u00e9, et reste une question non r\u00e9solue.", [["le", "ANATOMY", 12, 14]]], ["L'id\u00e9al serait un fond p\u00e9renne cibl\u00e9 pour les urgences sanitaires, mobilisable en cas de besoin.La recherche clinique en situation de crise sanitaireEn perspective, il faut pr\u00e9parer la recherche en situation de pand\u00e9mie, en particulier la recherche \u00e9pid\u00e9mio-clinique, en SHS et en sciences politiques, impliquant les personnes malades ou expos\u00e9es, comportant des contraintes sp\u00e9cifiques fortes en cas de crise, et ses interactions avec les recherches pouvant se d\u00e9velopper plus \u00e0 distance, \u00e0 partir d'informations stock\u00e9es (d\u00e9veloppement de mod\u00e8les math\u00e9matiques et informatiques testant des hypoth\u00e8ses/sc\u00e9narios, analyses g\u00e9n\u00e9tiques \u00e0 partir de bio-banques. . .).", [["La recherche clinique en situation", "TREATMENT", 96, 130]]], ["Des protocoles \u00ab prototypes \u00bb doivent \u00eatre pr\u00e9par\u00e9s pour \u00eatre rapidement activables si besoin.", [["Des protocoles \u00ab prototypes", "TREATMENT", 0, 27], ["doivent \u00eatre pr\u00e9par\u00e9s", "TREATMENT", 30, 51]]], ["Des projets portant sur des situations \u00e9pid\u00e9miques doivent \u00eatre soutenus par les d\u00e9cideurs et les agences de financement dans cette perspective, et ce pour tester et entra\u00eener les acteurs de recherche \u00e0 tous les niveaux, investigateurs, promoteurs, centres de m\u00e9thodologie et de gestion publics et priv\u00e9s, comit\u00e9s de protection des personnes, agence des m\u00e9dicaments, pour \u00e9tudier et d\u00e9velopper le plus pr\u00e9cocement possible, anti-infectieux et vaccins.", [["et ce pour tester", "TEST", 145, 162], ["des m\u00e9dicaments", "TREATMENT", 350, 365], ["pour \u00e9tudier et d\u00e9velopper le plus pr\u00e9cocement", "TREATMENT", 367, 413], ["anti-infectieux et vaccins", "TREATMENT", 424, 450]]], ["Il a pour but de pr\u00e9parer la recherche au cours des menaces \u00e9pid\u00e9miques infectieuses \u00e9mergentes, optimiser et coordonner les capacit\u00e9s de recherche des structures et des acteurs existants : syst\u00e8mes de surveillance, laboratoires de recherche, services hospitaliers (urgences, r\u00e9animations, services des maladies infectieuses) et entre Pays du Nord et Pays du Sud.", [["maladies infectieuses", "DISEASE", 303, 324], ["pr\u00e9parer la recherche au cours des", "TREATMENT", 17, 51]]], ["Cette organisation de la recherche cible les MIE y compris les zoonoses \u00e0 la fois sur la surveillance et l'alerte, le d\u00e9veloppement des outils math\u00e9matiques et \u00e9conomiques, le d\u00e9veloppement des outils diagnostiques, la mise en place des r\u00e9seaux et des outils pour faciliter la recherche clinique et les sciences sociales et les aspects li\u00e9s \u00e0 la communication.R\u00e9ponse int\u00e9gr\u00e9e aux urgences sanitairesEn France, il s'est construit, au d\u00e9cours de l'\u00e9pisode du SRAS, une approche clinique pour la prise en charge des personnes \u00e0 risque ou atteintes d'une MIE, avec un r\u00e9seau, aujourd'hui national, de coordination du risque \u00e9pid\u00e9mique et biologique (COREB), con\u00e7u comme une cellule op\u00e9rationnelle d'expertise et d'appui, en priorit\u00e9 aupr\u00e8s des SAMU et urgentistes, s'appuyant sur une coop\u00e9ration civilo-militaire.", [["le d\u00e9veloppement des", "TREATMENT", 115, 135], ["le d\u00e9veloppement des", "TREATMENT", 173, 193], ["la mise en place des", "TREATMENT", 216, 236]]], ["La mission g\u00e9n\u00e9rale du COREB est la mise en place d'un dispositif de coordination des urgences infectieuses, avec un plan de fonctionnement simple \u00e0 activer.", [["La mission", "TEST", 0, 10]]], ["Le COREB assure l'\u00e9laboration et l'actualisation de proc\u00e9dures rapidement mises \u00e0 disposition en cas de besoin, et a aussi des missions d'enseignement, d'information et de recherche pour am\u00e9liorer la dimension clinique de cette gestion du risque.", [["Le COREB", "TREATMENT", 0, 8]]], ["En 2010, le COREB a mis \u00e0 disposition une proc\u00e9dure standardis\u00e9e de prise en charge, par les urgences et par les SMUR, des patients suspects d'infections \u00e9mergentes en \u00cele-de-France.", [["infections", "DISEASE", 143, 153], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["d'infections", "PROBLEM", 141, 153]]], ["Celle-ci permet d'isoler un patient suspect et de d\u00e9clencher l'alerte, articulant de fa\u00e7on coh\u00e9rente, les mesures individuelles et collectives \u00e0 appliquer : d\u00e9pister, prot\u00e9ger, prendre en charge, alerter et orienter.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["Celle", "TEST", 0, 5]]], ["La structuration d'une coordination en r\u00e9seau sur ce th\u00e8me sous l'impulsion des autorit\u00e9s sanitaires permettrait de rendre plus efficace et plus s\u00fbre la pr\u00e9paration \u00e0 une alerte.R\u00e9ponse int\u00e9gr\u00e9e aux urgences sanitairesEn parall\u00e8le, l'\u00e9tablissement public de pr\u00e9paration et de r\u00e9ponse aux urgences sanitaires (EPRUS), mis en place en 2007, sous-tutelle du minist\u00e8re de la Sant\u00e9, est charg\u00e9 d'assurer l'organisation et l'appui logistique avec 3 missions principales :R\u00e9ponse int\u00e9gr\u00e9e aux urgences sanitaires\u2022 la gestion administrative, op\u00e9rationnelle et financi\u00e8re de la r\u00e9serve sanitaire ; \u2022 la constitution et la gestion des stocks strat\u00e9giques (d\u00e9finis chaque ann\u00e9e avec la Direction g\u00e9n\u00e9rale de la sant\u00e9) et des produits de sant\u00e9 et ; \u2022 l'apport d'une expertise logistique et m\u00e9dicale \u00e0 la coh\u00e9rence des plans de d\u00e9fense et de secours.R\u00e9ponse int\u00e9gr\u00e9e aux urgences sanitairesAfin d'assurer une r\u00e9ponse int\u00e9gr\u00e9e aux urgences sanitaires, l'EPRUS travaille notamment avec le service de sant\u00e9 des arm\u00e9es pour mettre en commun le stockage des produits et mat\u00e9riaux et essayer d'instaurer une collaboration permettant une compl\u00e9mentarit\u00e9 et une mobilisation coh\u00e9rente des moyens.", [["La structuration", "TEST", 0, 16], ["la gestion administrative", "TREATMENT", 507, 532], ["et financi\u00e8re de la r\u00e9serve sanitaire", "TREATMENT", 549, 586], ["\u2022 la constitution et la gestion", "TREATMENT", 589, 620], ["pour mettre en commun le stockage des", "TREATMENT", 1002, 1039]]]], "PMC7375310": []}